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Abstract 
The effect of flurbiprofen (FLU) and its nitric oxide (NO) releasing derivative, 
nitroflurbiprofen (NOF), were evaluated in a caecal ligation puncture (CLP) model of 
septic shock in the rat. Caecal ligation puncture reduced mean arterial blood pressure 
accompanied by increases (P<0.05) in plasma nitrite/nitrate (NOx), TNF-α and IL-1β 
concentrations, signs of inflammatory damage in lung, liver and increased mortality. 
FLU (21 mg kg-1, p.o.) or NOF (3-30 mg kg-1, p.o.) increased blood pressure, reduced 
organ damage and prolonged survival time. NOF (but not FLU) significantly reduced 
plasma TNF-α concentration at all time points. Neither drug affected plasma IL-1β 
concentration. These results suggest a novel, protective effect of both FLU and NOF 
in the CLP model of septic shock.  
Subsequently the use of NO donors (e.g. NOF) and NOS inhibitors (e.g. L-
NAME, 1400W) in the lipopolysaccharide (LPS) model of endotoxic shock was 
investigated so as to further elucidate the roles of NO and other gaseous mediators 
(e.g. hydrogen sulphide) that could possibly interact with NO. Administration of LPS 
(10 mg kg-1, i.p.; 6 h) resulted in an increase (P<0.05) in plasma NOx, TNF-α, and 
IL-1β concentrations, liver hydrogen sulphide (H2S) synthesis (from added cysteine), 
CBS/CSE mRNA, inducible nitric oxide synthase (iNOS), myeloperoxidase (MPO) 
activity (marker for neutrophil infiltration), and NF-κB and proteasome activation, 
whilst a decrease in liver endothelial nitric oxide synthase (eNOS). NOF (3-30 mg kg-
1, i.p.) administration resulted in a dose-dependent inhibition of the LPS-mediated 
increase in plasma NOx, TNF-α, and IL-1β concentrations, liver H2S synthesis, 
CBS/CSE mRNA, iNOS, MPO activity, and NF-κB and proteasome activation. FLU 
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(21 mg kg-1, i.p.) was without effect. L-NAME (25-100 mg kg-1, i.p.) administration 
resulted in a dose-dependent increase in plasma TNF-α, IL-1β concentrations, liver 
H2S synthesis, CBS/CSE mRNA, MPO activity, NF-κB and proteasome activation, 
whereas a dose-dependent inhibition of plasma NOx concentration, liver eNOS and 
iNOS. 1400W (1-10 mg kg-1, i.p.) administration resulted in a dose-dependent 
increase of liver eNOS, whereas a dose-dependent inhibition of plasma NOx, TNF-α, 
and IL-1β concentrations, liver iNOS, H2S synthesis, CBS/CSE mRNA, MPO 
activity, NF-κB and proteasome activation. 
These results show for the first time that both NOF and 1400W are able to 
downregulate the biosynthesis of pro-inflammatory H2S most probably via the 
inhibition of transduction of the proteasome – NF-κB pathway. Hence the proteasome 
may be intricately linked in the ‘cross talk’ between NO and H2S and may prove to be 
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 Despite extensive studies over the last two decades, the precise role of nitric 
oxide (NO) in many cardiovascular disease (CVD) states remains unclear. Numerous 
contradictory reports in the literature suggest that both inhibitors of nitric oxide 
synthase (NOS) and NO donors are beneficial in animal models of such disparate 
clinical conditions as septic/endotoxic (Vos et al., 1997; Zhang et al., 1997) and 
haemorrhagic shock (Shirhan et al., 2004; Anaya-Prado et al., 2004), stroke (Helps & 
Sims, 2007; Katsumi et al., 2007) and myocardial infarction (Penna et al., 2006; 
Katsumi et al., 2007). Recent studies also suggest that NO may work in concert with 
other gaseous mediators such as hydrogen sulphide (H2S) to play an important 
physiological role in the control of blood vessel contractility and vascular perfusion 
(Zhao et al., 2003). Furthermore, a disordered biosynthesis of H2S (perhaps as a result 
of changes in the expression of cystathionine γ lyase (CSE) and/or cystathionine β 
synthetase (CBS) which are enzymes that synthesizes H2S from cysteine) could 
probably contribute to the abovementioned clinical conditions (Collin et al., 2005; Li 
et al., 2005). 
Septic shock, with its complications, is still a major challenge in 
contemporary medicine. It is characterized by systemic hypotension, ischemia, and 
ultimately organ failure. It was thus considered worthwhile, in the first part of this 
project, to evaluate the effect of nitroflurbiprofen (NO donor) and flurbiprofen 
(NSAID) in a caecal ligation puncture (CLP) model of induced septic shock because, 
(i) NO has long been recognized as an important mediator of sepsis, although its 
precise role remains elusive, (ii) the role of prostanoids is unclear as is the potential 
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therapeutic benefit of non-steroidal anti-inflammatory drugs (NSAID) and, (iii) septic 
shock is associated with high mortality and alternative therapeutic strategies are much 
sought after (Chapter 5). Likewise, infections by Gram positive and negative bacteria 
and fungi can result in septic shock. In Gram negative disease, lipopolysaccharide 
(LPS) is strongly implicated in the pathophysiological response(s) that result in 
endotoxic shock. The CLP model, although perhaps less predictable and less 
reproducible, results in a model situation more akin to that seen clinically. On the 
other hand, the LPS model results in a more direct, reproducible alteration in host 
responses to immune challenge. Thus, for the second part of this project we decided 
to investigate the interaction between H2S and NO in the animal model of systemic 
inflammation viz. E. Coli LPS-induced endotoxic shock. For these experiments, the 
NO-releasing non-steroidal anti-inflammatory drug (NO-NSAID), nitroflurbiprofen 
(NOF) along with its parent molecule flurbiprofen (FLU), were again used (Chapter 
6). Furthermore, in an attempt, (i) to examine in more detail the apparent conundrum 
that exists between NO donors and NOS inhibitors, and at the same time (ii) to 
provide data for comparison with the effect of NOF, nitric oxide synthase (NOS) 
inhibitors, namely L-NAME (non-selective NOS inhibitor) and 1400W (selective 
iNOS inhibitor), were used in the LPS-induced endotoxic shock model, for the third 
part of the project (Chapter 7). 
 In the following introductory chapters, we shall provide background 
information concerning, (i) the different animal models of producing septic/endotoxic 
shock, (ii) the fundamental mechanisms leading to tissue and organ damage in sepsis, 
and (iii) the general biology of NO and H2S (Chapters 1-3). We shall then examine 
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the available literature for the experimental evidence implicating NO and/or H2S as 
an effector in sepsis, as well as results obtained with various pharmacologic 
interventions directed at NO and/or H2S in animal and/or clinical studies. The 
detailed methodology employed in this project shall be discussed in Chapter 4 along 
with the results obtained in Chapters 5-7.  
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Chapter 1: Sepsis, Septic Shock and Endotoxemia 
1.1 Introduction 
The word sepsis is derived from the Greek language (Σήψις, putrefaction). 
Pepsis was good, embodying the natural processes of maturation and fermentation 
while sepsis was bad and synonymous with putrefaction as characterised by bad 
smell. It was only thousands of years later before Louis Pasteur conclusively linked 
putrefaction to a bacterial cause. Sepsis is now known to be a heterogenous class of 
syndromes caused by a systemic inflammatory response to infection in a markedly 
heterogeneous population of patients. In fact, sepsis is not caused by a single, defined 
etiological agent and has no single diagnostic laboratory or clinical sign that confirms 
its diagnosis. The terminology of sepsis is further complicated by the vague and often 
incorrect terms used by physicians to describe clinical events in their patients. Terms 
such as “septicemia”, “sepsis syndrome”, “endotoxic shock” and “bloodstream 
infection” are unevenly applied by clinicians and investigators (Opal & Cross, 1999). 
In an effort to devise a uniform set of definitions for the classification of 
sepsis, consensus definitions (Table 1-1) have been generated by experts in the field 
(Bone et al., 1992). Thus sepsis is simply defined as a systemic inflammatory 
response syndrome (SIRS) caused by an infection (Bone et al., 1992). Basically there 
are two subcategories of sepsis, (i) severe sepsis, with dysfunction in one or more 
organ systems and (ii) septic shock, with hypotension not responsive to intravenous 
fluid loading. Alternatively, when two or more of the SIRS criteria (Table 1-1) are 
met without evidence of infection, patients may be diagnosed simply with “SIRS”. 
Patients with SIRS and acute organ dysfunction may be termed “severe SIRS”. Septic 
Chapter 1: Sepsis, Septic Shock & Endotoxemia 5
 
 






















Chapter 1: Sepsis, Septic Shock & Endotoxemia 6
shock, which is a severe form of sepsis, is associated with the development of 
progressive damage in multiple organs and remains a leading cause of morbidity and 
mortality in intensive care units worldwide. Mortality rates range from 20% for sepsis 
to 40% for severe sepsis to >60% for septic shock (Martin et al., 2003). According to 
CDC's (Center for Disease Control) National Center for Health Statistics, sepsis is the 
leading cause of death in non-coronary intensive care unit patients, and the 10th most 
common  cause  of  death  overall  in  the  United  States   alone  for  2003.  Similarly, 
according to Singapore’s Ministry of Health, sepsis is the 9th most common cause of 
death overall in Singapore for 2003. 
Despite numerous advances in our understanding of the pathophysiology of 
sepsis, therapy remains largely symptomatic and supportive and practical treatment of 
sepsis has not substantially changed in the last two decades. Treatment consists of 
fighting off infection with broad spectrum antibiotics and supporting failing organ 
systems with measures such as fluid loading, administration of inotropic and 
vasopressor agents, or renal replacement therapy (Dellinger, 2003). A problem in the 
adequate management of septic patients has been the delay in administering therapy 
after sepsis has been recognized. Published studies have demonstrated that for every 
hour delay in the administration of appropriate antibiotic therapy there is an 
associated 7% rise in mortality (Dellinger et al., 2004). Thus far, no breakthrough has 
occurred in the treatment of sepsis likely due to both the heterogeneity of the clinical 
situations involved and the extreme complexity of the host response to overwhelming 
infection. As such, the need to assess which animal model of inducing septic shock 
would best be utilized in our present project shall be discussed below. 
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1.2 Animal models 
Although often used synonymously, differences exist between the induction of 
sepsis and the induction of endotoxemia. In general, for a particular animal model, 
sepsis induction results in a less predictable and less reproducible alteration in host 
responses to the immune challenge, although it is very similar to that seen clinically. 
On the other hand, endotoxemia induction results in a more direct and reproducible 
alteration in host responses to the immune challenge (Sam II et al., 1997). 
 
1.2.1 Caecal ligation and puncture (CLP)-induced septic shock model 
Induction of sepsis is intrinsically more challenging than inducing 
endotoxemia since the immune challenge is episodic in nature. Some of the 
guidelines for progressive and lethal septic models outlined by Wichterman et al., 
(1980) in their review of septic modelling are stated as follows: 
(1) The animals should show clinical signs of sepsis namely malaise, 
fever, chills, generalised weakness. 
(2) The septic insult should occur over a period of time to allow the 
animal time to respond to the insult and attempt to overcome it. 
(3) The model should be reproducible enough so that at least the 
majority of the prepared animals are available for study. 
Clinically, patients experience intermittent release of toxin into the 
bloodstream from a septic focus. Thus in an effort to achieve a model similar to 
the situations faced by clinicians, a method which results in an episodic release of 
organisms into the bloodstream would be desirable. Since individuals with 
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identical septic insults may respond in a totally different manner, this 
physiological variability would also be expected to be observed in those models 
deemed “most clinically relevant”. As such, the method widely used today to 
induce sepsis in experimental animals is caecal ligation and puncture (CLP) 
(Wichterman et al., 1980) which satisfies the requirement of episodic release of 
microorganisms into the bloodstream. Nonetheless, the CLP model produces a 
rapidly lethal septic state with mortality varying from near 50% at 48 hours to 
100% at 84 hours (Doerschug et al., 2004) depending on the surgical technique 
employed i.e. number of punctures and size of needle (Wichterman et al., 1980). 
Evidently, this would thus introduce several factors which may vary between 
investigators. Another technical point which may result in widely disparate 
outcomes involves the location of the suture which is used to ligate the caecum of 
the experimental animal. On the whole, the abovementioned factors may not be as 
significant if consistently performed by the same investigator. However, they may 
become substantial between investigators as the reproduction of results may be 
difficult to achieve.  
 
1.2.2 Lipopolysaccharide (LPS)-induced endotoxic shock model 
Lipopolysaccharide (LPS), or endotoxin, is a Gram-negative bacterial 
product which is localised to, and emanates from, the cell wall of these organisms. 
This substance is the primary inciting mediator of the inflammatory response to 
these organisms in the host (see Chapter 1, Section 1.3.2.) and is composed of 
three primary components namely, the O (outer) polysaccharide, the core, and the 
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lipid component (Lipid A) (Reitschel et al., 1994). These components, while 
displaying some degree of heterogeneity when compared across genera and 
species of bacteria, do share certain homologous sequences which have been 
seized upon as potential targets of therapy, particularly in the Lipid A component. 
Lipid A has in fact been shown to be the portion of LPS which exerts the toxic 
effects and incites the inflammatory response of the host (Wang et al., 1992). 
Protective effects of monoclonal antibodies against the Lipid A component were 
demonstrated in vivo (Mead et al., 1994), yet clinical trials have been viewed with 
disappointment (Wenzel, 1992).  
It must be noted that endotoxemic animals exhibit changes that are 
species-specific. In pigs, sheep, and young equines, pulmonary hypertension with 
associated lung injury is commonly observed (Esbenshade et al., 1982; Olson et 
al., 1985; Ward et al., 1997). In dogs and rodents, the gastrointestinal (GI) tract is 
the principal affected organ without the development of significant pulmonary 
hypertension (Kuida et al., 1961). Sensitivities towards endotoxic challenges also 
vary among species. Pigs possess a significant sensitivity to endotoxin, as low 
doses (<5 μg kg-1) results in marked cardiopulmonary effects (Fink et al., 1989). 
On the other hand, dogs and rats (Kuida et al., 1961) may tolerate extremely high 
doses (1 mg kg-1) whereas extreme sensitivity is seen with guinea pigs as marked 
effects are observed upon administration of less than 1 μg kg-1 (Ferguson et al., 
1978). For comparison, endotoxin doses of 4 ng kg-1 induce a pyretic response 
and shock-like haemodynamic changes in healthy human volunteers (Suffredini et 
al., 1989). Furthermore, the clinical relevance of endotoxemic models of sepsis in 
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small rodents often has been criticised for their limited clinical relevance (Deitch, 
1998) for the following reasons: 
(1) These species have a much lower sensitivity to LPS compared with 
humans in whom the quantities of bacterial toxin sufficient to trigger a 
septic response amount to nanograms per kilogram body weight 
(Suffredini et al., 1989). 
(2) Plasma levels of LPS and cytokines attain much higher values in 
endotoxemic rodents than septic patients. 
(3) In the course of acute endotoxemia in rodents, cardiac output falls and 
systemic vascular resistance rises, while the inverse changes are noted 
in human sepsis. 
(4) A hallmark of the clinical situation is invasion by live bacteria rather 
than by a single toxin. 
 
1.3 Pathophysiology of sepsis 
From here onwards, we will refer to both “sepsis” and “endotoxemia” under 
the same collective term “sepsis” although we must keep in mind that there are 
differences between the terms as mentioned above (Chapter 1, Sections 1.2.1 and 
1.2.2). 
According to the present concept, sepsis results from the generalised 
activation of inflammatory cascades, following invasion of the bloodstream by 
bacteria, viruses, or parasites, with the systemic release of various toxic products 
(Parrillo, 1993). These include bacterial cell-cell components, such as endotoxin (see 
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Chapter 1, Section 1.2.2), lipoteichnoic acid from Gram-positive organisms, and 
various exotoxins (Glauser et al., 1994). Microorganisms and their products activate 
systemic host defenses, comprising both humoral (complement and coagulation 
cascade) and cellular components (monocyte/macrophage, neutrophils and 
endothelial cells).  Activated cells, in turn, release a vast array of mediators 
(cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1), 
arachidonic acid metabolites, and nitric oxide (NO)) that amplify the inflammatory 
response (Marsh & Wewers, 1996). 
Most cases of Gram-negative sepsis are caused by Enterobacteriaceae such as 
E. coli and Klebsiella species. Pseudomonas aeruginosa is the third commonest 
cause. Lipopolysaccharide is an important component of the outer membrane of 
Gram-negative bacteria and has a pivotal role in inducing Gram-negative sepsis. 
Basically, lipopolysaccharide binding protein in host cells binds to lipopolysaccharide 
in the bacteria and transfers it to CD14 (Ulevitch & Tobias, 1999). CD14 is a protein 
anchored in the outer leaflet of the plasma membrane, although it also exists as a 
soluble plasma protein that attaches lipopolysaccharide to CD14-negative cells, such 
as endothelial cells. CD14 is located in the extracellular space and therefore cannot 
induce cellular activation without a transmembrane signal transducing co-receptor 
(Figure 1-1).  
Due to a series of remarkable investigations the co-receptor for 
lipopolysaccharide was identified to be Toll-like receptor 4 (TLR4). Toll-like 
receptors (TLRs) were first discovered in Drosophila, where they were found to have  
 


















Figure 1-1: Interaction between Gram-negative and Gram-positive bacterial products and 
pattern recognition receptors expressed on immune cells. Components of bacterial cell walls (e.g.  
lipopolysaccharide, peptidoglycan, lipoteichoic acid, flagellin, and unmethylated CpG DNA 
sequences) interact with specific Toll-like receptors (TLRs) expressed on immune cells. The receptors 
then activate intracellular signalling pathways and transcription factors resulting in expression of the 
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a role  in  the  defence  of  flies  against  fungi  and  Gram-positive  bacteria 
(Hoffmann & Reichhart, 2002). Toll-like receptors were then identified in other 
species. Genetic studies in mice showed that mutations in the Tlr4 gene were linked 
to resistance to lipopolysaccharide, providing evidence that TLR4 was an essential 
component of the lipopolysaccharide receptor complex (Poltorak et al., 1998). MD-2, 
a secreted protein associated with the extracellular domain of TLR4, has also recently 
been shown to have an important role in responsiveness to lipopolysaccharide (Nagai 
et al., 2002).  
Subsequently, TLRs were shown to recognize other bacterial (e.g. lipoteichoic 
acid from Gram-positive bacteria) and viral nucleic acids and to trigger at least three 
major transcription factor pathways, resulting in the generation of activated and 
intranuclear nuclear factor (NF)-κB, activator protein (AP)-1, and interferon response 
factor (IRF)-3. NF-κB and AP-1 result in the transcription of many pro-inflammatory 
genes, whereas IRF-3 increases the production of interferon (IF)-β. 
Although Gram-negative infections were predominant in the 1960s and early 
1970s, Gram-positive infections have increased in the past two decades and now 
account for about half of cases of severe sepsis (Bochud et al., 2001). Staphylococci 
and streptococci are the commonest cause of Gram-positive sepsis. Gram-positive 
bacteria can cause sepsis by at least two mechanisms: (i) by producing exotoxins that 
act as superantigens and (ii) by components of their cell walls stimulating immune 
cells (Calandra, 2001). 
Superantigens (e.g. Staphylococcal enterotoxins, toxic shock syndrome toxin 
(TSST)-1, and streptococcal pyrogenic exotoxins) are molecules that bind to MHC 
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class II molecules of antigen presenting cells and to Vβ chains of T cell receptors. In 
doing so, they activate large numbers of T cells to produce massive amounts of pro-
inflammatory cytokines. Gram-positive bacteria without exotoxins can also induce 
shock, probably by stimulating innate immune responses through similar mechanisms 
to those in Gram-negative sepsis (Figure 1-1). Indeed, TLR2 has been shown to 
mediate cellular responses to heat killed Gram-positive bacteria and their cell wall 
structures (peptidoglycan, lipoproteins, lipoteichoic acid, and phenol soluble 
modulin) (Takeuchi et al., 1999).  
In fact, different TLRs respond to different microbial products to induce 
different transcription factors, leading to the expression of different genes, with 
varying clinical consequences. Clinical evidence supports this emerging paradigm 
and most data exist for the differences between Gram-negative and Gram-positive 
sepsis (Opal & Cohen, 1999). It was found that patients with Gram-negative sepsis 
had higher levels of the cytokines TNFα and IL-6, though it was not significant in the 
early severe sepsis group, but was significant among the late-onset group (Fisher et 
al., 1996). However, patients in whom a Gram-positive organism was isolated 
appeared to have a worse outcome per se (Brun-Buisson et al., 1996) possibly due to 
the increasing emergence of multiresistant organisms such as methicillin-resistant 
Staphylococcus aureus (Wang et al., 2003).  
Complex interactions between different mediators produce profound 
pathophysiological alterations, which ultimately lead to diffuse tissue injury and the 
progressive deterioration of organ function. This sequential system failure defines the 
multiple organ dysfunction syndrome (MODS), which accounts for the majority of 
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deaths among patients with sepsis (see Chapter 1, Section 1.1). Several overlapping 
mechanisms have been proposed to explain the development of MODS. These may 
be broadly divided into two groups namely, circulatory failure leading to an 
inadequate supply of oxygen (O2) to tissues, and direct cytotoxic effects of various 
mediators released in the course of generalised inflammation (Beal & Cerra, 1994; 
Parrillo, 1993). 
 
1.3.1 Circulatory failure 
Cardiovascular abnormalities in sepsis include both cardiac dysfunction 
and altered vascular tone, leading to a typical haemodynamic pattern of high 
cardiac output, low systemic vascular resistance, and hypotension refractory to 
vasopressor agents (Parrillo, 1993). 
In spite of the elevated cardiac output, myocardial depression is a constant 
finding in severe sepsis and septic shock. Cardiac dysfunction affects both the 
right and left ventricle, and may limit the adaptive changes in cardiac output 
(Parillo et al., 1990).  Its mechanisms are poorly understood, although circulating 
and locally produced myocardial depressant substances may be involved (Brady, 
1995; Parrillo, 1993).  
Alterations in vascular tone affect the arterial, venous, and microvascular 
components of the vascular system (Rackow & Astiz, 1993). In vitro, marked 
perturbations of the responses to vasoactive agents are observed in vessels 
exposed to endotoxin or taken from septic animals (Hollenberg et al., 1993; 
Mitchell et al., 1993). However for in vivo, differential effects are present in 
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various vascular beds. Thus vasoconstriction may predominate in certain organs 
(e.g. intestines, kidney) (Spain et al., 1994a; Spain et al., 1994b), while profound 
vasodilation occurs in others (e.g. skeletal muscle) (Lubbe et al., 1992). Of note, 
these changes are difficult to predict, being in all likelihood markedly dependent 
on the time and experimental conditions (e.g. septic versus endotoxic shock). 
Several mechanisms account for the loss of vascular homeostasis in sepsis. 
The normal balance between vasodilator (e.g. NO, vasodilating prostaglandins) 
and vasoconstricting influences (e.g. catecholamines, angiotensin II, platelet 
activating factor, thromboxane A2, endothelins (ETs)) becomes disrupted 
following the activation of systemic and local production of these mediators 
(Hinshaw, 1996). In addition, diffuse endothelial cell injury markedly increases 
microvascular permeability, leading to oedema formation (Laszlo et al., 1995). 
Further pathologic events affecting the microcirculation include disturbed 
rheologic properties of circulating blood cells (Astiz et al., 1995) and the 
formation of microthromboses following disseminated intravascular coagulation 
and the plugging of vessels by activated platelets and leukocytes (Astiz et al., 
1995; Hinshaw, 1996). All of these alterations contribute to impairment of the 
physiological mechanisms controlling microvascular blood flow that normally 
tightly couple local blood flows to local metabolic activity, allowing O2 to be 
delivered preferentially to regions of greater O2 need, both within and among 
organs (Nelson et al., 1987; Schumacker & Samsel, 1989). 
Sepsis-induced circulatory abnormalities typically produce a 
maldistribution of blood flow, which may divert O2 delivery from organs with 
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high metabolic requirements to organs with lower demands (Gutierrez, 1993). For 
example, decreased blood flow to the intestines (Zhang et al., 1995), liver (Van 
Lambalgen et al., 1994), and kidney (Spain et al., 1994b) has been consistently 
documented in experimental septic shock, contrasting with normal or increased 
flows generally reported to skeletal muscle (Townsend et al., 1986). In addition to 
this inter-organ redistribution of blood flow, intra-organ redistribution also occurs 
as demonstrated in the kidney (Spain et al., 1994b), intestine (Revelly et al., 
1996), and liver (Unger et al., 1989). These alterations may favour the 
development of localised zones of ischemia, resulting in an imbalance between 
regional O2 demand and delivery. 
 
1.3.2 Cytotoxic effect of mediators 
However other studies indicate that tissue ischemia may not entirely 
account for the metabolic abnormalities induced by sepsis at the cellular level. In 
several experimental studies, tissue anaerobiosis and impaired energy metabolism 
were found to develop in spite of normal tissue perfusion and O2 tension. For 
example, ATP levels in the skeletal muscle of septic rats were significantly 
decreased despite normal values of muscle PO2 (Astiz et al., 1988).  In 
endotoxemic rats, there was dissociation between tissue blood flows and high-
energy phosphate levels (Van Lambalgen et al., 1994).  In pigs challenged with 
endotoxin, intestinal mucosal acidosis developed in the absence of mucosal 
hypoxia (VanderMeer et al., 1995). Finally, in a similar porcine model, intestinal 
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mucosal ATP levels fell despite an increase in mucosal blood flow (Revelly et al., 
2000). 
It appears reasonable to assume that the upheaval in the cellular 
environment represented by the sequential release of multiple, highly bioactive 
inflammatory mediators may directly and profoundly affect the function of 
parenchymal cells and whole organs. Possible specific pathways are suggested by 
some animal studies. For example, in hepatocytes sensitized by prior exposure to 
LPS, leukotriene D4, an arachidonic acid metabolite widely produced in the 
course of inflammation, is able to stimulate the opening of chloride channels (an 
event which may be associated with cell death) (Meng et al., 1997). Another 
example in the mouse model of septic liver injury induced by LPS, the stimulation 
of the TNF-R1 receptor in hepatocytes appears necessary for the development of 
hepatocellular failure (Jaeschke et al., 1998). Interestingly, in this study, the 
immediate effect of TNF was to provoke the apoptosis of some hepatocytes, 
which in turn, stimulated the recruitment of neutrophils and subsequent 
parenchymal necrosis. 
It is also widely assumed that the products released in the 
microenvironment by activated neutrophils play an important role in the 
generation of tissue injury induced by sepsis. These products include the 
proteolytic enzymes and reactive oxygen species (ROS). The latter are highly 
reactive molecules able to induce a vast array of functional or structural damages 
at the molecular level and, in large part, through oxidant processes. It is a 
prevalent concept that ROS production is enhanced and that antioxidant defenses 
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are depressed in the course of sepsis and septic shock (Zimmerman, 1995). 
Besides activated neutrophils, other potential sources of ROS in sepsis include the 
activation of the xanthine oxidase pathway by ischemia reperfusion events 
(Schmidt et al., 1997), altered metabolism of eicosanoids, and disturbed 
mitochondrial respiration leading to enhanced electron bleed (Taylor et al., 1995). 
Many cell culture and animal investigations have established the pathophysiologic 
role of ROS in sepsis models (Demling et al., 1995; Lloyd et al., 1993; Schmidt et 
al., 1997; Taylor et al., 1995). These investigations have particularly emphasized 
the role of ROS in endothelial cytotoxicity (Minamiya et al., 1995). 
Besides TNF and ROS, other inducers of apoptosis have been shown to 
include steroids, IL-1, IL-6, IL-10, FasL, heat shock, nitric oxide (NO) and FasL-
expressing cytotoxic T lymphocytes (CTLs) (Roth & Hanspeter, 2004). Apoptotic 
cell death occurs primarily through three different pathways: (i) the extrinsic 
death receptor pathway (type I cells), (ii) the intrinsic (mitochondrial) pathway 
(type II cells) and (iii) the endoplasmic reticulum or stress-induced pathway 
(Janeway, 2004). The dysregulated apoptotic immune cell death may play a role 
in contributing to the immune dysfunction and multiple organ failure observed 
during sepsis and that blocking it can improve survival of experimental animals 
(Chung et al., 2003). The immune cells most affected by this dysregulated 
apoptotic cell death appear to be lymphocytes. Experiments conducted in RAG1-
/- mice that are totally deficient in mature T- and B-cells demonstrated that these 
mice have increased mortality in sepsis (Hotchkiss et al., 1999). Apoptosis of 
lymphocytes is frequently seen 12 hours following the onset of sepsis in the 
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thymus, spleen, and gut-associated lymphoid tissues (GALT). This in turn leads to 
immune surpression leaving the animal unable to fight the lethal effects of sepsis, 
resulting in multiple organ failure and eventual death. Furthermore, septic mice 
lacking the Fas cell death ligand had decreased mucosal B-lymphocyte apoptosis 
and improved survival compared with control mice (Chung et al., 1998). In 
addition, mice overexpressing the anti-apoptotic protein Bcl-2 in lymphocytes 
demonstrated improved survival in sepsis and their lymphocytes were resistant to 
sepsis-induced apoptosis (Hotchkiss et al., 1999). Finally, treatment of animals 
with compounds that inhibit activation of caspases (cell proteases that are 
activated in sepsis and result in disassembly of the cell) have been shown to 
improve survival in animal models of sepsis (Hotchkiss et al., 2000). Considered 
together, these studies present a compelling story that apoptosis-induced loss of 
cells of the immune system may be an important cause of the morbidity and 
mortality of this highly lethal disorder. 
In summary, severe sepsis and septic shock are characterized by multiple 
cardiovascular abnormalities, which include impairment in the distribution of 
microvascular blood flow that potentially lead to tissue ischemia. In addition, 
pathways of cellular injury, such as apoptosis-induced loss of cells of the immune 
system, which are entirely unrelated to O2 deprivation, are also likely to exist. It is 
within this complex pathophysiological framework that the role of NO, and thus 
its suitability as a therapeutic target shall be discussed (Chapter 2). 
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Chapter 2: Biology of Nitric Oxide (NO) 
2.1 Biosynthesis 
In mammalian cells, nitric oxide (NO) arises from the enzymatic oxidation of 
a terminal guanidino nitrogen of the amino acid, L-arginine (Furchgott & Zawadzki, 
1980) (Figure 2-1). Per mole of arginine, this reaction consumes 1 mol of molecular 
O2 and 1.5 mol of NADPH, yielding 1 mol of NO and 1 mol of L-citrulline. The 
responsible enzymes are a family of heme proteins known as NO synthases (NOS). 
All members of this family share a similar homodimeric structure, in which each 
monomer consists of a reductase domain and an oxygenase domain, separated by a 
short sequence (30 amino acids) for the attachment of the Ca2+-binding protein 
calmodulin. In addition to calmodulin, enzymatic activity requires the presence of 
four cofactors namely, flavin adenine di-nucleotide (FAD), flavin mono-nucleotide 
(FMN), tetrahydrobiopterin (BH4), and heme. 
There are three known isoforms of NOS, each the product of a different gene 
namely, neuronal NOS (nNOS or NOS-1), inducible NOS (iNOS or NOS-2), and 
endothelial NOS (eNOS or NOS-3). nNOS and eNOS were first described in rat 
cerebellum and bovine aortic endothelial cells respectively, but their tissue 
distribution is far wider than suggested by their names. Typical loci of nNOS 
expression include skeletal muscle and myenteric plexuses. eNOS is ubiquitous in 
vascular endothelium but may also be found in the placenta, kidney tubular epithelial 
cells (Forstermann et al., 1995), and neurons (Nathan & Xie, 1994a). In these tissues, 
the expression of nNOS and eNOS is constitutive, although it may be regulated 
(Michel  &  Feron,  1997).  For  instance,  the  levels  of  transcript  for  eNOS  in  the  















Figure 2-1: Current scheme for endothelium-dependent relaxation. Agent A, acting on receptor 
(R) of endothelial cell activates Ca2+ influx, with the increase in intracellular Ca2+ activating through 
calmodulin the endothelial nitric oxide synthase (eNOS), an oxygenase using L-arginine and NADPH 
as co-substrates, with FAD, FMN, and tetrahydrobiopterin as cofactors. NO diffuses to the smooth 
muscle cells where it activates guanylyl cyclase, with a resulting increase in cGMP, which initiates 
processes leading to relaxation. eNOS is expressed primarily in vascular endothelium, nNOS in 
neurons, and iNOS in macrophages. Both eNOS and nNOS are consitutively expressed and respond to 
Ca2+-calmodulin signaling. iNOS is induced by inflammatory mediators and is coupled to an activated 
calmodulin that does not require Ca2+ for activation. These three enzymes share L-Arginine as 
substrate, and many NOS inhibitors such as the L-Arginine analogs L-NMMA and L-NAME cannot 
distinguish isoforms. It must be noted that the three isoforms are differentially expressed throughout 
the cardiovascular system, and that one or more isoforms can be expressed in the same cell type. O2- 
and HbO2 are potent scavengers of NO (figure taken from Furchgott & Zawadzki, 1980).  
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vascular endothelial cells are increased by sheer stress (Topper et al., 1996) and 
exercise (Wang et al., 1997), variably affected by hypoxia (Toporsian et al., 2000), 
and reduced by inflammatory stimuli such as TNF-α (Nathan & Xie, 1994a). In the 
physiological state, the iNOS isoform is only present at a few locations, notably the 
respiratory epithelium, the gravid uterus (Nathan & Xie, 1994b) and perhaps the ileal 
mucosa (Hoffman et al., 1997). However, iNOS may be induced in a myriad of 
tissues by a wide array of agents. iNOS expression has been demonstrated in cell 
types as varied as macrophages, neutrophils, fibroblasts, vascular endothelial 
(Hoffman et al., 1999) and smooth muscle cells, endocardium, myocardium, renal 
tubular endothelium mesangial cells (Kunz et al., 1994), hepatocytes, pancreatic islet 
cells, neurons, astrocytes (Nathan & Xie, 1994b). The list of agents capable of 
inducing iNOS includes ultraviolet (UV) light, cyclic AMP-elevating agents, ozone, 
trauma, bacterial products (e.g. LPS, enterotoxins, lipoteichoic acid), and pro-
inflammatory cytokines (e.g. IL-1, interferon (IFN)-γ, TNF-α). Bacterial products and 
pro-inflammatory cytokines tend to act synergistically in promoting iNOS expression 
through signalling pathways that involve, but are not restricted to, activation of 
nuclear factor-κB (NF-κB). In contrast, many agents may oppose cytokine induction 
of iNOS. These include anti-inflammatory cytokines such as IL-10, growth factors 
such as tumour growth factor-β, and chemokines such as monocyte chemo-attractant 
protein-1 (Forstermann et al., 1995). 
In all isoforms of iNOS, calmodulin binding is an absolute prerequisite for 
enzymatic activity. In the cases of eNOS and nNOS, this binding necessitates 
relatively high concentrations of Ca2+, in the range of 0.1 – 1 µM (Forstermann et al., 
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1995). This property of the constitutive isoforms is crucial to the generalized role of 
NO in signalling because it allows the intermittent production of NO by cells in 
response to Ca2+ transients triggered by a pleiotropy of agonists. In contrast, iNOS is 
able to bind calmodulin at the nanomolar Ca2+ concentrations normally found in the 
cytosol in the basal state. Thus, once expressed, iNOS makes up for the steady 
production of NO at rates that may only be limited by the availability of substrates 
and cofactors. Mainly for these reasons the constitutive and inducible isoforms of 
NOS are often referred to as low- and high-output pathways of NO generation 
respectively.    
 
2.2 Biological chemistry and effects of NO 
At physiologic temperature and pressure, NO is a gas with water solubility of 
the same order of magnitude as O2 and CO2. Its complete lack of reactivity with water 
endows it a lipophilic character, allowing it unhindered passage through cellular 
membranes, thus accounting in large part for its biological role (Bonner & Stedman, 
1996). Although a free radical by virtue of its uneven number of valence shell 
electrons, the NO molecule is not highly reactive per se (Beckman & Koppenol, 
1996). In the biological milieu, its direct chemical interactions are limited to those 
with transition metals in various oxidation states, with other free radicals, and with 
molecular O2 (Wink & Mitchell, 1998). However the latter two classes of reactions 
give rise to more reactive compounds that are able to trigger cascades of events 
collectively termed “indirect” effects of NO. These may be conveniently contrasted 
with “direct” effects, the bulk part of which results from the modulation of enzymatic 
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activity related to interactions with iron contained in prosthetic groups. As a useful 
simplification, direct effects serve to promote homeostasis and occur at the low 
(nanomolar) NO concentrations that typically result from the regulated activation of 
constitutive NOS isoforms (i.e. nNOS and eNOS). In contrast, indirect effects may be 
deleterious to the host and occur at the high concentrations (micromolar) that are 
more easily achieved in the presence of continuous NO production, as related to 
iNOS expression. 
 
2.2.1 Direct effects of NO 
In vivo, an essential metabolic fate of NO that limits its local concentration 
is its diffusion into red blood cells, where it oxidises the ferrous iron of 
oxyhaemoglobin to yield the nitrate anion (NO3-) and methaemoglobin. In the 
physiological state, this mechanism is sufficient to keep the concentration of NO 
in the nanomolar range, at least in non-hydrophobic compartments (i.e. outside 
biological membranes) (Beckman & Koppenol, 1996). In these conditions, direct 
effects of NO will be prevalent. The best characterised of the effects is the 
activation of soluble guanylyl cyclase (sGC), leading to the formation of cyclic 
guanosine monophosphate (cGMP), which in turn proceeds through several 
downstream elements including cGMP-dependent protein kinases, cGMP-
regulated phosphodiesterases, and cGMP-gated ion channels (Denninger & 
Marletta, 1999). In part, through altered intracellular Ca2+ dynamics, these events 
mediate a wide range of physiological responses (Nathan & Xie, 1994a) namely, 
relaxation of vascular and non-vascular smooth muscle, inhibition of platelet 
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aggregation, and inhibition of leukocyte adhesion to the endothelium, which are 
the most relevant to the topic of sepsis. Another significant direct effect of NO is 
its interaction with cyclo-oxygenase (COX) mentioned in Chapter 2, Section 
2.2.3. Still another direct effect that merits comment in the framework of the 
present review is that NO at high concentrations competes with O2 at the active 
site of NOS, thus providing a feedback mechanism of its own synthesis 
(Griscavage et al., 1995). The constitutive isoforms of NOS are much more 
sensitive to this auto-inhibition than iNOS, which suggests that in conditions 
associated with iNOS expression, the enhanced NO flux from iNOS might reduce 
activity of eNOS. Evidence along this line will be cited in Chapter 2, Section 
2.3.4.  
Importantly, NO also down-regulates the activity of two key enzymes in 
oxidative metabolism namely, cytochrome oxidase (Brown, 1999), which 
catalyses the terminal step in the mitochondrial electron transport chain, and 
mitochondrial aconitase (Gardner et al., 1997), which plays an essential role in 
the citric acid cycle. The latter effect has been shown to be markedly enhanced in 
acidic conditions, such as those prevailing in shock of various aetiologies, 
indicating that even low levels of NO may have a profound negative influence on 
cellular energetic in such circumstances (Gardner et al., 1997). In contrast with 
this potentially deleterious action, NO may be highly protective against oxidative 
stress by acting at several levels namely, (i) it is able to reduce highly toxic 
hypervalent metal- O2 complexes such as the ferryl cation (Fe4+ = O) produced 
from the interaction of hydrogen peroxide with heme (Jourd’heuil et al., 1998), 
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(ii) it inhibits iron-catalysed generation of the hydroxyl radical (Fenton reaction) 
(Miles et al., 1996), (iii) it reacts with lipid hydroperoxyl radicals to terminate 
chain lipid peroxidation (Wink & Mitchell, 1998), and (iv) it scavenges the 
superoxide radical (Rubbo et al., 1994). 
To summarize, the direct biological effects of NO range from 
physiological regulation to protection to cytotoxicity, depending on particular 
circumstances, such as the amount produced and the specific chemical 
environment. This ambivalent character of NO will become even more apparent 
when its indirect effects are considered.   
 
2.2.2 Indirect effects of NO 
The indirect effects of NO can be divided into two different groups 
namely, (i) reactions of NO with O2 and, (ii) NO with superoxide. In the first 
instance when NO reacts with O2, NO decays to nitrite (NO2-) by a reaction with 
O2 in aqueous solutions, via steps involving the generation of NO2 and a potent 
nitrosating species, dinitrogen trioxide (N2O3). The rate of this reaction is 
inversely proportional to the square of NO concentration and thus its importance 
is mostly marginal in physiological conditions (Beckman & Koppenol, 1996). 
However due to the lipophilic character of both NO and O2, the reaction is 
markedly accelerated in the hydrophobic compartment of biological membranes, 
where formation of N2O3 may increase by a factor of 15,000 in conditions of high 
NO production (Miller & Sandoval, 1999), indicating that N2O3 can become a 
significant nitrosating agent in specific conditions and specific locations. 
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Generation of N2O3 can lead to the formation of N-nitrosamines, which are 
carcinogenic compounds (Hecht, 1997), and S-nitrosothiols. S-nitrosylation of 
proteins is increasingly recognised as a ubiquitous regulatory reaction comparable 
with phosphorylation, and S-nitrosothiols appear to play significant roles in a 
large number of biological processes (Broillet, 1999). For example, activation of 
Ca2+-dependent K+ channels in vascular smooth muscle via S-nitrosylation has 
been shown to partially account for NO-mediated vascular relaxation (Bolotina et 
al., 1994). It is noteworthy that S-nitrosylation of critical thiol groups inhibits the 
activity of glyceraldehyde-3-phosphate dehydrogenase (GADPH) (Mohr et al., 
1999). In conditions of anaerobic metabolism, such as that induced by tissue 
hypoxia in shock states, the blockade of GADPH is liable to suppress glycolysis 
as the last source of ATP generation and thus, to precipitate energetic deprivation 
and cell death. The relationships of nitrosative stress and NF-κB activity will be 
commented upon in Chapter 2, Section 2.2.3. Finally, reduced glutathione (GSH), 
due to its high affinity for both reactive nitrogen and O2 species, is a central 
biomolecule involved in the cellular defence against nitrosative and oxidative 
stress (Wink & Mitchell, 1998). Depletion of GSH has been shown to markedly 
increase NO-dependent cytotoxicity (Walker et al., 1995). S-nitrosothiols, 
including the S-nitroso-adduct of GSH itself (S-nitrosoglutathione) may inhibit 
several enzymatic pathways involved in the maintenance of the GSH pool. It 
appears that in circumstances associated with high NO production, nitrosative 
stress enhances the cellular susceptibility to oxidant-mediated damage, providing 
an important cycle of cytotoxic amplification in inflammatory conditions.  
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On the other hand, NO rapidly reacts with the superoxide radical (O2-) to 
yield peroxynitrite, a highly reactive oxidant species, at near diffusion limited 
rate. The half-life of peroxynitrite is short (~ 1 sec), but sufficient to allow 
significant interactions with biomolecules. It is currently appreciated that most 
biological effects of peroxynitrite are due either to its protonated form, 
peroxynitrous acid (HOONO), or to reactive intermediates formed in the reaction 
of peroxynitrite with CO2 (Squadrito & Pryor, 1998). Several studies have shown 
that peroxynitrite formation in biological systems is mostly restricted to quite 
specific conditions characterised by abnormally high and approximately equal 
fluxes of NO and O2- (Miles et al., 1996). At physiological levels of NO 
production, the tissue concentrations of superoxide dismutase (SOD) are 
sufficient to divert O2- away from NO towards transformation into H2O2. At high 
levels of NO production, a significant imbalance between the fluxes of NO and 
O2- leads to rapid scavenging of any peroxynitrite formed by the species present 
in excess, according to either reaction 1 or reaction 2: 
 
(1) HOONO + O2- + H+ Æ NO2 + O2 + H2O 
(2) HOONO + NO Æ NO2 + NO2- 
 
Therefore if one considers two distinct source of both NO and O2-, one can 
predict that excess NO near its source will dictate nitrosative chemistry 
(formation of N2O3), as well as direct effects of NO (Wink & Mitchell, 1998). 
Diffusing away towards the O2- source, NO dilutes so that at some point between 
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both sources peroxynitrite formation prevails. These considerations may have 
important implications in the cytotoxicity elicited by inflammatory cells. Different 
time courses and rates of O2- and NO production will allow preferential biological 
targeting, while limiting consequences on the cell of origin. In this regard, it 
appears that endothelial cells probably are critically situated to suffer from much 
of the peroxynitrite-mediated oxidative damage in inflammatory conditions.  
Peroxynitrite is in fact a major source of oxidant stress, both directly (e.g. 
initiation of lipid peroxidation (Hogg & Kalyanaraman, 1999)) and indirectly. The 
indirect enhancement of oxidant stress, by peroxynitrite is mediated by its 
reaction with GSH, which inactivates this key element of antioxidant defences 
(Arteel et al., 1999). It is now known that most of the deleterious effects on 
cellular energetic previously attributed to NO itself in fact are mediated by 
peroxynitrite, which is able to irreversibly inhibit several steps in the 
mitochondrial electron transport chain (ETC) via binding to Fe-S clusters (Brown, 
1999). In addition to its direct effect on mitochondria, peroxynitrite also impairs 
cellular energetic by an indirect way, implicating DNA damage and activation of 
the nuclear enzyme poly-(ADP-ribose) polymerase (PARP), a pathway 
recognised as a major mechanism of NO/peroxynitrite-mediated cytotoxicity 
(Szabo & Dawson, 1998). Peroxynitrite may produce two types of DNA damage 
namely (i) the modification of DNA bases via both oxidation and nitration 
reactions and, (ii) the induction of nicks and breaks in the DNA strand (Szabo & 
Ohshima, 1997). DNA single-strand breakage is the obligatory trigger for the 
activation of PARP, which then catalyses the cleavage of its substrate 
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nicotinamide adenine dinucleotide into ADP-ribose and nicotinamide (Szabo et 
al., 1997). PARP covalently attaches ADP-ribose to various nuclear proteins and 
rapidly depletes the cellular nicotinamide adenine dinucleotide stores, thereby 
slowing the rate of glycolysis, electron transport, and ATP formation, thus 
resulting in cell dysfunction and death via the necrotic pathway (Szabo & 
Dawson, 1998). Several biological effects of peroxynitrite are related to nitration 
of tyrosine residues in proteins. Indeed, the presence of nitrotyrosine in tissues has 
been regarded as a footprint of peroxynitrite generation (Beckman & Koppenol, 
1996), although it is now known that tyrosine nitration may also occur through 
another pathway involving the reaction of the nitrite anion with leukocyte-derived 
hypochlorous acid (Eiserich et al., 1998). Tyrosine nitration of manganese SOD 
in mitochondria leads to enzyme inhibition (MacMillan-Crow et al., 1996), with 
the possible consequence of promoting peroxynitrite generation in the 
mitochondria. Disorganization of cell architecture by nitration of cytoskeletal 
proteins has also been described (Banan et al., 2000). 
 
2.2.3 NO and inflammation 
Abundant data indicate that, depending on concentration and particular 
circumstances, NO may exert either pro- or anti-inflammatory effects. As an 
example, NO has complex effects on the biosynthesis of prostanoid mediators of 
inflammation, being able to either stimulate or inhibit COX (Goodwin et al., 
1999), to inhibit thromboxane synthase, and to affect prostacyclin synthase in a 
bimodal manner (i.e. activation by low concentrations and inhibition by high 
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concentrations of NO (Wade & Fitzpatrick, 1997). NO has major interactions 
with the pathways of gene expression controlled by the transcription factor NF-
κB. When activated by various extracellular inflammatory triggers (e.g. 
stimulation of CD14 by LPS, stimulation of TNF or IL-1 receptors, oxidant 
stress), NF-κB translocates to the nucleus, where it induces the transcription of 
numerous genes coding for proteins involved in inflammation, such as cytokines, 
leukocyte-endothelial adhesion molecules, and iNOS (Janssen-Heininger et al., 
2000). Both activation (Kalra et al., 2000) and inhibition (delaTorre et al., 1999) 
of NF-κB activity by NO have been described. Although the actual outcome may 
depend on cell type and specific conditions, studies showed that modest up-
regulation of NO production related to incipient iNOS expression at an early stage 
of inflammation would stimulate NF-κB activity, thus resulting in self-
amplification of the inflammatory response (Janssen-Heininger et al., 2000). Later 
on, by contrast, higher concentrations of NO would have the opposite effect, 
providing a feedback mechanism that would oppose unlimited expression of 
genes regulated by NF-κB. 
 
2.2.4 NO: A biological double-faced Janus? 
We have summarised the multifaceted actions of NO, many of which may 
seem contradictory at first glance (Moncada et al., 1991). However a critical 
analysis of the physiological chemistry involved provides a conceptual framework 
that helps to distinguish between beneficial versus detrimental effects of NO. 
Depending on the rate, timing, and spatial distribution of NO production, as well 
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as the chemical microenvironment (e.g. presence of ROS, redox status of the cell), 
NO acts either as a direct signalling messenger or as an indirect toxic effector via 
the formation of various reactive nitrogen species (RNS). Indeed both functions 
may be occurring at the same time (i.e. spatially targeted production of NO may 
simultaneously enhance the antimicrobial function of the neutrophil respiratory 
burst while protecting host cells from oxidant injury (Fang, 1997) and perhaps 
preventing the uncontrolled explosion of the inflammatory response (e.g. down-
regulation of NF-κB activation). At other times, the cytotoxic potential of RNS 
may turn against the host, as has been well documented in some murine models of 
infection, such as Influenza A pneumonitis (Karupiah et al., 1998) or intestinal 
and liver injury caused by T. gondii (Khan et al., 1997). These considerations are 
of paramount importance to anyone striving to reconcile the mass of apparently 
contradictory data concerning the role of NO in the pathogenesis of tissue damage 
incurred by the host in the course of severe sepsis and septic shock.  
 
2.3 Evidence for the involvement of NO in sepsis and septic shock 
2.3.1 In vivo overproduction of NO in sepsis 
The strength of the evidence that associates sepsis and overproduction of 
NO varies depending on animal species and type of septic insult. The most 
abundant data are available in small rodents (rats and mice) exposed to a large 
dose of LPS (i.e. milligram/kilogram) administered as bolus by the intravenous 
(i.v.) or intraperitoneal (i.p.) route. In these conditions, there is classically a 
biphasic fall in arterial blood pressure, with early hypotension, followed by 
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transient recovery and then delayed hypotension, starting in the 3rd – 4th hr of 
endotoxemia. Both stages of hypotension are related to a fall in cardiac output 
(hypodynamic type of shock) associated with a marked depression of vascular 
reactivity to vasoconstrictor agents (Fink & Heard, 1990). Early activation of 
eNOS and delayed expression of iNOS may be the major events responsible for 
this typical biphasic fall of arterial blood pressure (Szabo, 1995). In addition to 
causing cardiovascular collapse, endotoxin administration in these conditions 
induces tissue hypoxia, multiple organ damage, and dysfunction, thus reproducing 
several consequences of septic shock (see Chapter 1, Section 1.3). In these 
models, the plasma concentration of nitrite and nitrate (NOx), a global indicator of 
whole body NO production, progressively rises in a few hours from a baseline in 
the range of a few micromolar to several hundred (Millar & Thiermermann, 1997; 
Szabo et al., 1995) or even thousands of micromolar (Liaudet et al., 1998). An 
abundance of studies have linked this overproduction to the stimulated expression 
of iNOS, as shown either with Northern and Western analysis or by the assay of 
Ca2+-independent NOS activity in organs as diverse as the lung (Crespo et al., 
1999), liver (Hom et al., 1995), intestine (Brown & Tepperman, 1997), stomach 
(Castaneda et al., 1999), pancreas (De Kimpe et al., 1995), spleen (Losonczy et 
al., 2000), myocardium (Ullrich et al., 2000), aorta (Wu et al., 1999), diaphragm 
(Lin et al., 1998), and pulmonary arteries (Terraz et al., 1999). With 
immunohistochemistry or in situ hybridization, the iNOS protein or mRNA have 
been localised to a variety of cell types, including vascular smooth muscle, 
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vascular endothelium, cardiac myocytes, airway epithelium, and inflammatory 
cells (Liu et al., 1997). 
As mentioned earlier (Chapter 1, Section 1.2.2), endotoxemic models of 
sepsis in small rodents often has been criticised for their limited clinical 
relevance. In the rat, for example, 4- to 5-fold increase in plasma NO3- or NOx 
above normal have been reported from the 6th to the 24th hr following CLP, with 
absolute concentrations in the range of 50 µM (i.e. far lower than the peak values 
in endotoxemia) (Aranow et al., 1996; Shieh et al., 2000). Diffuse iNOS 
expression has also been documented in these infectious models (Okamoto et al., 
2000; Shieh et al., 2000). Data on the time course of lung iNOS expression in rat 
CLP point to a greater level of complexity than hitherto appreciated. Although 
iNOS mRNA steadily increased until the 42nd hr post CLP, the amount of iNOS 
protein peaked before the 24th hr and largely declined thereafter, suggesting that 
post-transcriptional mechanisms progressively develop to limit the importance of 
iNOS expression in this model (Okamoto et al., 2000). In larger mammals, the 
evidence for an association of sepsis with NO overproduction is much less 
detailed and also less convincing than in rodents. In the dog, endotoxemia (Forfia 
et al., 1998) has been associated with relatively modest increases in plasma NOx 
(< 50% above control), even when the observation period extended to 24 hr or 
longer (Cobb et al., 1995). In this species, the myocardial enzymatic activity of 
iNOS and eNOS increased 4- and 6-fold respectively, 6 hr after the injection of 
LPS (Wolfard et al., 2000), and the iNOS protein was detected by 
immunohistochemistry in the lung interstitium, capillary walls, and alveolar 
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inflammatory cells after 24 hr of bacteremia (Freeman et al., 1998). In porcine, 
neither short-term (< 5 hr) (Saetre et al., 2000) nor more prolonged (9-18 hr) 
endotoxemia (Pastor et al., 2000) was associated with an increase in the plasma 
NOx levels. At 6 and 9 hr after continuous i.v. infusion of LPS in the pig, iNOS 
mRNA in the liver had a diffuse appearance (Pastor et al., 2000), with the 
expression of the iNOS protein restricted to regions around the large veins in the 
liver. In sheep, similar to the dog, i.v. bolus injections of LPS raise plasma NOx 
modestly (Allman et al., 1996). It must be underscored that these experimental 
models of sepsis in large mammals are associated with major hemodynamic 
disturbances, and are being used quite extensively in pathophysiologic 
investigations of sepsis and septic shock. 
Not surprisingly, the evidence for an overproduction of NO in human 
sepsis and septic shock is circumstantial and is essentially based on the 
demonstration of higher plasma levels of NOx in small groups of septic patients in 
comparison with non-septic controls (Satoi et al., 2000; Tagan et al., 1998; 
Terregino et al., 2000). In spite of possible differences related to criteria for the 
definition of sepsis (Chapter 1, Section 1.1) and analytical methodology, it may 
be stated that the mean absolute concentrations reported by these studies rarely 
exceeded 100µM, a range in better agreement with experimental observations 
from bacteremic, as opposed to endotoxic models in rodents. Several authors 
discussed the possibility that these relatively modest elevations might reflect 
decreased NOx excretion by the kidney rather than NO overproduction (de Werra 
et al., 1997; Wong et al., 1995). However they noted that plasma NOx could be 
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elevated even in septic patients without any evidence of impaired renal function. 
Furthermore, two independent studies found that plasma NOx was significantly 
higher in patients with septic compared with cardiogenic shock (two conditions in 
which renal function impairment is equally likely) (Tagan et al., 1998). 
Collectively, these data suggest that NO overproduction indeed does occur in 
human sepsis although probably not to the same extent as in rodent endotoxemic 
models. Several of the cited studies reported a certain degree of correlation 
between plasma NOx and the severity of sepsis, as assessed either by the number 
of organ failure (Groeneveld et al., 1996) or by hemodynamic status (Annane et 
al., 2000). However such correlations have not been found in other studies (van 
der Berg et al., 1994), and elevation of plasma NOx is not obligatory in severe 
sepsis (Pastor & Suter, 1998), as shown by observations in trauma (Ochoa et al., 
1991) or neutropenic patients (Neilly et al., 1995). Furthermore, neutrophils from 
septic patients have been reported to display abnormally high amounts of iNOS 
mRNA (Tsukahara et al., 1998) or NOS activity (Goode et al., 1995). The iNOS 
protein has been detected in alveolar macrophages obtained by bronchoalveolar 
lavage from septic subjects with, but not without, the acute respiratory distress 
syndrome (Kobayashi et al., 1998), the acute respiratory distress syndrome being 
a well-known complication of sepsis. In a study carried out by Annane and co-
workers (2000), a group of patients in septic shock required emergency surgical 
debridement of cellulitis. iNOS activity was measured in skin, muscle, fat, and 
artery samples obtained on that occasion. Compared with normal tissue dissected 
at some distance from the nidus of infection, iNOS activity was massively 
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increased in all samples taken from necrotic areas, although not from surrounding 
inflamed areas.  
 
2.3.2 NOS gene disruption 
Considering that the main reason for NO overproduction in sepsis is the 
appearance of iNOS in various locations, our knowledge on the pathological role 
of NO in this condition should at least in theory benefit enormously from studies 
carried out in animals genetically unable to express this enzyme. The targeted 
disruption of the iNOS gene in the mouse was carried out concomitantly by three 
independent groups, who all issued their first reports in 1995 (Laubach et al., 
1995; MacMicking et al., 1995; Wei et al., 1995). Mice either heterozygous 
(iNOS +/-) or homozygous for the mutation (iNOS -/-) were found to be fertile 
and phenotypically undistinguishable from their wild-type littermates (iNOS +/+) 
in the absence of immunologic stimulation. On activation in vitro with LPS/IFN-γ 
or other stimuli, the peritoneal macrophages of iNOS -/- individuals has a 
preserved respiratory burst (MacMicking et al., 1997), but produced no NOx and 
failed to express iNOS mRNA, as well as the iNOS protein (Laubach et al., 1995; 
MacMicking et al., 1995; Wei et al., 1995). On acute exposure to LPS in vivo, the 
iNOS -/- mice failed to show an increase in blood levels of nitrate/nitrite (NOx) 
(Laubach et al., 1995; MacMicking et al., 1995), although the mutation had no 
effect on the time course of cytokine (TNF-α) concentration in the plasma 
(MacMicking et al., 1995). The mutation significantly attenuated the hypotensive 
effect of LPS in conditions of anesthesia, but was without effect on LPS-induced 
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liver injury (MacMicking et al., 1995). In terms of LPS-induced death, the three 
studies, which differed regarding the genetic background of the transgenic 
animals, yielded somewhat discordant results. Wei et al., (1995) reported 
complete protection afforded by the mutation. In contrast, Laubach et al., (1995) 
found that the iNOS -/- mice were not protected. Testing several doses of LPS in 
both anesthetized and conscious mice, MacMicking et al., (1995) found a 
protective effect of the mutation only in anesthetized mice or conscious mice 
injected with a high dose of LPS. In the absence of a concomitant treatment with 
parenteral fluids and antimicrobial agents, the mortality following polymicrobial 
sepsis induced by CLP was either increased (Cobb et al., 1999) or not 
significantly different (Hollenberg et al., 2000) in iNOS -/- compared with iNOS 
+/+ mice. However, when fluids and antibiotics were administered, survival to the 
septic insult was clearly better in knockouts than in wild-type littermates (55% vs. 
24%, P<0.01) (Hollenberg et al., 2000). 
Interestingly, recent work using bone marrow-derived macrophages 
(BMDMφs) generated from eNOS -/- and wild type mice indicate a reciprocal 
relationship between eNOS-derived NO and NO produced by iNOS, such that 
constitutive low level NO production is essential for maximal iNOS expression in 
response to LPS in these cells (Connelly et al., 2003; Connelly et al., 2005). Thus 
it would seem that eNOS is needed to obtain maximal iNOS expression and, in 
turn, eNOS might play a pro-inflammatory role in septic shock. In aortic rings of 
eNOS -/- mice, LPS-induced changes in vascular reactivity and iNOS expression 
were profoundly suppressed as compared to wild type mice (Vo et al., 2005). 
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Conversely, it was found that LPS-treated eNOS -/- mice exhibited increased 
susceptibility to endotoxin-induced acute renal failure as seen by a rise in serum 
creatinine, decrease in glomerular filtration rate and renal blood flow, mild 
tubular necrosis, and increased fractional excretion of sodium (Wang et al., 2004). 
Also, a study carried out by Kozak & Kozak (2003) showed that lack of eNOS, 
led to the exaggeration of fever in mice induced by turpentine oil and had no 
effect on the febrile response to LPS. Lack of iNOS or nNOS, on the other hand, 
led to a partial reduction of fever in LPS mice and no effect on fever induced by 
injection of turpentine. Thus it would seem that iNOS and nNOS are involved in 
the generation of fever in mice injected with LPS, while eNOS appeared to 
contribute to downregulation of fever induced by turpentine (Kozak & Kozak, 
2003). 
Sepsis was found to impair both EDRF- and EDHF-mediated dilation in 
response to acetylcholine in skeletal muscle of wild type mice (Lidington et al., 
2007). In contrast, nNOS -/- mice were conferred protection against this 
impairment when the dilation occured via the EDRF but not EDHF pathway 
(Lidington et al., 2007). Furthermore nNOS, rather than iNOS, appeared to play 
an important role in modulating LPS-stimulated PMN recruitment and lung 
clearance of K. pneumoniae, and in turn protecting the lung from stressor-induced 
lung injury (Greenberg et al., 1999).  
In summary, data from genetically engineered mice that lack the capability 
to express NOS support neither a predominantly deleterious effect nor a 
protective effect of NO overproduction in sepsis. These results must be viewed 
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with consideration of the limitations inherent in the use of transgenic animals for 
such purpose. For instance, one can never be sure that the mutants have not 
evolved mechanisms that compensate for the missing gene product, although no 
evidence of such a confounding factor has been found. For instance, these mice 
do not overexpress other isoforms of NOS on stimulation with LPS (Kristof et al., 
1998). Moreover, the data is limited to the single species in which the genetic 
manipulation has been possible. Finally, the function of the targeted gene product 
is totally suppressed during the complete course of the pathologic process. In the 
case of iNOS, and remembering the intrinsically dual effects of NO, as outlined in 
Chapter 2, Section 2.2, this leaves open the possibility that suppression of activity, 
either partially and/or limited to a specific timeframe, could still benefit the septic 
host. Presently, and in spite of the disadvantages in terms of specificity, the only 
feasible approach to investigate the issue is the modulation of NOS activity via 
pharmacological means. 
 
2.3.3 NOS inhibitors 
To investigate the possible role of NO in the pathogenesis of severe sepsis 
and septic shock, the primary approach has been via the administration of agents 
able to block NOS activity. To that effect, the most widely used compounds have 
been analogues of L-arginine, such as NG-nitro-L-arginine (L-NNA), NG-nitro-L-
arginine methyl ester (L-NAME), or NG-mono-methyl-L-arginine (L-NMMA) 
(Figure 2-1). Although specialized biochemical studies revealed some minor 
potency and selectivity differences along with slightly different pharmacokinetic 
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profiles, they are generally referred to as non-selective, strong, competitive 
antagonists of L-arginine binding to the catalytic site of NOS (Rees et al., 1990). 
The only known endogenous inhibitor of NOS is asymmetrical dimethyl arginine 
(ADMA), which probably plays a role in some cases of renal failure (Vallance & 
Leiper, 2004). Most in vivo experimental and clinical data have been accumulated 
by the use of these compounds. Briefly, their administration to shocked patients 
(Petros et al., 1991) and animals (Thiemermann & Vane, 1990) restores blood 
pressure and systemic vascular resistance. Additionally, hypotension induced in 
vivo in dogs by the well-known septic shock mediator TNF-α can also be reversed 
by these compounds (Kilbourn et al., 1990). However, the abovementioned L-
arginine analogues, which non-selectively block the activities of all isoforms of 
NOS, proved to have essentially deleterious effects in experimental endotoxic 
shock. For example, the non-selective NOS inhibitors reduced cardiac output and 
blood flow to splanchnic organs (Liaudet et al., 1996), exacerbation of 
microvascular hyperpermeability (Filep et al., 1997), enhancement of tissue 
damage and/or amplification of inflammation in the liver, intestine, kidney, and 
lung (Vos et al., 1997; Wang et al., 1994; Schwartz et al., 1997; Olszanecki & 
Chlopicki, 1999), reduction of myocardial contractility (Afulukwe et al., 2000), 
aggravation of systemic lactic acidosis (Pedoto et al., 1998), more marked 
bacterial translocation from the gut lumen into the mesenteric lymph nodes 
(Eleftheriadis et al., 2000), and increased mortality (Koga et al., 1995). One 
possible reason behind the deleterious effects of the non-selective NOS inhibitors 
is the lack of discrimination of these compounds among the different isoforms of 
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NOS (Wright et al., 1992). Indeed, while targeting iNOS-mediated 
overproduction of NO might be useful, concomitant inhibition of eNOS is likely 
counterproductive by impairing essential functions of the endothelium such as 
agonist-stimulated vasodilation and down-regulation of activated blood cell 
adherence. The importance of eNOS-derived NO in septic conditions has been 
emphasized by the observation that transgenic mice over-expressing eNOS were 
partly protected against LPS (Yamashita et al., 2000). Previously, the importance 
of eNOS-derived NO had been suggested by data showing that some detrimental 
effects of non-selective inhibitors could be abrogated by the co-administration of 
an NO donor, such as S-nitrosopenicillamine (Boughton-Smith et al., 1990), or by 
inhalation of the NO gas (Neviere et al., 2000). Also, drugs that prevent the 
induction of iNOS have been beneficial in conditions where non-selective NOS 
inhibitors were deleterious (Nava et al., 1991). Finally, it already has been noted 
that sepsis per se leads to endothelial dysfunction, which in part, may be related to 
reduced eNOS expression and activity (Liu et al., 1996). In such conditions, 
further inhibition of eNOS by non-selective inhibitors can exacerbate endothelial 
dysfunction and further impair microvascular homeostasis. These considerations 
imply that a more suitable approach in septic shock would be the use of agents 
able to selectively inhibit the activity of iNOS. 
Several compounds with relative selectivity towards iNOS have been 
developed and tested in vivo in experimental sepsis. N-(3-
(aminomethyl)benzyl)acetamidine (1400W) is the most selective inhibitor of 
purified human iNOS reported to date (Garvey et al., 1997). All previously 
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described selective inhibitors of iNOS such as isothioureas (Southan et al., 1995), 
aminoguanidine (Wolff & Lubeskie, 1995), cyclic amidines (Moore et al., 1996), 
and N-iminoethyl-L-ornithine (Conner et al., 1995) are at best 30-fold more 
potent against iNOS than eNOS. 1400W was shown to be greater than 5000- and 
200-fold more potent against purified human iNOS than eNOS and nNOS 
respectively. In contrast to non-selective NOS inhibitors, which increase vascular 
reactivity and arterial blood pressure at all stages of endotoxic shock, the effects 
of selective iNOS inhibitors were restricted to the delayed, iNOS-dependent stage, 
whereby there was an improvement in arterial blood pressure (Szabo et al., 1994) 
and in the vascular reactivity to vasoconstrictors (Thiemermann et al., 1995), or 
the contractility of vascular rings in vitro (Szabo et al., 1996). In addition, 
administration of selective iNOS inhibitors to endotoxemic rodents decreased 
(Szabo et al., 1994) or did not change mortality (Yen et al., 1997), but never 
increased it. Furthermore, studies done by both Schwartz et al., (1997) and 
Fischer et al., (1999), support the finding that in endotoxemia, iNOS-derived NO 
may inhibit eNOS, leading to endothelial dysfunction that may be reversed by 
selective iNOS inhibitors. When administered to normal rats, selective iNOS 
inhibitors did not elicit significant pressor responses, confirming a lack of eNOS 
inhibition, at least when using low doses. To be complete, several rodent studies 
failed to show any beneficial effect of selective iNOS inhibitors on LPS-induced 
organ damage (Gundersen et al., 1997; Vos et al., 1997; Wray et al., 1998). There 
are a few reports describing the deleterious effects of these compounds on lung or 
liver injury (Huang et al., 1997; Pheng et al., 1995). In one study, a very high 
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(150 mg kg-1) and potentially non-selective dose of aminoguanidine was 
employed (Pheng et al., 1995). Thus, it must be stressed that selectivity for iNOS 
for all these compounds is only relative and that they may block all NOS isoforms 
when used at sufficiently high doses (Rosselet et al., 1998). 
The administration of selective iNOS inhibitors has been consistently 
beneficial in rodent endotoxic (LPS) shock models, suggesting a prominent 
deleterious effect of NO overproduction in these conditions. However, the 
evidence gathered from bacteremic models (i.e. CLP-induced septic shock model) 
showed that the implication of NO overproduction in cardiovascular failure 
appears less well established than in endotoxic shock models. The findings from 
these studies were heterogeneous, both in terms of cardiovascular effects and 
survival. They include: (i) exacerbation by L-NAME of renal and intestinal 
vasoconstriction (Spain et al., 1994a; Spain et al., 1994b), (ii) aggravation by 
aminoguanidine, in large dose (150 mg kg-1), of intestinal mucosal and liver 
damage (Lorente et al., 2000), (iii) reversal by L-NNA of vascular hyporeactivity 
to norepinephrine (NE) (Landin et al., 1994), (iv) prevention of acute 
cardiovascular collapse and prolonged survival for at least a few hours by L-
NMMA (Strand et al., 1998), and (v) improvement of cardiac output and organ 
blood flow by S-aminoethyl-isothiourea (Saetre et al., 2000). These observations 
do not preclude, and may provide evidence for, a participation of NO 
overproduction to organ injury in bacteremic sepsis. However, in view of the 
multiple and opposing roles of NO, the effects of NOS inhibitors on the outcome 
of sepsis appear highly dependent on the experimental conditions, which include 
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the dose and timing of intervention as discussed previously (Chapter 1, Section 
1.2).  
 
2.3.4 NO donors 
Thus apart from encouraging results with selective inhibitors of iNOS in 
sepsis, it must be noted that there still exists a vast amount of information on the 
potentially dangerous side-effects of non-selective NOS inhibition in sepsis as 
mentioned above (Chapter 2, Section 2.3.3). In fact, some studies show that 
pathology and mortality can actually be increased by these non-selective 
inhibitors administered in vivo in rodents and canines (Cobb et al., 1992; Evans et 
al., 1994; Nava et al., 1992). Accordingly, LPS-treated rabbits (Pastor et al., 
1995) and dogs (Zhang et al., 1997) benefited from NO supplementation during 
shock which helped maintain organ perfusion. Interestingly, in the canine model, 
the effects of an NO donor were organ specific that is, fractional blood flow 
increased in the mesenteric bed, remained unchanged in the renal bed but 
decreased in the femoral bed upon SIN-1 (3-morpholino-sydnonimine) treatment. 
In another experimental setting, the NO donor, S-nitroso-N-acetylpenicillamine 
(SNAP), provided significant protection in murine traumatic shock (Christopher 
et al., 1994). 
In recent years, a novel class of nitric oxide-releasing non-steroidal anti-
inflammatory drug (NO-NSAID) derivatives has recently been described which 
exert anti-inflammatory activities but produce significantly less gastrointestinal 
injury than the parent non-steroidal anti-inflammatory drugs (NSAIDs) from 
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which they were derived (for reviews, see Burgaud et al., 2002; Ignarro et al., 
2002; Keeble & Moore, 2002; Wallace & Soldato, 2003). Despite suppressing 
gastric prostaglandin synthesis, NO-NSAIDs do not reduce gastric mucosal blood 
flow (Wallace et al., 1994a). This is presumably attributable to the vasodilator 
properties of the NO released from these compounds. It is important to note, 
however, that the NO-NSAIDs do not alter systemic arterial blood pressure in 
healthy laboratory animals or in healthy human volunteers (Wallace et al., 1995a; 
Yamamoto et al., 2000), so the NO release must occur slowly and in amounts too 
small to significantly affect systemic vascular tone. Pharmacokinetic studies have 
in fact confirmed this prolonged release of small amounts of NO from NO-
NSAIDs (Carini et al., 2001). This slow release of NO is due to the involvement 
of esterases in NO-NSAID catabolism, which confirms that an ester bond links 
the parent compound to the nitroxybutyl moiety (Cirino et al., 1995) (Figure 2-2). 
While standard NSAIDs induce neutrophil adherence to the vascular endothelium 
(Asako et al., 1992), NO-NSAIDs do not (Wallace et al., 1994b). Again, it is 
most likely that NO released from these agents accounts for the lack of neutrophil 
adherence. Indeed, NO-NSAIDs can suppress neutrophil adherence induced by 
potent chemotaxins, thus expanding the anti-inflammatory profile of these drugs 
over that of the parent drugs (Wallace et al., 1999). Interestingly, a study done in 
endotoxic rats administered with the NO-NSAID, flurbiprofen 4-
nitroxybutylester, showed that despite being unable to affect the acute systemic 
effects of endotoxin administration, it was still able to protect the gastrointestinal 
mucosa from injury, possibly through preservation of mucosal blood flow 
















Figure 2-2: The enzymatic catabolism of NO-NSAID. The NO released from the NO-NSAID 
derivatives is able to counteract some of the detrimental effects of cyclooxygenase inhibition, 
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(Wallace et al., 1995b). In another study, administration of nitroparacetamol had 
no effect on organ dysfunction, which is a critical symptom of endotoxaemia 
(Marshall et al., 2006).   However   nitroparacetamol   was   able to target pro- 
inflammatory   processes   that   result   in    the    down-regulation   of 
iNOS/COX-2 induction and possibly vascular soluble guanylyl cyclase (GC).  
Likewise, down-regulation of iNOS, induced by LPS administration in rat 
neutrophils, was observed upon treatment with NOF (Mariotto et al., 1995a). In 
addition, NOF, but not its ‘parent’ drug, was able to decrease organ damage and 
other pro-inflammatory mediators in the rat endotoxic shock model (Anuar et al., 
2006b). Thus the accrued evidence suggests that the contribution of NO to the 
pathophysiology of septic shock is in fact highly heterogeneous and therefore, 
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Chapter 3: Biology of Hydrogen Sulphide (H2S) 
3.1 Biosynthesis 
Hydrogen sulphide (H2S) is produced in significant amounts in most tissues. 
The highest rate of production occurs in the liver, kidney, cardiovascular system, and 
brain (Doeller et al., 2005). The only known substrate for the generation of 
endogenous H2S is L-cysteine. L-cysteine is a sulphur-containing amino acid derived 
from alimentary sources, synthesized from L-methionine through the so-called 
“transsulphuration pathway” with homocysteine (Hcy) as an intermediate, or liberated 
from endogenous proteins. There are two major pathways of cysteine (Cys) 
catabolism (Iciek et al., 2005; Stipanuk et al., 2004). One of them is oxidation of thiol 
(–SH) group by cysteine dioxygenase (CDO) to cysteinesulfinate, which may be 
decarboxylated to hypotaurine or converted to pyruvate and sulphite, subsequently 
oxidized to sulfate by sulphite oxidase (SO) (Figure 3-1). The second pathway, 
referred to as “desulphhydration”, is associated with the removal of Cys sulphur atom 
without its oxidation and results in H2S production (Figure 3-1). This process may be 
catalysed by either of the two enzymes of the Hcy transsulphuration pathway namely, 
cystathionine β-synthase (CBS, EC 4.2.1.22) and cystathionine γ-lyase (CSE, EC 
4.4.1.1) (Figure 3-2). Both are pyridoxal 5’-phosphate (vitamin B6)-dependent but 
differ in the specific mechanism of H2S formation. CSE catalyses the conversion of 
cystine (a cysteine disulphide) to thiocysteine, pyruvate and ammonia. Subsequently, 
thiocysteine then nonenzymatically decomposes to Cys and H2S. The major 
mechanism of H2S production by CBS involves probably the condensation of Hcy 















Figure 3-1: Generation of hydrogen sulphide (H2S) by cystathionine β-synthase and 
cystathionine γ-lyase. Cystathionine β-synthase (CBS) catalyses the production of cystathionine by 
transferring serine to homocysteine. Cystathionine γ -lyase (CSE), a pyridoxal 5′-phosphate-dependent 
enzyme, subsequently converts cystathionine to cysteine. CSE catalyses a β-disulphide elimination 
reaction that results in the production of pyruvate and thiocysteine. Thiocysteine may react with 
cysteine or other thiols to form hydrogen sulphide (H2S). One pathway of cysteine metabolism 
involves its oxidation to cysteinesulphinate by cysteine deoxygenase (CDO). This then gets further 
converted to hypotaurine by cysteinesulphinate decarboxylase, and subsequently to taurine by a non-
enzymatic reaction or by hypotaurine dehydrogenase. The above reactions predominantly take place in 
the cytosol. The conversion of cysteinesulphinate to β-sulphinpyruvate by aspartate aminotransferase, 
followed by a non-enzymatic reaction, can also yield sulphite. Sulphite gets oxidized to sulphate by 
sulphite oxidase (SO) by a glutathione (GSH)-dependent process. 















Figure 3-2: The biosynthesis, mechanism of action and principal biological effects of hydrogen 
sulphide (H2S). Cystathionine-γ-lyase (CSE) or cystathionine-β-synthase (CBS) catalyse the 
production of H2S from cysteine in the donor cell. An influx of Ca2+ binds to calmodulin (CaM), 
thereby activating CBS. Factors that activate CSE have yet to be determined. H2S is released, 
presumably by free diffusion, to act on the target cell and in turn increase adenylyl cyclase (AC) 
activity. Thus this raises the intracellular concentration of cAMP, and/or activates KATP channels 
directly to cause hyperpolarization (neurons) or smooth muscle relaxation. It should be noted that 
whether H2S acts on a separate target cell or on the cell from which it is released (i.e. an autocrine 
effect) is not yet clear. H2S is broken down either chemically or by sequestration with macromolecules 
such as haemoglobin or glutathione. Major biological effects of released H2S include smooth muscle 
relaxation and promotion of neuronal long-term potentiation (LTP). Both DL-propargylglycine (PAG), 
and β-cyano-L-alanine (BCA) are CSE selective inhibitors, while aminooxyacetic acid (AOA) is a 
CBS selective inhibitor (adapted from Moore et al., 2003). 
Chapter 3: Biology of Hydrogen Sulphide (H2S) 53
with Cys to yield cystathionine. H2S is thus liberated during this reaction (Chen et al., 
2004). 
It should be noted that this reaction is closely related to the canonical reaction 
catalysed by CBS in the transsulphuration pathway, with the exception that Cys 
instead of serine condenses with Hcy, and H2S instead of H2O is released. Both CBS 
and CSE are widely distributed in tissues. However, CBS is the major H2S-producing 
enzyme in the central nervous system (Abe & Kimura, 1996; Eto & Kimura, 2002b) 
whereas CSE is the predominant source of H2S in the cardiovascular system (Li et al., 
2006). In some tissues such as the liver and kidney, both enzymes contribute to H2S 
generation (Stipanuk et al., 1990).  
Little is known about the regulation of H2S-producing enzymes. In the brain, 
electrical stimulation and excitatory neurotransmitter, glutamate, rapidly increase 
CBS activity in a Ca2+/calmodulin-dependent manner (Eto et al., 2002). Both N-
methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionate (AMPA) glutamate receptors are involved in this effect. S-
adenosyl-methionine (SAM), an intermediate product of methionine metabolism and 
a major donor of methyl groups, is an allosteric activator of CBS (Eto & Kimura, 
2002a). Sex hormones regulate brain H2S since CBS activity and H2S levels are 
higher in male than in female mice and castration of male mice decreases H2S 
formation (Eto & Kimura, 2002a). A nitric oxide donor, sodium nitroprusside (SNP), 
increases the activity of brain CBS in vitro. Nonetheless, this effect is nitric oxide 
(NO)-independent and results from chemical modification of the enzyme’s cysteine 
groups (Eto & Kimura, 2002b). In contrast, NO itself may bind to and inactivate CBS 
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(Taoka et al., 2001). In homogenates of the rat aorta, NO donors acutely increase 
CSE-dependent H2S generation in a cGMP-dependent manner (Zhao et al., 2003). 
Moreover, prolonged incubation of cultured vascular smooth muscle cells in the 
presence of NO donors increases CSE mRNA and protein levels (Zhao et al., 2001). 
The physiological significance of NO in the regulation of H2S production is also 
supported by the observation that circulating H2S level as well as CSE gene 
expression and enzymatic activity in the cardiovascular system are reduced in rats 
chronically treated with NOS inhibitor (Zhong et al., 2003). Hence, NO is probably a 
physiological regulator of H2S production in the cardiovascular system (CVS). 
 
3.2 Biological chemistry and effects of H2S 
Under physiologically relevant conditions, i.e. in aqueous solutions and at pH 
7.4, one third of H2S is not dissociated and two thirds dissociate into H+ and 
hydrosulphide ion (HS–), which subsequently decomposes to H+ and sulfide ion (S2–). 
However, the latter reaction occurs only at a high pH. As a result, S2– does not occur 
in vivo at substantial amounts. Sodium hydrosulphide (NaHS) is commonly used as 
an H2S donor since it dissociates to Na+ and HS–. The latter then binds H+ to form 
H2S. Similar to NO, H2S is lipophilic and freely permeates plasma membranes, 
although due to partial dissociation membranes are relatively less permeable to H2S 
than to NO. H2S is detectable in serum and most tissues (~ 50 µM) (Li et al., 2006). 
Its physiological level in the brain is up to three-fold higher than in serum and is in 
fact close to toxic concentration (Dello Russo et al., 2000). 
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3.2.1 Direct effects of H2S 
H2S is a vasodilator. It is able to cause relaxation in precontracted rat 
aorta, dilate mesenteric resistance arterioles and produce dose-dependent fall in 
blood pressure in the anaesthetised rat (Zhao & Wang, 2002; Cheng et al., 2004). 
In many systems, the effect of H2S does not involve an increase in cyclic 
guanosine monophosphate (cGMP) or cyclic adenosine monophosphate (cAMP). 
Rather, it is mediated by the opening of ATP-sensitive potassium channels (KATP) 
(for review, see Li et al., 2006; Moore et al., 2003; Wang, 2002). Briefly, an 
influx of Ca2+, perhaps triggered by the activation of NMDA receptors by 
glutamate or via separate channels, binds to calmodulin (CaM), thereby activating 
CBS. Factors that activate CSE have yet to be determined. H2S is then released to 
act on the target cell, resulting in the increase in adenylyl cyclase (AC) activity. 
This would in turn raise the intracellular concentration of cAMP, and/or activate 
KATP channels directly to cause either vasodilation in smooth muscle or 
hyperpolarisation in neurons (Moore et al., 2003) (Figure 3-2). This conclusion is 
mostly based on the observation that many effects of H2S are mimicked by KATP 
openers such as pinacidil or diazoxide and abolished by their inhibitors 
(sulfonylurea derivatives) such as glibenclamide. Only in a few studies the 
stimulatory effect of H2S on KATP channels was demonstrated directly by 
measuring KATP channel current by the patch-clamp method (Cheng et al., 2004; 
Tang et al., 2005). Stimulation of KATP channels can not only occur in the 
vascular smooth muscle cells resulting in vasodilation, but also in the 
myocardium (Geng et al., 2004), pancreatic β-cells (Yang et al., 2005), neurons 
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(Kimura et al., 2006), carotid sinus (Xiao et al., 2006), and smooth muscle of the 
colon (Distrutti et al., 2006). The precise mechanism through which H2S 
stimulates KATP channels is still unclear.  
H2S is a strong reducing agent. Therefore, it has been suggested that some 
of its effects may be mediated by protection of protein thiol (–SH) groups from 
oxidation. However, all studies performed to date indicate that effects of H2S 
applied at physiological concentration are not reproduced or only partially 
mimicked by thiol-protecting agents, suggesting that this is not a major 
mechanism of H2S action (Abe & Kimura, 1996).  
A mechanism by which H2S may exert antioxidant effect involves 
stimulation of cysteine transport to the cells and enhancement of glutathione 
synthesis (Kimura & Kimura, 2004). Moreover, H2S has been demonstrated to 
stimulate heme oxygenase (HO) expression and carbon monoxide (CO) 
production, and to have bidirectional effects on the extracellular signal-regulated 
kinases (ERK) (Du et al., 2004; Oh et al., 2006) and inducible NO synthase 
(NOS) (Jeong et al., 2006; Oh et al., 2006). It is unclear if these effects are 
primary or result from the stimulation of other targets such as KATP channels.  
In addition, H2S produces transient receptor potential vanilloid 1 
(TRPV1)-dependent contractile effects in the rat urinary bladder (Patacchini et al., 
2005) and mediates neurogenic inflammation in caerulein-evoked pancreatitis via 
TRPV1 activation (Bhatia et al., 2006; Hutter et al., 2005). Interestingly, H2S is 
also able to modify potassium calcium (KCa) channels to decrease the sensitivity 
of KCa to NO (Wang, 2002) and to promote hippocampal long-term potentiation 
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(LTP) by enhancing the sensitivity of NMDA receptors to glutamate (Wang, 
2002; Kimura, 2002).  
 
3.2.2 Indirect effects of H2S 
H2S is a highly reactive molecule and may react easily with other 
compounds, especially with reactive oxygen and nitrogen species (ROS and 
RNS). It has been demonstrated that H2S reacts with at least four different ROS, 
superoxide radical anion (Mitsuhashi et al., 2005), hydrogen peroxide (Geng et 
al., 2004), peroxynitrite (Whiteman et al., 2004) and hypochlorite (Whiteman et 
al., 2005). All of them are physiologically relevant ROS or RNS. Superoxide 
radical anion (O2–) is produced by NADPH oxidase present in phagocytes as well 
as by the related non-phagocytic NADPH oxidases expressed in many cell types, 
in particular in the cardiovascular system and the kidney. Hydrogen peroxide 
(H2O2) is produced from O2– in the reaction catalyzed by superoxide dismutase. 
Peroxynitrite (ONOO–) is the product of spontaneous reaction between 
superoxide and NO, whereas hypochlorite (ClO–) is produced from H2O2 by 
neutrophil myeloperoxidase (MPO). All these compounds are highly reactive and 
their interaction with H2S results in the protection of proteins and lipids from 
ROS/RNS-mediated damage (Whiteman et al., 2004; Whiteman et al., 2005). The 
significance of H2S reaction with O2– is ambiguous since the product, sulphite, 
may have both toxic (Collin & Thiemermann, 2005) and antioxidant (Mitsuhashi 
et al., 2001) properties, most likely depending on its concentration. H2S also 
reacts with NO to form a nitrosothiol compound with as yet undefined chemical 
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structure (Whiteman et al., 2006). Interestingly, in contrast to other nitrosothiols 
(R-S-NO) which are considered to be a reservoir of NO and often mimic its 
activity, the nitrosothiol originating from H2S and NO is inactive. It has been 
suggested that H2S may scavenge the excess of NO produced in the inflammatory 
state (Whiteman et al., 2006), but may also limit the availability of NO 
continuously produced at physiological concentrations (Ali et al., 2006).  
 
3.2.3 H2S and inflammation 
Most in vivo studies (Chapter 3, Section 3.3.1) strongly suggest that H2S is 
a proinflammatory mediator. However, the mechanism through which H2S 
aggravates inflammation is not clear. In addition, the results of in vitro 
experiments are not so unambiguous and demonstrate either pro- or anti-
inflammatory potential of H2S. For example, Na2S inhibited formyl-methionyl-
leucyl-phenylalanine (FMLP)-induced chemotaxis and degranulation of 
polymorphonuclear leukocytes (Mariggio et al., 1997). In addition, H2S donors 
inhibited aspirin-induced leukocyte adhesion to the endothelium of rat mesenteric 
venules, whereas inhibitors of H2S synthesis elicited leukocyte adhesion (Zanardo 
et al., 2006). On the other hand, NaHS inhibited apoptosis of isolated human 
neutrophils while having no effect on their bactericidal properties (Rinaldi et al., 
2006). Interestingly, in the same study NaHS had no effect on viability of 
eosinophils and enhanced apoptosis of lymphocytes. In cultured murine 
RAW264.7 macrophages, H2S solution suppressed the LPS-induced expression of 
inducible NO synthase (iNOS). This effect was mediated by H2S-induced 
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activation of ERK, increased expression of heme oxygenase-1 and CO 
production, and CO-mediated inhibition of pro-inflammatory transcription factor, 
nuclear factor-κB (Oh et al., 2006). Interestingly, LPS as well as proinflammatory 
cytokines up-regulated the CSE gene expression, which may explain other 
observations of increased H2S production in various inflammatory states (Oh et 
al., 2006). Recently, Mitsuhashi et al., (2005) have demonstrated that FMLP-
activated neutrophils nonenzymatically convert H2S to sulphite (SO32–) in 
NADPH oxidase and ROS-dependent manner, most likely through the following 
reaction: 
 
(1) H2S + 2O2– Æ SO32– + H2O 
 
These observations were confirmed in vivo by demonstrating that LPS 
increased serum sulphite level (Mitsuhashi et al., 2005), and are consistent with 
previous findings that LPS induced sulphite production by isolated leukocytes 
(Mitsuhashi et al., 1998). Serum sulphite is increased in patients with pneumonia 
(Mitsuhashi et al., 2004), as well as in LPS-treated rats (Mitsuhashi et al., 1998). 
Sulphite may be an important bactericidal compound produced by inflammatory 
cells, but may also contribute to tissue injury during inflammation. Normal level 
of sulphite in tissues and body fluids is very low due to its rapid conversion to 
sulphate by sulphite oxidase. However, increased concentration of sulphite is 
highly toxic as observed in sulphur dioxide poisoning or in patients with inherited 
sulphite oxidase deficiency (Ozturk et al., 2006). Indeed, sulphite itself dose-
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dependently stimulates the oxidative burst of neutrophils (Labbe et al., 1998) and 
their adhesion to the endothelium (Shigehara et al., 2002). Sulphite may also react 
with peroxynitrite to form toxic sulphite radicals (Reist et al., 1998). These 
observations suggest that overproduction of H2S during the inflammation, 
although primarily aimed to enhance non-specific host defence, may perpetuate 
the inflammatory reaction and cause tissue damage. 
Several studies indicate that H2S is overproduced not only in sepsis but 
also in more localized forms of inflammation. For example, experimental acute 
pancreatitis induced in the mouse by repeated caerulein administration is 
associated with the increase in CSE mRNA expression level and enzymatic 
activity in the pancreas. Moreover, DL-propargylglycine (PAG) administered 
before or after caerulein reduced pancreatic acinar cell injury, decreased MPO 
activity and inflammatory cell infiltration in the pancreatic tissue, and partially 
normalized plasma amylase activity. In addition, PAG ameliorated pancreatitis-
associated lung inflammation (Bhatia et al., 2005a). Hindpaw oedema induced by 
intra-planar injection of carrageenan in the rat is a commonly used model of local 
inflammation and a good example of ambiguous results concerning the role of 
H2S in inflammatory reaction. Bhatia et al., (2005b) have observed that 
carrageenan increases local H2S formation and that PAG reduces oedema 
formation as well as leukocyte infiltration in this model. On the other hand, 
Zanardo et al., (2006) have observed that carrageenan-induced paw oedema was 
suppressed by NaHS and Na2S and enhanced by inhibitors of H2S synthesis. 
Suppression of oedema formation by H2S donors was mimicked by KATP channel 
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agonists and reversed by their antagonists. The reason for the discrepancies 
between these two studies (Bhatia et al., 2005b; Zanardo et al., 2006) is not clear. 
Stimulation of afferent sensory nerves may contribute to the inflammatory 
response through so-called “neurogenic inflammation”, associated with the 
release of substance P (SP), neurokinin-A and calcitonin gene-related peptide 
(CGRP). These mediators induce a series of inflammatory responses, especially in 
the airways, which include vasodilation, extravasation of plasma proteins leading 
to oedema, bronchoconstriction, mucus secretion and recruitment of inflammatory 
and immune cells. Trevisani et al., (2005) have demonstrated that NaHS, 
similarly to capsaicin, induced CGRP and SP release from the sensory nerves in 
the guinea-pig airways. NaHS induced a dose-dependent contraction of isolated 
bronchial and tracheal rings and its effect was abolished by the desensitization of 
sensory nerves with high concentration of capsaicin, by TRPV1 antagonists, 
capsazepine and ruthenium red, as well as by a mixture of neurokinin NK1 and 
NK2 receptor antagonists. Interestingly, intraperitoneal injection of NaHS to 
healthy mice induced substantial inflammatory reaction in the lung as evidenced 
by increased concentration of substance P, proinflammatory cytokines, tumour 
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and lung MPO activity 
(Bhatia et al., 2006). These effects were abolished by a specific NK1 receptor (a 
substance P receptor) antagonist, CP-96,345, but not by NK2 or CGRP receptor 
antagonists. In addition, the inflammatory effect of H2S was abolished by 
capsazepine and was not observed in mice lacking substance P and neurokinin-A 
due to the knockout of their common precursor gene, preprotachykinin-A (Bhatia 
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et al., 2006). These data indicate that H2S per se may induce neurogenic 
inflammation even in the absence of other noxious insults. 
Interestingly, before the epoch of new research into H2S, Lyons et al., 
(2001) demonstrated that plasma sulphaemoglobin was higher in children with 
sepsis than in healthy controls, which indirectly suggested the overproduction of 
H2S. In addition, plasma H2S concentration is increased by almost 50% in patients 
with stable chronic obstructive bronchopulmonary disease (COPD) in comparison 
to the control group (Chen et al., 2005). Interestingly, in patients with exacerbated 
COPD, H2S level was lower than in those with stable disease and was inversely 
correlated with pulmonary artery systolic pressure, which suggests that pulmonary 
hypertension per se has a deleterious effect on H2S production in humans. 
 
3.2.4 H2S: A biological double-faced Janus? 
Taken together, the data presented above strongly suggest that apart from 
NO, H2S is another inorganic gaseous mediator in the cardiovascular and nervous 
system. However, our current knowledge about its role in physiology and 
pathology is still fragmentary. Many effects of H2S are controversial. For 
example, H2S has been demonstrated to either stimulate or inhibit certain 
intracellular transduction pathways, to stimulate (Deplancke & Gaskins, 2003) or 
inhibit (Du et al., 2004; Yang et al., 2004a) cell proliferation, to activate (Yang et 
al., 2004b, Yang et al., 2006) or block (Rinaldi et al., 2006) apoptosis, to be 
overproduced (Zhu et al., 2007) or deficient (Bian et al., 2006; Geng et al., 2004) 
in myocardial ischemia, and to be pro- (Bhatia et al., 2005b) or anti-inflammatory 
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(Zanardo et al., 2006) in the carrageenan model of hindpaw oedema. Only a few 
studies have demonstrated alterations in H2S level in human diseases, and in most 
cases this was achieved indirectly by measuring H2S-related compounds such as 
thiosulphate (Belardinelli et al., 2001) or sulphaemoglobin (Lyons et al., 2001) 
rather than H2S itself.  
 
3.3 Evidence for the involvement of H2S in sepsis and septic shock 
3.3.1 In vivo overproduction of H2S in sepsis 
Septic shock, which often accompanies sepsis induced by infection with 
Gram-negative bacteria, is characterized by generalized vasodilation and 
hypotension. Overproduction of NO by cytokine-induced enzymes, inducible NO 
synthase contributes to this vasodilation (Yet et al., 1997). H2S is also 
overproduced in vascular tissue of rats with experimental septic shock induced by 
caecal ligation and puncture, as well as in endotoxemic shock induced by 
lipopolysaccharide (LPS) administration (Hui et al., 2003). In addition, H2S level 
negatively correlates with blood pressure and myocardial contractility, suggesting 
its pathogenic role in the haemodynamic collapse. Notably, at least one study has 
demonstrated that LPS-induced hypotension is attenuated by glibenclamide 
suggesting the involvement of abnormal activation of KATP channels (Gardiner et 
al., 1999). Recently, we have demonstrated (Anuar et al., 2006b) that an NO-
releasing derivative of the anti-inflammatory drug flurbiprofen, nitroflurbiprofen, 
dose-dependently inhibits hepatic H2S production and CSE mRNA in LPS-treated 
rats. In addition, nitroflurbiprofen but not its parent drug decreases plasma 
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concentration of proinflammatory cytokines, TNF-α and IL-1β, as well as MPO 
activity (Anuar et al., 2006b). These data suggest that H2S may be targeted by 
drugs which affect nitric oxide. 
It should be noted that H2S overproduction in a given disease does not 
necessarily indicate that it is a deleterious agent. If its deleterious role has been 
established by protective effect of CBS/CSE inhibitors, it may be concluded that 
H2S is indeed a link in the pathogenetic chain. In such cases (e.g. sepsis) blocking 
H2S production is a potential therapeutic strategy. However, H2S overproduction 
may also be associated with a protective role (e.g. febrile seizures). In such cases, 
H2S production may be considered as an adaptive response, although probably 
insufficient to block disease development, and additional supplementation of H2S 
may be therapeutically useful. Deficiency of H2S is observed in diseases in which 
it plays a protective role (e.g. arterial hypertension, gastric mucosal injury), and 
H2S donors may provide some therapeutic benefit. In theory, reduced production 
of H2S could also be a compensatory response to limit its non-beneficial effects. 
However, examples of some are not known to date. Until now, H2S generation has 
not been specifically targeted in humans. Clearly, the effect of currently used 
therapies on H2S levels in human diseases should be explored before any attempts 
to use specific H2S modulators are made. 
 
3.3.2 CBS/CSE gene disruption 
Genomic manipulation of H2S biosynthesis is an underdeveloped area 
with great potential. A heterozygous deficiency of CBS mice has been established 
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(Eberhardt et al., 2000). Eberhardt and co-workers (2000) found that in the animal 
disease model of mild hyperhomocysteinemia, endothelial dysfunction appeared 
early in CBS (-/+) mice in the absence of structural arterial abnormalities. Thus, 
the transgenic animal model with CBS and/or CSE deletion will be needed to 
establish the contribution of this enzyme to endogenous H2S levels in vascular 
tissues especially with regards to sepsis. 
 
3.3.3 CBS/CSE inhibitors 
Mok et al., (2004) have demonstrated that plasma H2S is increased in rats 
with hemorrhagic shock and that CSE inhibitors and glibenclamide increase mean 
arterial pressure in these animals, which indicates that deleterious haemodynamic 
effect of H2S excess is not confined to the septic shock. Several subsequent 
studies confirmed that plasma H2S concentration as well as CSE expression and 
activity in the liver and kidney are increased in LPS treated mice (Li et al., 2005) 
and in caecal ligation and puncture model of sepsis in the mouse (Zhang et al., 
2006). In addition, these studies strongly suggest that H2S not only contributes to 
hypotension but also augments the inflammatory response and end-organ damage 
associated with sepsis. Thus, PAG treatment attenuates the inflammatory response 
as evidenced by the reduction of myeloperoxidase activity (a marker of neutrophil 
infiltration) in the lung and liver in a mouse model of sepsis (Zhang et al., 2006). 
In addition, PAG reduced mortality after caecal ligation and puncture (Zhang et 
al., 2006). Interestingly, in LPS-injected rats PAG reduced liver and skeletal 
muscle damage without altering blood pressure, which suggests that its protective 
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effect was independent of the improvement of haemodynamics (Collin et al., 
2005). 
It must be noted that the currently used CBS and CSE inhibitors are 
unsuitable for pharmacotherapy and not ideal even for research. Both the CBS 
and CSE inhibitors are not completely specific and also inhibit other vitamin B6-
dependent enzymes. Furthermore, they have a very limited ability to permeate 
plasma membranes. However, even completely specific CBS or CSE inhibitors 
will not only affect H2S level but also Hcy metabolism, which may be non-
beneficial or even deleterious in certain circumstances. 
 
3.3.4 H2S donors 
In contrast, NaHS aggravated histological lesions in the lung and liver as 
well as increased the tissue MPO activity and plasma TNF-α concentration 
(Zhang et al., 2006). Similar results were obtained in LPS-injected rat (Collin et 
al., 2005) and mice (Li et al., 2005). Moreover, NaHS was also shown to up-
regulate leukocyte rolling and attachment, as well as tissue levels of adhesion 
molecules in sepsis (Zhang et al., 2007). 
However, pretreatment with H2S solution or NaHS resulted in the 
inhibition of LPS-induced iNOS expression and NO production in RAW264.7 
macrophages (Oh et al., 2006). In addition, LPS-induced NF-κB activation was 
diminished in RAW264.7 macrophages pre-incubated with H2S solution (Oh et 
al., 2006). Likewise, administration of the H2S-releasing NSAID, S-diclofenac, in 
LPS-treated rats, but not its ‘parent’ drug, resulted in the inhibition of LPS-
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induced inflammation and gastric toxicity (Li et al., 2007). S-diclofenac 
administration was also able to inhibit NF-κB activation and the subsequent 
expression of genes encoding enzymes which synthesize NO, prostanoids, and 
pro-inflammatory cytokines (Li et al., 2007). Hence the previous picture of H2S 
playing a detrimental role in the pathological sequelae of sepsis, is oversimplified. 
In the light of new data, it would seem that H2S, like NO, plays both a detrimental 
and beneficial role in sepsis.  
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Chapter 4: Materials and Methods 
4.1 Materials 




Figure 4-1: Structural formula of flurbiprofen (FLU). 
 
(C15H13FO2), Molecular weight = 244.26, 5g/vial was a generous gift from 
Dr. P. Del Soldato, NicOx S.A., Sophia Antipolis, Cedex, France. FLU was 
dissolved in ethanol:olive oil, 5:95 for the following experiments. 
 




Figure 4-2: Structural formula of nitroflurbiprofen (HCT-1026). 
 
(C19H17FO2NO3) Molecular weight = 418.37, 5g/vial, was a generous gift 
from Dr. P. Del Soldato, NicOx S.A., Sophia Antipolis, Cedex, France. NOF was 
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Figure 4-3: Structural formula of L-NAME. 
 
(C7H15N5O4·HCl), Molecular weight = 269.69, 5g/vial, was obtained from 
Sigma-Aldrich, St. Louis, MO, U.S.A. L-NAME was dissolved in saline. 
 




     Figure 4-4: Structural formula of 1400W. 
 
(C10H15N3), Molecular weight = 177.25, 100mg/vial, was obtained from 
Cayman Chemical Company, Ann Arbor, Mich., U.S.A. 1400W was dissolved in 
saline.  
 
4.1.5 Clinical Research Cocktail (CRC) 
Clinical Research Cocktail (CRC) is a mixture of hypnorm (1 ml; Jansen 
Pharmaceutica, Beerse, Belgium) containing fentanyl (0.315 mg), fluanisone (10 
mg) and 1 ml of midazolam (Roche, Basel, Switzerland [5 ml of dormicum in 2 
ml water]). CRC was obtained from the Animal Holding Unit (AHU) of National 
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University of Singapore (NUS) and was kept in a vial wrapped in aluminium foil 
at room temperature. 
 
4.2 Equipment 
4.2.1 96-well Microplate Reader Sunrise Tecan 
Tecan Systems, Inc. San Jose, CA, U.S.A 
4.2.2 AxioCam MRc5 Microscope  
Carl Zeiss MicroImaging GmbH, Standort, Göttingen, Germany 
4.2.3 Bio-Rad PowerPac Basic 
Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A 
4.2.4 Bio-Rad ChemiDoc Xrs 
Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A 
4.2.5 Direct-Q® 3 Ultrapure Water Systems 
Millipore Corporation, Billerica, MA, U.S.A 
4.2.6 Grant Water Bath 
Grant Instruments, Grants Pass, OR, U.S.A 
4.2.7 Heidolph DIAX 900 Homogeniser 
Heidolph Instruments GmbH & Co. KG, Walpersdorfer Str., Schwabach, 
Germany 
4.2.8 Heidolph Reax Top Vortex Mixer/Shaker 
Heidolph Instruments GmbH & Co. KG, Walpersdorfer Str., Schwabach, 
Germany 
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4.2.9 Hettich Zentrifugen Universal 32R Centrifuge 
Andreas Hettich GmbH & Co KG, Föhrenstr., Tuttlingen, Germany 
4.2.10 Hirayama HVE-50 Autoclave Sterilizer 
Hirayama Manufacturing Corporation, Kasukabe-shi, Saitama, Japan 
4.2.11 Leica Histology Systems HI1220, RM2255, EG1150C, EG1150H, 
TP1020  
Leica Microsystems GmbH, Ernst-Leitz-Strasse, Wetzlar, Germany 
4.2.12 Mettler-Toledo AG135 (max=31g/101g d=0.01mg/0.1mg) 
Mettler-Toledo, Inc., Columbus, OH, U.S.A 
4.2.13 Mini Centrifuge, 120V 
Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A 
4.2.14 PowerLab/4SP 
ADInstruments Pte Ltd, Bella Vista, NSW, Australia 
4.2.15 Precisa BJ410C (max=410g d=0.01g) 
Precisa Gravimetrics AG, Moosmattstrasse, Dietikon, Switzerland 
4.2.16 PTC-200 Gradient Thermal Cycler 
MJ Research, Inc., Waltham, MA, U.S.A 
4.2.17 Rocking Platform Mixer CR300 
FinePCR, Gunpo-si, Gyenggi-do, Korea 
4.2.18 Rotator HAG 
FinePCR, Gunpo-si, Gyenggi-do, Korea 
4.2.19 S20 SevenEasyTM pH Meter 
Mettler-Toledo, Inc., Columbus, OH, U.S.A 
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4.2.20 Shimadzu BioSpec-1601 DNA/Protein/Enzyme Analyzer 
Shimadzu Corporation, Nakagyo-ku, Kyoto, Japan 
4.2.21 Sonics Vibra-Cell VCX130 Sonicator  
Sonics & Materials, Inc., Newtown, CT, U.S.A 
4.2.22 Spectra Max Gemini EM Spectrophotometer 
Molecular Devices Corporation, Sunnyvale, CA, U.S.A 
4.2.23 Wide Mini-Sub Cell GT 
Bio-Rad Laboratories, Inc., Hercules, CA, U.S.A 
4.2.24 XCell SureLockTM Mini-Cell 
Invitrogen Corporation, Carlsbad, CA, U.S.A 
4.2.25 Techne Dri-Block DB-2A 
Techne Incorporated, Burlington, NJ, U.S.A 
 
4.3 Animals 
A total of 330 male Sprague-Dawley rats weighing 200-300 g were used for 
the caecal ligation puncture (CLP)-induced septic shock model and 
lipopolysaccharide (LPS)-induced endotoxic shock model (Table 4-1). Animals were 
obtained from the Laboratory Animal Centre (LAC) and were housed in the Animal 
Holding Unit (AHU) in single cages with rat pellets. The animals were fed ordinary 
animal chow and water was given ad lib. 
The “Guide for the Care and Use of Laboratory Animals” published by the US 
National Institutes of Health (NIH Publication No. 85-23, revised 1996) were 
followed   in   the   following   experiments   which   were   approved   by    the   NUS 

















A total of 330 male Sprague-Dawley rats weighing 200-300 g were used. CLP, Caecal 
Ligation Puncture; LPS, Lipopolysaccharide; VEH, Vehicle; FLU, Flurbiprofen; NOF, 
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Institutional Animal Care and Use Committee (IACUC). 
 
4.4 PowerLab Calibration 
The PowerLab was calibrated before carrying out experiments requiring blood 
pressure measurement. Each pressure transducer was exposed to atmospheric pressure 
(0 mm Hg) and then connected to a sphygmomanometer with the pressure raised 
between 120 and 150mm Hg. Blood pressure measurements on Chart (Version 5.1) 
were adjusted to reflect the correct pressures according to the software 
manufacturer’s instructions. 
 
4.5 Surgical Procedures 
4.5.1 Surgical Instruments 
All surgical instruments were autoclaved before use. Microdissecting 
scissors and fine forceps were used for a two-step puncture and insertion method 
for cannulation of the left femoral artery. Other surgical instruments such as 
clamping and surgical scissors, large forceps, surgical scalpel, needle with 
surtures, plain surtures and shaver were also used as required. 
 
4.5.2 Cannula 
A 15cm long cannula (internal diameter, 0.28 mm) was prepared from 
polyethylene tubing (PE-50; Becton, Dickinson and Company, Franklin Lakes, 
NJ, U.S.A). Polyethylene tubing (PE-10) was used to tie a small knot about 5cm 
from the top end of the cannula (PE-50). This was then secured using superglue 
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and left overnight to dry. This knot facilitated the anchoring of the cannula in a 
fixed position within the cannulated artery by tying plain surtures around the 
opening of the cannulated artery to the knot found on the cannula. In order to 
prevent air-bubbles from becoming trapped within the length of the cannula that is 
filled with heparin-saline solution (50 U ml-1), a short blunt-end pin (with its 
sharp end removed using pliers) measuring approximately 1cm in length was used 
to insert into the exposed end of the cannula.  
 
4.5.3 Caecal Ligation Puncture (CLP)-induced septic shock model 
Animals were fasted overnight before the experiment but were given water 
ad libitum. The following day, animals were administered either flurbiprofen (21 
mg kg-1, p.o), a mol for mol equivalent dose of nitroflurbiprofen (30 mg kg-1, p.o.) 
or an appropriate volume (2 ml kg-1, p.o.) of vehicle (ethanol:olive oil, 5:95 v v-1), 
1 h before the induction of polymicrobial sepsis. 
Polymicrobial sepsis was induced by caecal ligation puncture (CLP) 
essentially as described previously (Zhou et al., 2001). Rats were anaesthetized 
with 0.3 ml/100 g (i.p.) of CRC for induction and 0.1 ml/100g (i.p.) for 
maintenance, as and if, required. All surgical procedures were carried out under 
sterile conditions. The fur around the scalp area of the rat was shaved. A small cut 
was made at the midpoint between the ears of the rat using a pair of surgical 
scissors. This cut was sufficient to allow for the exteriorization of the cannula at 
the end of the procedure. 
The animal was then turned over and the stomach and pelvis-leg region 
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was shaved. A surgical scalpel was used to make an approximately 1 cm 
longitudinal incision, exposing the underlying muscles and connective tissue in 
the region surrounding the left femoral artery (Figure 4-5a). The left femoral 
artery was carefully exposed by blunt dissection between associated muscles 
(Figure 4-5b). Once the left femoral artery was exposed, a small stiff cardboard 
paper was then used to support it. The proximal end of the artery was clamped 
while a short length of plain surgical surtures was used to tie off the distal end of 
the artery. Before the artery was cannulated, the longer end of the cannula was 
first exteriorized by tunneling subcutaneously from the vascular incision site at 
the pelvis-leg region of the rat to the small cut made midpoint between the ears of 
the rat. The longer end of the cannula was then attached to a 1ml syringe 
containing 50 U ml-1 heparin-saline solution and this was then flushed through the 
cannula to remove any air bubbles. Once the cannula was flushed, a small cut in 
the artery was made using the microdissecting scissors. A pair of fine forceps was 
then used to facilitate the insertion of the shorter end of the cannula (with the 
knot) into the artery. The cannula was then inserted to the knot found on the 
cannula. Before the cannula was secured, the clamp was removed and a small 
amount of blood was drawn into the syringe to check for patency. The blood was 
then injected back into the rat along with 0.4ml of the 50 U ml-1 heparin-saline 
solution, making sure that the blood within the cannula was totally flushed back 
into the rat. A second short suture was then used to fix and tie the artery to the 
knot on the cannula, thereby anchoring it securely. Finally the two threads were 
then tied to further ensure that the  indwelling cannula would  not  move  after  the  


















Figure 4-5a: Diagram showing the location of the rat’s left femoral artery (taken from The 





















Figure 4-5b: Picture showing the underlying muscles and connective tissue in the region 
surrounding the left femoral artery. The left femoral artery was carefully exposed by blunt 
dissection between associated muscles. Once the left femoral artery was exposed, a small stiff 
cardboard paper was then used to support it. The proximal end of the artery was clamped while a 
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operation. The incision made to the pelvis-leg region of the rat was then closed. 
Subsequently a midline laparotomy was carried out to expose the caecum 
which was then ligated with 4/0 silk suture distal to the ileocaecal valve and 
punctured twice with an 18-gauge needle (Zhou et al., 2001). Sham-operated 
animals underwent the same surgical procedure except that the caecum was 
neither ligated nor punctured.  The midline incision was thereafter closed in two 
layers. 
The rat was then turned over and the syringe connected to the cannula was 
replaced with the blunt-end pin, making sure that no air bubbles became trapped 
in the process. The cut present at the midpoint of the head was carefully covered 
using Bosworth dental acrylide. The dental acrylide once hardened, secured the 
exteriorized cannula. Flushing of the cannula with 0.2ml of the 50 U ml-1 of 
heparin-saline solution was carried out twice a day (12 hours apart) so as to 
ensure long-term cannula patency during subsequent periodic measurement of 
mean arterial blood pressure (MABP) (Figure 4-1c). The animals were then 
allowed to recover in separate cages with food and water provided ad libitum. 
Following recovery, animals were housed singly throughout the remaining 
period (3 days) of the experiment and MABP measurement was monitored via a 
pressure transducer connected to a Powerlab, at 1, 6, 12, 24, and 48 h. At the end 
of each time interval, 5 rats per treatment group were terminally anaesthetized (1 
ml/kg of CRC, i.p.) and blood (approximately 5ml, 50 Uml-1 heparin) obtained by 
cardiac puncture was centrifuged at 3000 rpm for 10 min so as to obtain the 
plasma. Plasma samples  were  then  stored  at  -80°C  prior  to  assay  for  plasma 






















Figure 4-5c: Male Sprague-Dawley rat with exteriorized cannula connected to the 









Chapter 4: Materials and Methods 81
nitrite/nitrate (NOx) (Chapter 4, Section 4.7.2), TNF-α and IL-1β (Chapter 4, 
Chapter4, Section 4.7.3). Tissues (liver, lung, and caecum) were also removed for 
histology as described below (Chapter 4, Section 4.7.1). 
 
4.5.4 Lipopolysaccharide (LPS)-induced endotoxic shock model 
Conscious rats (male, Sprague-Dawley, 250-280 g) were injected i.p. with 
either saline (2.5 ml kg-1, Sham), E.Coli LPS (10 mg kg-1, LPS treated) or LPS 
pre-treated with either flurbiprofen (21 mg kg-1, i.p.), a mol for mol equivalent 
dose of nitroflurbiprofen (3-30 mg kg-1, i.p.), L-NAME (25-100 mg kg-1, i.p.), 
1400W (1-10 mg kg-1, i.p.) or an appropriate volume (2 ml kg-1, i.p.) of vehicle 
(ethanol:olive oil, 5:95 v v-1 or saline 0.9% w v-1 NaCl). 6 h later, rats were 
terminally anaesthetized (1 ml kg-1, i.p.) with CRC and blood (approx. 5 ml, 50 U 
ml-1 heparin) obtained by cardiac puncture was centrifuged at 3000 rpm for 10 
min so as to obtain the plasma. Plasma samples were then stored at -80°C prior to 
assay for plasma nitrite/nitrate (NOx) (Chapter 4, Section 4.7.2), TNF-α and IL-
1β (Chapter 4, Section 4.7.3). Liver and kidney samples were also removed and 
kept in cryotubes that were frozen in liquid nitrogen and stored at -80°C. They 
were later assayed for protein eNOS and iNOS expression, H2S synthesizing 
ability, CBS and CSE mRNA expression, myeloperoxidase (MPO) activity, NF-
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4.6 Survival Studies 
In the caecal ligation puncture (CLP)-induced septic shock model, the time of 
onset of mortality of the animals from the different treatment groups namely, sham, 
caecal ligation puncture (CLP) or CLP pre-treatment with either flurbiprofen (21 mg 
kg-1, p.o.) or nitroflurbiprofen (30 mg kg-1, p.o.) was noted over a period of 48 h. 
 
4.7 Biochemical Assays 
4.7.1 Histological examination of tissues 
Liver, lung and cecum segments (approx. 100 mg) were fixed in 10% v v-1 
phosphate-buffered formalin (pH 7.4) for 24 h and then embedded in paraffin. 
Sections (4 μm) were cut using a microtome, stained with hematoxylin and eosin 
(H&E) and viewed by light microscopy (Carl Zeiss AxioCam MRc5) at ×400 
magnification. For each rat, a total of 12 tissue sections were examined, where for 
each tissue section 5 fields were viewed for the determination of the extent of 
organ damage. Observers were blinded to the treatment. 
 
4.7.2 Measurement of plasma nitrite/nitrate (NOx) 
Aliquots (80 μl) of thawed plasma were incubated (37o C, 30 min, final 
incubation volume of 200 μl) with nitrite reductase (10 mU) in the presence of 
NADPH (100 μmol l-1) to reduce nitrate to nitrite and then centrifuged 
(14,000 rpm, 25 min, 4°C).  The resulting supernatant as well as sodium nitrite 
standard (100 μl; 5-35 µmol l-1) were added, in duplicate, to 96-well microplate 
(Figure 4-6). Thereafter, Greiss  reagent (0.2% w v-1 N-1-napthyl ethylenediamine  














Figure 4-6: Representative sodium nitrite standard curve. Graph of absorbance (OD) against 
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dihydrochloride and 2% w v-1 sulfanilamide in 5% v v-1 H3PO4) was added to the 
above mixture in a ratio of 1:1 (v v-1) and incubated for 10 min at room 
temperature after which absorbance was determined at 550 nm in a 96-well 
microplate reader (Tecan Systems, Inc., San Jose, CA, U.S.A.). The concentration 
of nitrite (indicative of NOx in the original samples) was calculated from a 
standard curve of NaNO2 (5-35 µmol l-1) and expressed as μmol l-1 nitrite. 
 
4.7.3 Measurement of plasma TNF-α and IL-1β 
TNF-α and IL-1β were measured in plasma aliquots (75 µl and 50 µl 
respectively) by ELISA using commercially available kits according to the 
manufacturer’s instructions (R&D Systems, Inc., McKinley Place, MN, U.S.A.).  
Briefly, this assay employs the quantitative sandwich enzyme 
immunoassay technique. An affinity purified polyclonal antibody specific for the 
rat cytokine (TNF-α or IL-1β) was pre-coated onto a 96-well microplate. 50 µl of 
assay diluent (supplied by manufacturer) along with 50 µl of standards (12.5-800 
pg ml-1 for TNF-α or 31.2-2000 pg ml-1 for IL-1β), controls (supplied by 
manufacturer) (Figure 4-7), or samples were added, in duplicate, to the 
microplate. The microplate was then covered and left to incubate for 2 h at room 
temperature. Subsequently the microplate was washed to remove any unbound 
antibody-enzyme reagent. 100 µl of enzyme-linked polyclonal antibody specific 
for the rat cytokine was then added to the wells. The microplate was again 
covered and left to incubate for 2 h at room temperature. Following a wash, 100 
µl substrate solution was  added to the wells,  covered,  protected  from  light  and  














Figure 4-7a: Representative TNF-α standard curve. Log graph of absorbance (OD) against 








































Figure 4-7b: Representative IL-1β standard curve. Log graph of absorbance (OD) against IL-
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incubated for 30 min. The enzyme reaction yielded a blue product that turned 
yellow when 100 µl of the stop solution was added. The absorbance was 
determined at 450 nm with a reference wavelength of either 540 nm or 570 nm, in 
a 96-well microplate reader (Tecan Systems, Inc. San Jose, CA, U.S.A.). The 
sample values were then read off the standard curve and are expressed as pg ml-1 
of each cytokine in plasma.  
 
4.7.4 Measurement of liver and kidney myeloperoxidase (MPO) activity 
Neutrophil sequestration in liver and kidney was quantified by measuring 
tissue myeloperoxidase (MPO) activity. Tissues (50 mg) were thawed and 
homogenized in 1 ml of 20 mM sodium phosphate buffer (pH 7.4), centrifuged 
(10,000 × g, 10 min, 4°C) and the resulting pellet resuspended in 1 ml of 50 mM 
sodium phosphate buffer (pH 6.0) containing 0.5% w v-1 
hexadecyltrimethylammonium bromide (Sigma-Aldrich Corp. St. Louis, MO, 
U.S.A.). The suspension was subjected to four cycles of freezing and thawing and 
further disrupted by sonication (40 seconds). The sample was then centrifuged 
(10,000 × g, 5 min, 4°C) and the supernatant used for the MPO assay. The 
reaction mixture consisted of the supernatant (50 μl), 1.6 mM 
tetramethylbenzidine (Sigma-Aldrich Corp. St. Louis, MO, U.S.A.), 80 mM 
sodium phosphate buffer (pH 5.4), and 0.3 mM hydrogen peroxide (reagent 
volume: 50 μl). This mixture was incubated at 37°C for 110 sec, the reaction 
terminated with 50 μl of 0.18 M H2SO4 and the absorbance measured at 450 nm 
using a 96-well microplate reader (Tecan Systems, Inc. San Jose, CA, U.S.A.). 
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The absorbance was then corrected for the DNA content of the tissue sample and 
results are expressed as enzyme activity (fold increase over control). 
 
4.7.5 Detection of liver eNOS and iNOS expression by western blot analysis 
Tissue (150 mg) was thawed and homogenized in 4 ml of ice cold 
homogenization buffer (250mM sucrose, 20mM Tris, 1mM Dithiothreitol (DTT)). 
The homogenates were centrifuged at 4°C, 9,000 × g for 30 minutes. Supernatants 
were collected and centrifuged at 4°C, 14,000 × g for 30 minutes. Protease 
Inhibitor Cocktail (F. Hoffmann-La Roche Ltd., Grenzacherstrasse, Basel, 
Switzerland) was added to the final supernatants. Western blotting conditions 
were conducted essentially as described (Whiteman et al., 2004; 2005) using an 
enhanced chemiluminescence detection kit (Amersham Biosciences, Amersham, 
Buckinghamshire, England) followed by analysis using a Kodak Image Analyser 
(IS440CF, NEN Life Science, Boston, MA, USA) and captured images analyzed 
using Kodak digital science 1D image analysis software. Protein concentration 
was determined using a commercial kit (Bio-Rad Dc protein assay, Bio-Rad Ltd, 
Hercules, CA, U.S.A.) and either 100 µg or 30 µg total protein was analyzed for 
eNOS and iNOS respectively. 
 
4.7.6 Assay for liver and kidney H2S synthesis 
Tissue (50 mg) was thawed and homogenized in 1 ml ice-cold 
homogenization buffer (100 mM potassium phosphate pH 7.4). The reaction 
mixture (total volume, 500 μl) contained L-cysteine (10 mM, 20 μl), pyridoxal 5’-
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phosphate (2 mM, 20 μl), saline (30 μl) and tissue homogenate (430 μl). The 
reaction was performed in parafilmed eppendorf tubes and initiated by 
transferring the tubes from ice to a water bath at 37°C. In some experiments, the 
enzymatic reaction was stopped immediately by addition of trichloroacetic acid 
(10% w v-1, 250 μl)   to   denature   protein   prior to addition of cysteine.  After 
incubation for 30 min (Figure 4-8a), zinc acetate (1% w v-1, 250 μl) was added to 
trap evolved H2S, followed by tricholoroacetic acid. Subsequently, N,N-dimethyl-
p-phenylenediamine sulphate (20 μM, 133 μl) in 7.2M HCl and FeCl3 (30 μM, 
133 μl) in 1.2M HCl were added and the absorbance of the resulting solution (670 
nm) measured 15 min thereafter, using a 96-well microplate reader (Tecan 
Systems, Inc. San Jose, CA, U.S.A.). The basal concentration of H2S was 
determined in incubates in which trichloroacetic acid was added at zero time (T = 
0) prior to addition of cysteine and incubation (37°C, 30 min). At the end of this 
period, trichloroacetic acid was added and H2S generated assayed 
spectrophotometrically as described above. All samples were assayed in 
duplicate. The H2S concentration of each sample was calculated against a 
calibration curve of sodium hydrosulphide (NaHS; 3.12-250 μM) (Figure 4-8b) 
and results are expressed as nmole H2S formed mg-1 protein (determined by the 



















Figure 4-8a: Graph of H2S synthesis from added L-cysteine over time (min) in liver 
homogenates of sham rats. H2S formation from L-cysteine from liver homogenates of sham rats 
(n=5) peaked between 30 to 50 min and subsequently decreased (but remained greater than 































































Figure 4-8c: Representative Bradford Assay standard curve. Graph of absorbance (OD) 
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4.7.7 Measurement of liver CBS and CSE mRNA expression 
Tissue (100 mg) was thawed and homogenized in 1 ml ice-cold TRIzol 
reagent (Invitrogen, Carlsbad, CA, U.S.A.) and thereafter incubated for 10 min at 
room temperature. Samples were mixed with chloroform (0.2 ml), vigorously 
shaken and incubated at room temperature for 3 min, followed by centrifugation 
(12,000 × g, 4°C, 15 min). The upper aqueous phase was transferred to an 
eppendorf tube and isopropanol (0.5 ml) was added.  
After further incubation at room temperature (10 min), samples were 
centrifuged (12,000 × g, 4°C, 10 min) and the resulting RNA pellet was washed 
with 75% v v-1 ethanol (1.5 ml) and centrifuged again (7500 × g, 4°C, 5 min). 
Supernatants were discarded and the RNA pellets were air-dried (5-10 min), 
dissolved in diethyl pyrocarbonate (DEPC)-treated water (20-80 μl) and incubated 
(55-60°C) for 10 min. The concentration of isolated nucleic acids was determined 
spectrophotometrically by measuring the absorbance at 260 nm. All samples were 
stored at -80°C until required.  
One-step RT-PCR method was employed in this study (QIAGEN® one-
step RT-PCR kit, Qiagen Inc. Valencia, CA, U.S.A.). Total RNA template (1 μg) 
was mixed with 5 x RT-PCR buffer (4 μl), dNTP mix (400 μM, 0.8 μl), 1.2 μl of 
each primer (0.6 μM), enzyme mix (0.8 μl, a mixture of omniscript, sensiscript 
reverse transcriptases and HotStar Taq DNA polymerase) and DEPC-treated 
water. The final volume was 20 μl. For the detection of CBS mRNA, the forward 
primer sequence used was 5’-GAGCGAGCCGGAACCTTGAAGC-3’, and the 
reverse primer sequence was 5’- CACCTATCCACCACCGCCCTGTC-3’. For 
Chapter 4: Materials and Methods 94
the detection of CSE mRNA, the forward primer sequence used was 5’-
CATGGATGAAGTGTATGGAGGC-3’, and the reverse primer sequence was 5’-
CGGCAGCAGAGGTAACAATCG-3’. For the detection of GADPH mRNA, the 
forward primer sequence used was 5’-CATGGTCTACATGTTCCAGT-3’, and 
the reverse primer sequence was 5’-GGCTAAGCAGTTGGTGGTGC -3’. The 
PCR product size for CBS, CSE and GAPDH was 579 bp, 445 bp and 349 bp 
respectively. RT-PCR was performed at 50°C for 30 min and at 95°C for 15 min 
for reverse transcription, followed by 36 cycles (CBS and CSE) or 25 cycles 
(GAPDH) of PCR reaction consisting of 94°C (30 s) for denaturation, 60°C 
(CBS) or 58.5°C (CSE) or 55°C (GAPDH) (30 s) for primer-specific annealing, 
and 72°C (30 s) for extension. In addition, the reaction without RNA template 
(none template control (NTC)) was also performed as a negative control. PCR 
products were analysed by 1.5% w v-1 agarose ethidium bromide gel 
electrophoresis and imaged under ultraviolet light by the MultiGenius Bioimaging 
system (Syngene, Cambridge, U.K.). The band intensity was semi-quantified by 
densitometry using Gel analysis software (Syngene, Cambridge, U.K.). 
 
4.7.8 Preparation of nuclear extracts and determination of NF-κB 
activation 
Nuclear extracts of liver were prepared using a Compartmental Protein 
Extraction Kit as described by the manufacturer (CHEMICON International, Inc., 
Temecula, CA, U.S.A.). Briefly, liver (100 mg) was thawed and homogenized in 
500 µl of ice-cold Buffer C supplied by manufacturer (HEPES (pH 7.9), MgCl2, 
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KCl, EDTA, Sucrose, Glycerol, Sodium OrthoVanadate), rotated (4°C for 20 
min) and centrifuged (20,000 × g at 4°C for 20 min).  The supernatant was 
discarded whilst the pellet was washed and re-suspended in 400 µl of ice-cold 
Buffer W supplied by manufacturer (HEPES (pH 7.9), MgCl2, KCl, EDTA, 
Sucrose, Glycerol, Sodium OrthoVanadate), rotated (4°C for 20 min) and again 
centrifuged (20,000 × g at 4°C for 20 min). The supernatant was once more 
discarded whilst the pellet was re-suspended in 100 µl of ice-cold Buffer N 
supplied by manufacturer (HEPES (pH 7.9), MgCl2, NaCl, EDTA, Glycerol, 
Sodium OrthoVanadate), rotated (4°C for 20 min) and centrifuged (20,000 × g at 
4°C for 20 min). The resulting supernatant which contained the nuclear proteins 
was stored at -80°C prior to the NF-κB assay. Protein concentrations in nuclear 
extracts were determined using the Bradford assay (Bio-Rad Ltd, Hercules, CA, 
U.S.A.).  
To monitor NF-κB activation in liver, we used a TransAM NF-κB p65 
Transcription Factor Assay Kit (Active Motif, Tokyo, Japan). The kit consists of a 
96-well plate into which oligonucleotide containing the NF-κB consensus site (5’-
GGGACTTTCC-3’) is bound. The active form of NF-κB in the nuclear extract (5 
µg total nuclear protein was loaded into each well) specifically binds to this 
consensus site and is recognised by a primary antibody (100 µl). A horseradish 
peroxidase-conjugated secondary antibody (100 µl) provides the basis for the 
colorimetric quantification. The absorbance of the resulting solution was 
measured 5 min thereafter (450 nm with a reference wavelength of 655nm), using 
a 96-well microplate reader (Tecan Systems, Inc. San Jose, CA, U.S.A.). The 
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wild-type consensus oligonucleotide is provided as a competitor for NF-κB 
binding in order to monitor the specificity of the assay. The oligonucleotide will 
prevent NF-κB binding to the probe immobilized on the plate. Conversely, the 
mutated consensus oligonucleotide should have no effect on NF-κB binding. To 
allow for optimum competition, the oligonucleotide was added to the well prior to 
the addition of nuclear extract. Results were expressed as percentages of the 
positive control (TNF-α-stimulated HeLa whole cell extract) provided by the 
manufacturer. 
 
4.7.9 Assay for determination of proteolytic activity of liver proteasome 
Fluorogenic peptide substrates (Calbiochem, Merck KGaA, Darmstadt, 
Germany) namely, substrate II (Z-Leu-Leu-Glu-AMC), substrate III (Suc-Leu-
Leu-Val-Tyr-AMC) and substrate VI (Z-Ala-Arg-Arg-AMC) were used to assay 
postglutamate, chymotrypsin-like and trypsin-like peptidase activities of liver cell 
proteasome respectively. Briefly, liver samples (50 mg) were thawed and 
homogenized in 1 ml ice-cold homogenization buffer (10 mM Tris, pH 7.5, 5 mM 
EDTA, 1 mM DTT, 5 mM ATP, 20% v v-1 glycerol, 0.04% v v-1 Nonidet P-40). 
Protein concentration was determined by the Bradford assay (Bio-Rad Ltd, 
Hercules, CA, U.S.A.). An equal amount of protein (5 µg) was incubated (10 min) 
with 50 µM of substrate II, III or VI in assay buffer (50 mM Tris and 0.5 mM 
DTT). Proteolytic activity (20 min) was then measured using Spectra Max Gemini 
EM Spectrophotometer (Molecular Devices Corporation, Sunnyvale, CA, U.S.A) 
with excitation wavelength of 360 nm and emission wavelength of 465 nm. 
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Results were expressed as RFU/min to indicate the proteolytic activity of the 
different proteasome substrates. 
 
4.8 Statistical Analysis 
Data show mean ± SEM. Statistical analysis was performed using the 
statistical software SPSS 13.0 for Windows Student Version (2005). The statistical 
significance of differences between mean values was analyzed using one-way 
ANOVA followed by post hoc Tukey test. A P value of <0.05 was taken to indicate a 
statistically significant difference. The statistical significance of differences between 
survival times was analyzed using the Kaplan-Meier survival analysis. A P value of 
<0.05 was taken to indicate a statistically significant difference. 
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Chapter 5: Flurbiprofen and nitroflurbiprofen protect 
against septic shock in rats 
5.1 Introduction 
 Nitric oxide releasing non-steroidal anti-inflammatory drugs (NO-NSAIDs) is 
a novel group of drugs with potential therapeutic applications in a variety of clinical 
conditions. They are synthesized by the linkage of an NO-releasing moiety to 
conventional non-steroidal anti-inflammatory drugs (NSAID) such as flurbiprofen 
(e.g., nitroflurbiprofen, HCT 1026) (Chapter 2, Section 2.3.4). 
 At present, conventional NSAIDs are one of the mainstay treatments for 
inflammatory disease alongside glucocorticoids and antibiotics. However, NSAIDs 
have potentially serious side effects in the gastrointestinal tract, namely gastric 
ulceration, which limit their therapeutic usefulness (Fries et al., 1998). This is a result 
of direct NSAID injury to the mucosal epithelium and indirectly from the drug’s 
ability to inhibit prostaglandin synthesis and attenuate the mucosal protective 
mechanisms normally elicited in response to injurious agents. The barrier function of 
mucus is very important in protecting the mucosa (Allen et al., 1993), and the 
thickness of the mucus layer in the stomach and duodenum of the rat is dramatically 
reduced by indomethacin (Akiba et al., 2000, Sababi et al., 1995), thereby increasing 
the susceptibility of these organs to injury. Conversely, mucus secretion and gel 
thickness in the stomach and duodenum are increased by prostaglandin stimulation 
(Akiba et al., 2000). Another possible mechanism for NSAIDs to induce damage is 
by promoting leukocyte-endothelial adhesion. Evidence for this involves increased 
synthesis of TNF-α, leukotriene B4 and upregulation of ICAM-1 on NSAID 
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treatment (Wallace et al., 1993). 
 The NO-NSAID may therefore be considered as one of a long list (e.g. 
enteric-coating of tablets, pro-drugs and selective cyclooxygenase-2 (COX-2) 
inhibitors) of therapeutic attempts to overcome the gastric injury caused by NSAID. 
NO has been shown to be an important regulator of mucus secretion in the stomach 
(Brown et al., 1993), and the NO synthase (NOS) inhibitor N-nitro-L-arginine (L-
NNA) reduced mucus accumulation in the rat duodenum (Sababi et al., 1995). NO is 
also an important mediator of vascular tone in the gastrointestinal tract, as well as 
influencing the adherence of leukocytes to the endothelium. Inhibition of NO 
synthesis enhances the adhesion of leukocytes to endothelium in the cat (Kubes et al., 
1991). Furthermore, expression of the β2 adhesion molecules on neutrophils (Banick 
et al., 1997) and P-selectin on the vascular endothelium (Davenpeck et al., 1994) is 
inhibited by NO. Thus the mechanism by which NO-NSAID reduce gastrointestinal 
toxicity of the ‘parent’ NSAID in animals and man is by (i) an NO-induced increase 
in mucosal blood flow, (ii) an NO-induced increase in mucus production, and/or (iii) 
an NO-induced reduction in leukocyte adhesion within the mucosal microcirculation 
(Fiorucci et al., 1999; Takeuchi et al., 1998). 
 In addition to their gastroprotective properties, NO-NSAIDs are also of 
interest because they exhibit enhanced anti-inflammatory activity in a number of 
animal models c.f. the ‘parent’ NSAID (Al-Swayeh et al., 1999a; Al-Swayeh et al., 
1999b; Yuan et al., 2003). Similarly, nitric oxide releasing steroids such as 
nitroprednisolone and nitroflunisolide exhibited greater anti-inflammatory activity 
than the ‘parent’ compound in an experimental model of arthritis (Paul-Clark et al., 
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2000) and in the carrageenan-airpouch model of inflammation in the rat (Wallace et 
al., 2004).  In man, septic shock is associated with severe hypotension and frequently 
leads to damage and ultimately reduced function of a range of organs including liver, 
kidney, heart and pancreas – a state referred to as multiple organ dysfunction 
(MODS). 
Flurbiprofen (FLU) is an established inhibitor of pro-inflammatory prostanoid 
biosynthesis which acts by blocking cyclooxygenase-1 and -2 (COX-1 and COX-2) 
enzyme activity. Nitroflurbiprofen (NOF) and other NO-releasing nonsteroidal anti-
inflammatory drugs (NO-NSAID) were originally developed in an attempt to reduce 
or even eliminate the gastrotoxicity which is a characteristic feature of FLU and 
related NSAID. Once administered to experimental animals, NOF is broken down to 
yield FLU and NO which is believed to protect against gastric damage either by 
dilating mucosal blood vessels or preventing leucocyte entrapment and engorgement 
in the mucosal vasculature. Furthermore, maintenance of the gastrointestinal mucosa 
by NOF may be critical in sepsis, since it would prevent the translocation of bacteria 
from the intestine into the systemic circulation (Hotchkiss et al., 2003). 
Considerable evidence both in experimental animals and in man has now been 
accumulated which testifies to the markedly reduced gastrointestinal side effects (c.f. 
the ‘parent’ NSAID) (Fiorucci et al., 1999; Takeuchi et al., 1998). In addition, it was 
previously reported that NO-NSAID such as nitroaspirin and NOF (Al-Swayeh et al., 
1999a; Al-Swayeh et al., 1999b) exhibit greater efficacy (on a mol for mol basis) as 
anti-inflammatory agents against carrageenan-induced hindpaw oedema in the rat 
which effect may be secondary to an NO-mediated inhibition of the induction of a 
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range of pro-inflammatory enzymes (e.g. COX-2, iNOS) (Cirino et al., 1996; 
Mariotto et al., 1995a) and cytokines (e.g. IL-1β and TNF-α as a result of inhibition 
of transcription via the nuclear factor kappa B (NF-κB) pathway (Wallace et al., 
2004; Mariotto et al., 1995a; Fratelli et al., 2003).  
It was thus considered worthwhile to evaluate the effect of the NO-releasing 
NSAID, nitroflurbiprofen (NOF) and its parent molecule, flurbiprofen (FLU) in an 
animal model of systemic inflammatory disease viz. caecal ligation puncture (CLP)-
induced septic shock. This particular condition was chosen for the first part of the 
project because, (i) NO has long been recognized as an important mediator of sepsis, 
(for reviews, see Rees, 1995; Wong & Billiar, 1995), although its precise role remains 
elusive, (ii) the role of prostanoids is unclear as is the potential therapeutic benefit of 
NSAID in this condition and, (iii) septic shock is associated with high mortality and 
alternative therapeutic strategies are much sought after. Some of the results reported 
in this chapter have been published (Anuar et al., 2006a). 
 
5.2 Results 
5.2.1 Effect of flurbiprofen and nitroflurbiprofen on blood pressure  
In control experiments, no change in blood pressure (up to 48 h) was noted 
in sham-operated animals. In contrast, blood pressure of animals in both the 
caecal ligation puncture (CLP) and vehicle (VEH) groups were significantly 
reduced at 6 h and declined even further at 12 h and 24 h after CLP (Figure 5-1). 
Blood pressure of animals administered either flurbiprofen (FLU) or 
nitroflurbiprofen (NOF) (80.4 ± 2.1 and 79.8 ± 1.2 mmHg respectively, 12h, n=8,  















Figure 5-1: Mean arterial blood pressure of rats subjected to sham operation (Sham), caecal 
ligation puncture (CLP) or CLP pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH),  flurbiprofen (21 mg kg-1, p.o., FLU) or nitroflurbiprofen (30 mg kg-1, 
p.o., NOF). Results show mean arterial blood pressure (mm Hg) 1, 6, 12, 24 and 48 h after 
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P<0.05 c.f. 72.5 ± 1.0 mmHg CLP rats) also declined following induction of CLP 
but remained significantly higher (P<0.05) then CLP and VEH groups (72.0 ± 0.7 
mmHg respectively, 12h, n=6) at all respective time points except 1 h post-sepsis 
(Figure 5-1). 
 
5.2.2 Effect of flurbiprofen and nitroflurbiprofen on survival 
All animals subjected to sham surgical operation survived for 48 h at 
which point the experiment was routinely halted. In contrast, all animals subjected 
to CLP failed to survive this same time period (Table 5-1, Figure 5-2). The mean 
survival time for both CLP and VEH rats was 26 ± 3 h (Figure 5-2). Pre-treatment 
of animals with either FLU or NOF increased survival time (35 ± 3 h and 37 ± 2 h 
respectively, n=12, P<0.05 c.f. CLP rats) (Figure 5-2). 
 
5.2.3 Effect of flurbiprofen and nitroflurbiprofen on CLP-induced tissue 
damage 
Tissues from animals killed at 12 hr after CLP were examined and showed 
inflammatory damage typical of septic shock in both the CLP (Figure 5-3d, e, f) 
and VEH (Figure 5-3g, h, i) group of animals unlike that in CLP animals pre-
treated with FLU (Figure 5-3j, k, l) or NOF (Figure 5-3m, n, o). Histological 
examination of lung revealed significantly higher alveolar congestion, oedema, 
cellular (mostly neutrophil) infiltrates (see arrows-tips) and widening of alveolar 
septa in both the CLP (Figure 5-3e) and VEH (Figure 5-3h) groups. Lung 
specimens of CLP rats pre-treated  with  NOF  (Figure 5-3n)  hardly  showed  any  




















Results show the number of rats which survived after sham operation (Sham), 
caecal ligation puncture (CLP) or CLP pre-treatment with either equivalent 
volume of vehicle (2 ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, p.o., FLU) or 
nitroflurbiprofen (30 mg kg-1, p.o., NOF) up to 48 h. All animals subjected to sham 
operation survived for more than 48 h at which point the experiment was routinely 






































Figure 5-2: Kaplan-Meier survival analysis for survival times of caecal ligation puncture 
(CLP) or CLP pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), 
flurbiprofen (21 mg kg-1, p.o., FLU) or nitroflurbiprofen (30 mg kg-1, p.o., NOF). Results 
show cumulative survival at different time intervals (12, 24, 36, and 48 h) after surgery, and are 






















Figure 5-3: Haematoxylin and eosin (H&E) staining of rats subjected to (Fig. 5-3a, b, c) 
sham operation (Sham), (Fig. 5-3d, e, f) caecal ligation puncture (CLP), or CLP followed 
thereafter by treatment with either (Fig. 5-3g, h, i) equivalent volume of vehicle (2 ml kg-1, 
i.p., VEH), (Fig. 5-3j, k, l) flurbiprofen (21 mg kg-1, p.o., FLU) or (Fig. 5-3m, n, o) 
nitroflurbiprofen (30 mg kg-1, p.o., NOF). All five groups of rats were sacrificed at 12 h (n=5). 
Fig. 5-3a, d, g, j and m are liver while Fig. 5-3b, e, h, k and n are lung and Fig. 5-3c, f, i, l and o 
are caecum. Leakage of blood or infiltration of cellular (mostly neutrophils) infiltrates (arrow-tips) 
into extracellular spaces of major organs was observed in the CLP and VEH rats (Fig. 5-3d, e, f, g, 
h, i). Both the FLU and NOF rats showed improved organ morphology (Fig. 5-3j, k, l, m, n, o). 
(Fig. 5-3a-o at ×400 magnification) 
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sign of alveolar septa widening, although pre-treatment with FLU (Figure 5-3k) 
showed a slight widening in the alveolar septa as compared to sham-operated  rats 
(Figure 5-3b). Lung specimens of CLP rats pre-treated with FLU (Figure 5-3k) 
also showed slight alveolar congestion, oedema, and neutrophil infiltrates (see 
arrows-tips). However, this was not apparent for NOF lung specimens (Figure 5-
3n). Similar to the gross observations, cellular infiltrates (see arrow-tips) and 
damaged histoarchitecture were observed in the caecum of both CLP (Figure 5-
3d, f) and VEH (Figure 5-3g, i) groups. Caecal inflammation in CLP (Figure 5-3f) 
and VEH (Figure 5-3i) rats was characterized by predominantly mononuclear cell 
infiltration of the lamina propria with scattered eosinophils and very few 
neutrophils. In addition, both CLP and VEH groups had marked thickening of the 
mucosa, crypt hyperplasia with rare crypt abscesses, reduction of mucus-secreting 
goblet  cells,  and  early  ulcerations  in  the  mucosa  (Figure 5-3f, i).  In  contrast, 
caecal sections from CLP rats pre-treated with either FLU (Figure 5-3l) or NOF 
(Figure 5-3o) showed little evidence of inflammation, with thinner caecal walls, 
presence of goblet cells, reduced cellular infiltration and minor crypt 
abnormalities. Likewise, severe sinusoidal congestion (see arrow-tips) and 
hepatocellular necrosis was present in liver tissue from both CLP (Figure 5-3d) 
and VEH (Figure 5-3g) groups. Conversely, minimal damage was noted in liver 
specimens from CLP rats pre-treated with either FLU (Figure 5-3j) or NOF 
(Figure 5-3m).  
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5.2.4 Effect of flurbiprofen and nitroflurbiprofen on plasma NOx, IL-1β 
and TNF-α in CLP rats 
Low concentrations of both IL-1β and TNF-α (<10 pg ml-1) were detected 
in the plasma of sham rats at all time points whereas plasma nitrite/nitrate 
(NOx) was detected at 1 h and remained constant throughout (< 50 μM) (Figure 
5-4). Both the NOx and cytokines (TNF-α and IL-1β) assays have their lower 
detection limits of 50nM and <5 pg ml-1 respectively. CLP-induced septic shock 
was associated with significantly increased (n=5, P<0.05) plasma concentrations 
of NOx (6, 12 and 24 h), TNF-α  (6, 12 and 24 h) and IL-1β  (1, 6, 12 and 24 h) 
(c.f. sham rats) (Figure 5-4). Pre-treatment of CLP rats with either FLU or NOF 
did not affect the resulting rise in plasma IL-1β concentration (c.f. CLP rats) 
(Figure 5-4c). However, pre-treatment with NOF but not FLU resulted in a 
significant reduction (n=5, P<0.05) in plasma TNF-α concentration at 6, 12 and 
24 h (Figure 5-4b) and a significant increase (n=5, P<0.05) in plasma NOx 

























Figure 5-4a: Plasma concentration of NOx of rats subjected to sham operation (Sham), 
caecal ligation puncture (CLP) or CLP pre-treatment with either equivalent volume of 
vehicle (2 ml kg-1, i.p., VEH),  flurbiprofen (21 mg kg-1, p.o., FLU) or nitroflurbiprofen (30 
mg kg-1, p.o., NOF). Results show concentration at 1, 6, 12, 24 and 48 h after surgery, and are 























Figure 5-5b: Plasma concentration of TNF-α of rats subjected to sham operation (Sham), 
caecal ligation puncture (CLP) or CLP pre-treatment with either equivalent volume of 
vehicle (2 ml kg-1, i.p., VEH),  flurbiprofen (21 mg kg-1, p.o., FLU) or nitroflurbiprofen (30 
mg kg-1, p.o., NOF). Results show concentration at 1, 6, 12, 24 and 48 h after surgery, and are 























Figure 5-6c: Plasma concentration of IL-1β of rats subjected to sham operation (Sham), 
caecal ligation puncture (CLP) or CLP pre-treatment with either equivalent volume of 
vehicle (2 ml kg-1, i.p., VEH),  flurbiprofen (21 mg kg-1, p.o., FLU) or nitroflurbiprofen (30 
mg kg-1, p.o., NOF). Results show concentration at 1, 6, 12, 24 and 48 h after surgery, and are 
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5.3 Discussion 
Caecal ligation puncture (CLP) is an established model of sepsis/peritonitis in 
animals and has been employed in numerous studies as a model of this condition in 
man (Esmon, 2004). The CLP model of sepsis in rat or mouse is associated with 
decreased blood pressure, increased plasma and tissue concentration of a range of 
pro-inflammatory cytokines most notably TNF-α (Beutler & Grau, 1993; Hack et al., 
1997) and IL-1β (Pruitt et al., 1995) as well as generation of inducible nitric oxide 
synthase (iNOS) with resultant enhanced formation of NO in tissues and raised 
plasma NOx concentration (Rees 1995; Wong & Billiar, 1995). It is also associated 
with significant tissue damage (notably in the lung) which may be enhanced by 
concurrent administration of bacterial endotoxin (McMasters et al., 1994). 
In the present study, significantly elevated plasma levels of NOx, IL-1β and 
TNF-α were detected in rats subjected to CLP (Figure 5-4). In addition, CLP was also 
associated with markedly reduced blood pressure which was apparent 6 h after 
surgery and continued to decline thereafter (Figure 5-1). Furthermore, histological 
examination of lung, kidney and caecum from animals subjected to CLP (Figure 5-3) 
provided clear evidence of tissue inflammatory damage typical of septic shock 
including oedema and alveolar thickening in the lung, damage in histoarchitecture 
and sinusoidal congestion in the liver, marked thickening of the mucosa and crypt 
hyperplasia in the caecum, and increased leukocyte (mostly neutrophil) infiltration in 
these organs (Figure 5-3). Such biochemical and histological manifestations no doubt 
played a large part in the increased mortality of CLP rats (c.f. sham-operated rats) 
which was also noted in the present study.  
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Both FLU and NOF treatment (mol for mol equivalent dose) administered 
orally 1 h before CLP, ameliorated CLP-induced septic shock as evidenced by, (i) 
partial restoration of blood pressure to values obtained in sham rats (Figure 5-1), (ii) 
prolonged survival time (Figure 5-2) and (iii) reduced tissue damage determined 
histologically (Figure 5-3). No significant difference in anti-inflammatory activity 
between the two drugs was detected in this animal model as far as these parameters 
are concerned. In an attempt to determine the mechanism of the protective effect of 
FLU and NOF in this model we monitored plasma concentrations of NOx, IL-1β and 
TNF-α concentrations. A significant (P<0.05) increase in plasma NOx in CLP 
animals was detected at 6, 12 and 24 h (but not at 1 h post-sepsis) which presumably 
reflects activity of inducible nitric oxide synthase (iNOS) indicative of an ongoing 
inflammatory state (Figure 5-4a). Both FLU and NOF pre-treatment tended to 
increase plasma levels of NOx but this proved to be significant only for NOF at all 
time points except 1 h post-sepsis (Figure 5-4a). Τhe rise in plasma NOx in these 
animals following NOF pre-treatment may well be a consequence of the catabolism 
of this compound to NO (and hence to NOx) within the bloodstream. Thus, future 
studies measuring the expression levels of iNOS should be carried out so as to 
ascertain whether the rise in plasma NOx in these animals following NOF pre-
treatment is due to the catabolism of NOF to NO or an increase in iNOS expression. 
CLP-induced septic shock was also associated with elevated plasma levels of 
both TNF-α and IL-1β concentrations at all time points except 1 h post-sepsis for 
plasma TNF-α (Figure 5-4b, c). Previous published reports have identified similar 
increases in plasma levels of both IL-1β and TNF-α in this model of septic shock 
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(e.g. Koo et al., 1999). Treatment of animals with either FLU or NOF did not affect 
the rise in plasma IL-1β concentration (Figure 5-4b, c). However, NOF (but not FLU) 
administration significantly reduced the sepsis-induced rise in plasma TNF-α 
concentration at all time points except 1 h post-sepsis (Figure 5-4b, c). The present in 
vivo data therefore confirms the previous in vitro observation that NOF (but not FLU) 
reduced E. coli lipopolysaccharide (LPS) induced TNF-α formation in human blood 
(Marshall & Moore, 2004). Interestingly, nitroaspirin (an alternative NO-NSAID) has 
been shown to reduce plasma levels of both TNF-α and IL-1β following injection of 
LPS in the rat (Fiorucci et al., 2002). No such effect of NOF was identified in the 
present work which may reflect either differences in the mechanism of action of the 
two drugs or perhaps differences between the CLP model of septic shock used in this 
study and LPS-induced endotoxic shock.  
In conclusion, we show here that both FLU (NSAID) and NOF (NO-NSAID) 
protect against CLP-induced septic shock and prolong survival in such animals. The 
mechanism of action of these compounds does not appear to involve inhibition of the 
formation of pro-inflammatory NO, TNF-α or IL-1β. Since the therapeutic use of 
FLU is associated with significant gastrotoxicity which is not apparent with NOF, the 
present data suggest that NOF may be of value in the treatment of septic shock in 
man. Because of the greatly reduced gastrointestinal, renal and cardiovascular toxicity 
associated with NOF, this drug may also be used at higher doses and perhaps in 
conjunction with other medications, if necessary. Moreover, the addition of an NO-
releasing moiety to FLU has also been reported in studies to confer a number of 
positive effects in terms of enhancing the anti-inflammatory, analgesic and anti-
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thrombotic properties relative to the ‘parent’ FLU (Chapter 2, Section 2.3.4). As such, 
NOF, and possibly other NO-NSAIDs, clearly represent a promising new class of 
drugs that may well provide safer and more effective therapies for sepsis and other 
inflammatory disorders. 
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Chapter 6: Nitroflurbiprofen reduces pro-inflammatory H2S 
formation in LPS rats 
6.1 Introduction 
Until relatively recently hydrogen sulphide (H2S) was considered a toxic 
environmental pollutant of little or no physiological significance. However, it is now 
clear that H2S is synthesised naturally in a range of mammalian and non-mammalian 
tissues by two pyridoxal phosphate dependent enzymes (cystathionine β synthetase, 
CBS and cystathionine γ lyase, CSE) acting on cysteine as substrate and most likely 
plays a part in physiological and pathophysiological processes (Chapter 3, Section 
3.1). 
Recently, attention has been focused on the possible role of H2S in 
inflammation. In fact, as discussed earlier (Chapter 3, Section 3.2.3), work in this and 
other laboratories has provided evidence of a role for H2S as a pro-inflammatory 
mediator in various animal models of haemorrhagic (Mok et al., 2004) and endotoxic 
(Collin et al., 2005; Li et al., 2005) shock as well as in caerulein-induced pancreatitis 
(Bhatia et al., 2005a) and carrageenan-induced hindpaw oedema in the rat (Bhatia et 
al., 2005b) (Chapter 3, Section 3.2.3). In each of these disease models, tissue CSE 
expression is up-regulated leading to enhanced H2S biosynthesis and plasma levels 
whilst CSE inhibitors (e.g. DL-propargylglycine) have been shown to exhibit 
pronounced anti-inflammatory activity.  
Numerous analogies exist between H2S and nitric oxide (NO). Both are cell 
permeable gases under physiological conditions and are synthesised in a range of 
mammalian cell types and tissues from simple amino acids (cysteine and arginine 
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respectively). In addition both gases occur naturally in the bloodstream (H2S 
concentration in human plasma, approximately, 50 μM Richardson et al., 2000; NO 
detected as its stable breakdown products, nitrate and nitrite, NOx). Furthermore H2S 
and NO exhibit vasodilator activity in vitro and in vivo albeit by different 
mechanisms (for H2S most probably opening of smooth muscle KATP channels (Zhao 
et al., 2001) and for NO activation of soluble guanylate cyclase) and the cellular 
synthesis of each mediator is enhanced in a variety of inflammatory disorders most 
probably following the induction of CBS, CSE and inducible nitric oxide synthase 
(iNOS) in inflammatory and other cells (Evans, 1995).  
NF-κB denotes a ubiquitous family of transcription factors that transduce a 
wide range of noxious or inflammatory stimuli into the coordinated activation of 
multiple genes, including those coding for cytokines, cytokine receptors, adhesion 
molecules, and anti-apoptotic proteins (Ghosh & Karin, 2002). NF-κB thus serves as 
a critical element in immune and inflammatory responses and in cell survival and 
proliferation, with central roles in host defense and in acute and chronic disorders of 
immune function. NF-κB can upregulate the expression of all major NO synthases 
(nNOS, iNOS, and eNOS) (Kleinert et al., 2003). However the mechanism(s) by 
which CBS and CSE expression is up-regulated either in vitro or in vivo is not known. 
It is well established that NF-κB is complexed with and sequestered in the cytoplasm 
by inhibitory IκB (inhibitor of NF-κB) proteins and that many activating stimuli 
induce phosphorylation of IκB by the IκB-kinase complex (IKKα, IKKβ, and IKKγ), 
initiate IκB ubiquitinylation and degradation by means of the 26S proteasome, and 
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allow the translocation of NF-κB to the nucleus (Ghosh & Karin, 2002; Qureshi et 
al., 2003).  
Intriguingly, recent studies have suggested that NO may work in concert (i.e. 
‘cross talk’) with H2S. A number of potential ‘cross-over’ points between H2S and 
NO have been reported. For example, H2S stabilises NO in solution (Sorensen et al., 
1980) and augments NO release from S-nitrosothiols (Roediger & Babidge, 2000). 
Furthermore, NO acts on cultured smooth muscle cells to increase both H2S 
production and CSE expression (Zhao et al., 2001). Both NO and H2S bind to, and 
are consequently quenched by, haemoglobin (Searcy & Lee, 1998). In addition, H2S 
scavenges peroxynitrite (Whiteman et al., 2004). Finally, the vasorelaxant effect of 
NO is variously augmented or inhibited (Zhao et al., 2003) by the presence of H2S. 
Whilst the precise nature of this ‘cross talk’ remains unclear it seems reasonable to 
suggest that the overall biological effect of H2S on smooth muscle (and other 
systems) in vivo may well be inextricably linked with the synthesis/activity of NO. 
Both lipopolysaccharide (LPS)-induced endotoxic shock model and caecal 
ligation puncture (CLP)-induced septic shock model result in circulatory 
derangements which manifest as perfusion maldistributions leading to widespread 
organ failure and ultimately death. As mentioned previously, the CLP model, 
although less predictable and less reproducible, results in a situation more akin to that 
seen clinically. On the other hand, the LPS model results in a more direct, 
reproducible alteration in host responses to immune challenge (Chapter 1, Section 
1.2). Thus for the second part of this project we decided to investigate the interaction 
between H2S and NO in the animal model of systemic inflammation viz. E. Coli LPS-
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induced endotoxic shock. For these experiments, the NO-releasing non-steroidal anti-
inflammatory drug (NO-NSAID), nitroflurbiprofen (NOF) along with its parent 
molecule flurbiprofen (FLU), were again used. Some of the results described in this 
chapter have been published (Anuar et al 2006b). 
 
6.2 Results 
6.2.1 Effect of flurbiprofen and nitroflurbiprofen on plasma NOx, TNF-
α and IL-1β  in LPS rats  
Nitrite/nitrate (NOx) was detected in the plasma of rats at 6 h after 
injection with saline (Figure 6-1). Low concentrations of both TNF-α and IL-1β  
(<10 pg ml-1) were also detected in plasma of rats 6 h after injection with saline 
(Figure 6-1). Both the NOx and cytokines (TNF-α and IL-1β) assays have their 
lower detection limits of 50nM and <5 pg ml-1 respectively. Conversely, LPS-
induced septic shock was associated with significantly increased (n=5, P<0.05) 
plasma concentrations of NOx, TNF-α, and IL-1β  (c.f. sham rats) (Figure 6-1).  
Pre-treatment of LPS-injected rats with flurbiprofen (FLU) did not affect the 
resulting rise in plasma NOx, TNF-α, and IL-1β concentrations (c.f. LPS rats) 
(Figure 6-1). In contrast, nitroflurbiprofen (NOF) administration resulted in a 
significant (n=5, P<0.05) dose-dependent inhibition of LPS-mediated increase in 


















Figure 6-1a: Plasma concentration of NOx of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, 
i.p., NOF). Results show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, 































Figure 6-1b: Plasma concentration of TNF-α of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, 
i.p., NOF). Results show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, 
+P<0.05 c.f. LPS, #P<0.05 c.f. FLU (21mg kg-1), ^P<0.05 c.f. NOF (3mg kg-1). 
 





























Figure 6-1c: Plasma concentration of IL-1β of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, 
i.p., NOF). Results show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, 
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6.2.2 Effect of flurbiprofen and nitroflurbiprofen on liver and kidney 
injury in LPS rats 
Evidence of liver and kidney injury in rats injected with LPS and killed 6 
h thereafter was indicated by a significant increase (n=5, P<0.05) in liver and 
kidney myeloperoxidase (MPO) (c.f. sham rats) as a measure of neutrophil 
infiltration (Figure 6-2).  Pre-treatment of LPS-injected rats with FLU did not 
inhibit MPO activity either in the liver or kidney (c.f. LPS rats). However, pre-
treatment with NOF in LPS-injected rats resulted in a significant (n=5, P<0.05) 
dose-dependent inhibition of MPO activity in the liver but not in the kidney (c.f. 
LPS rats) (Figure 6-2). 
 
6.2.3 Effect of flurbiprofen and nitroflurbiprofen on liver iNOS expression 
in LPS rats 
Liver iNOS expression was not detected in rats injected with saline 
(Figure 6-3). However rats injected with LPS and killed 6 h thereafter showed 
significant induction (n=5, P<0.05) in the expression of iNOS in the liver (c.f. 
sham rats) (Figure 6-3). Pre-treatment of LPS-injected rats with FLU did not 
affect the resulting increase in the expression of iNOS in the liver (c.f. LPS rats) 
(Figure 6-3). Even so, NOF administration caused a significant inhibition (n=5, 


















Figure 6-2: Effect of flurbiprofen or nitroflurbiprofen on MPO activity. Homogenates were 
prepared from liver or kidney removed from rats killed 6 h after injection of either saline (Sham), 
E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., 
VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, i.p., NOF). Results 
indicate fold increase in MPO activity over control in arbitrary units, and are mean ± SEM, n=5, 






























Figure 6-3: (a) Representative blot from one liver showing the presence of iNOS (~130kDa). 
(b) Quantitation of liver (shown in (a)) iNOS. Homogenates were prepared from liver removed 
from rats killed 6 h after injection of either saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment 
with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., 
FLU) or nitroflurbiprofen (3-30 mg kg-1, i.p., NOF). Results indicate fold increase over LPS in 
arbitrary units, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. FLU 
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6.2.4 Effect of flurbiprofen and nitroflurbiprofen on liver and kidney H2S 
biosynthesis in LPS rats 
Incubation of liver or kidney homogenates (30 min at 37°C) with cysteine 
(10mM) and pyridoxal 5’-phosphate (2mM) resulted in the formation of 
significant amounts of H2S as determined spectrophotometrically. The formation 
of H2S by liver and kidney homogenates from LPS-injected rats was significantly 
greater (n=5, P<0.05) than in homogenates prepared from rats injected with saline 
(Figure 6-4). Pre-treatment of LPS-injected rats with FLU did not affect the 
resulting rise in formation of significant amounts of H2S both in the liver and 
kidney (c.f. LPS rats) (Figure 6-4). In contrast, NOF administration resulted in a 
significant (n=5, P<0.05) dose-dependent inhibition of the LPS-mediated increase 
in H2S formation both in the liver and kidney (c.f. LPS rats) (Figure 6-4). 
 
6.2.5 Effect of flurbiprofen and nitroflurbiprofen on liver CBS and CSE 
mRNA in LPS rats 
H2S is synthesised naturally in a range of mammalian and non-mammalian 
tissues by two pyridoxal phosphate-dependent enzymes (cystathionine β 
synthetase (CBS) and cystathionine γ lyase (CSE)) that act on cysteine as 
substrate. In this study, it was found that rat liver homogenates from sham rats 
contained detectable amounts of mRNA for both CBS and CSE (Figure 6-5). Rats 
injected with LPS and killed 6 h thereafter showed significant increase (n=5, 
P<0.05) in CBS and CSE mRNA expression (c.f. sham rats) (Figure 6-5).  Pre-
treatment with FLU did not affect either CBS or CSE mRNA expression in LPS- 














Figure 6-4: Formation of H2S from cysteine (10 mM) in the presence of pyridoxal 5’-
phosphate (1 mM) following incubation (37°C, 30 min). Homogenates were prepared from liver 
or kidney removed from rats killed 6 h after injection of either saline (Sham), E.Coli LPS (LPS) or 
LPS pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), flurbiprofen (21 
mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, i.p., NOF). Results show H2S formation as 
nmole formed mg protein-1, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, 



























Figure 6-5: (a) Representative blots from one liver showing the presence of CBS and CSE 
(579 bp and 445 bp respectively, 36 cycles). (b) Quantitation of liver (shown in (a)) CBS and 
CSE. Homogenates were prepared from liver removed from rats killed 6 h after injection of either 
saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, i.p., 
NOF). Results indicate fold increase over control in arbitrary units, and are mean ± SEM, n=5, 
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injected rats (Figure 6-5). Conversely, NOF administration resulted in a 
significant (n=5, P<0.05) dose-dependent inhibition of LPS-mediated increase in 
both CBS and CSE mRNA expression (c.f. LPS rats) (Figure 6-5). 
 
6.2.6 Effect of flurbiprofen and nitroflurbiprofen on liver NF-κB activation 
in LPS rats 
Rats injected with LPS and killed 6 h thereafter showed significant 
increase (n=5, P<0.05) in NF-κB activation in the liver as compared to rats 
injected with saline (Figure 6-6). Pre-treatment with FLU did not affect the NF-
κB activation in the liver of LPS-injected rats (Figure 6-6). On the other hand, 
NOF administration resulted in a significant (n=5, P<0.05) dose-dependent 
inhibition of LPS-mediated increase in NF-κB activation in the liver (c.f. LPS 
rats) (Figure 6-6). 
 
6.2.7 Effect of flurbiprofen and nitroflurbiprofen on proteolytic activity of 
liver proteasome in LPS rats 
Low proteolytic activity of liver proteasome was detected for 3 different 
substrates namely, substrates II, III and VI (<20 RFU/min) in sham rats (Figure 6-
7). Conversely, a significant increase (n=5, P<0.05) in proteolytic activity in liver 
proteasome for substrates II, III and VI, in LPS-injected rats was observed (c.f. 
sham rats) (Figure 6-7). Pre-treatment of LPS-injected rats with FLU only 
resulted in a significant inhibition (n=5, P<0.05) in the proteolytic activity of liver 
proteasome for substrate VI in LPS-injected rats  (c.f. LPS rats)  (Figure 6-7).  On  















Figure 6-6: Effect of flurbiprofen or nitroflurbiprofen on NF-κB activation in the liver of 
rats at 6 h after LPS injection. Nuclear extracts from liver homogenates were prepared from rats 
killed 6 h after injection of either saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment with 
either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), flurbiprofen (21 mg kg-1, i.p., FLU) or 
nitroflurbiprofen (3-30 mg kg-1, i.p., NOF). Results indicate the relative percentage of NF-κB 
activation over the positive control (TNF-α-stimulated HeLa whole cell extract) provided by the 
manufacturer, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. FLU 





















Figure 6-7: Effect of flurbiprofen or nitroflurbiprofen on the proteolytic activity of liver 
proteasome. Substrate II (Z-Leu-Leu-Glu-AMC), substrate III (Suc-Leu-Leu-Val-Tyr-AMC) and 
substrate VI (Z-Ala-Arg-Arg-AMC) were used to assay for the postglutamate, chymotrypsin-like 
and trypsin-like peptidase activities of the liver cells proteasome, respectively. Homogenates were 
prepared from liver removed from rats killed 6 h after injection of either saline (Sham), E.Coli 
LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), 
flurbiprofen (21 mg kg-1, i.p., FLU) or nitroflurbiprofen (3-30 mg kg-1, i.p., NOF). Results indicate 
the proteolytic activity in RFU/min, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. 
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the other hand, NOF administration resulted in a significant (n=5, P<0.05) dose-
dependent inhibition in proteolytic activity of liver proteasome for substrates II, III 
and VI in LPS-injected rats (c.f. LPS rats) (Figure 6-7). 
 
6.3 Discussion 
It was previously reported that LPS administration in the mouse resulted in an 
increase in plasma H2S concentration coupled with up-regulated liver and kidney 
CSE mRNA expression (Li et al., 2005). Furthermore, DL-propargylglycine, an 
inhibitor of CSE enzyme activity, abrogated endotoxic shock in the rat as evidenced 
by a reduction in plasma markers of liver (aspartate aminotransferase), pancreas 
(lipase) and skeletal muscle (creatinine kinase) damage (Collin et al., 2005). 
Moreover, H2S administration (by injection of NaHS – a water-soluble H2S donor 
drug) resulted in augmented liver and kidney MPO activity as well as microscopic 
changes in the lung, liver and kidney typical of an inflammatory insult (Li et al., 
2005). Based on these studies we have proposed that H2S acts as a pro-inflammatory 
mediator in endotoxic shock. A similar pro-inflammatory effect of H2S has been 
reported in other inflammatory conditions including caerulein-induced pancreatitis 
(Bhatia et al., 2005b) and carrageenan-induced hindpaw oedema (Bhatia et al., 
2005a). Although it must be noted that previous studies have also shown anti-
inflammatory effects of H2S in the model of hindpaw oedema (Zanardo et al., 2006). 
This was previously discussed in Chapter 3, Section 3.2.4. 
The aetiology of LPS-evoked endotoxic shock is complex and undoubtedly 
involves the over-production of a number of different mediators other than H2S. For 
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example, it has long been recognised that the excessive formation of NO, as a 
consequence of up-regulation of iNOS, plays an important role in the cardiovascular 
depression and organ damage associated with endotoxic and septic shock (Stein et al., 
1996). Furthermore, several recent reports have suggested that H2S and NO interact 
together in such a way as to modify the biological activity of each mediator (see 
Chapter 6, Section 6.1 for references). However, whether such an interaction takes 
place in pathological states such as endotoxic shock, or indeed in other examples of 
inflammatory disease, is not known. As such, it seemed of interest to determine 
whether exogenously provided NO affected the up-regulated biosynthesis of H2S 
which we have reported in LPS-injected animals. Nitroflurbiprofen (NOF) was used 
as the NO donor in the present series of experiments. This particular NO donor was 
chosen since LPS-induced endotoxic shock in the rat becomes evident over a 
relatively long time period (up to 6 h) and as such administration of classical NO 
donors such as sodium nitroprusside which produce a rapid, but transient (min), 
release of NO is inappropriate. It is now well established in the literature that the 
administration of NOF (or indeed other NO-NSAID) to animals (Aldini et al., 2002) 
or man (Zacharowski et al., 2004) results in esteratic cleavage of the parent molecule 
and leads to the slow release (maximum plasma concentrations at 2-4 h) of both 
component molecules i.e. NO and flurbiprofen (FLU). An added advantage of the use 
of NOF in these experiments is that it does not alter blood pressure in the rat (Keeble 
et al., 2001) most probably due to the slow time course of NO release. Such a 
vasodepressor effect would likely confound the interpretation of the present results. 
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We demonstrate here that NOF produced a dose related inhibition of LPS-
mediated endotoxic shock in the rat as evidenced by reduced plasma TNF-α and IL-
1β concentration (Figure 6-1b, c) and liver and kidney MPO activity (indicative of 
neutrophil infiltration in these organs) (Figure 6-2) coupled with a significant fall in 
plasma NOx concentration (Figure 6-1a) and liver iNOS protein expression (Figure 6-
3). The decrease in plasma NOx concentration was not as great as the decline in 
plasma TNF-α and IL-1β levels (Figure 6-1) which presumably reflect the ability of 
other cytokines to up-regulate iNOS expression. FLU pre-treatment was without 
effect on all parameters studied indicating that NO, released following cleavage of 
NOF, was the molecule responsible for the changes observed. These data suggest that 
at least part of the mechanism of action of NOF may be attributed to an NO-mediated 
downregulation of iNOS with consequent diminished biosynthesis of pro-
inflammatory and vasodilator NO. In support of this possibility, it was previously 
shown that NOF inhibits LPS-induced generation of TNF-α and IL-1β in whole 
human blood (Marshall & Moore, 2004) whilst others have observed a similar 
inhibitory effect of this molecule in cultured macrophages and neutrophils exposed to 
LPS (Mariotto et al., 1995a; Mariotto et al., 1995b).  
Of even greater significance, we also provide evidence that NOF 
administration affects the metabolism of endogenous H2S. Animals administered 
NOF exhibited reduced liver and kidney H2S synthesising activity (measured ex vivo) 
(Figure 6-4) associated with decreased liver CBS and CSE mRNA expression (Figure 
6-5). Again, FLU was devoid of such activity indicating that NO, released from NOF 
in vivo, was responsible for the changes in H2S metabolism observed. These data 
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suggest that exogenous NO (provided by NOF) downregulates not only the 
biosynthesis of NO but also that of H2S. Whether endogenous NO exerts a similar 
effect on H2S metabolism in either physiological or pathophysiological states 
warrants further study.  
The molecular mechanism by which NO (released from NOF) downregulates 
iNOS protein and both CBS and CSE mRNA expression has also been investigated. 
We observed that pre-treatment of LPS-injected animals with NOF (but not FLU) 
caused a dose related inhibition of liver NF-κB activation (Figure 6-6). There are 
several reports in the literature that NO modulates NF-κB activity either by 
interfering with the phosphorylation of IκB (Peng et al., 1995; Marshall et al., 2004) 
and/or by inhibition of NF-κB-DNA binding affinity by nitrosation of the p50 subunit 
(Matthews et al., 1996; Marshall et al., 2004). Interestingly, nitroaspirin (a structural 
analogue of NOF) has previously been reported to reduce transduction via the NF-κB 
pathway in cultured macrophages (Cui et al., 2001) as has NOF in cultured L929 cells 
(Fratelli et al., 2003). The present data may additionally be taken to suggest that NO 
(released from NOF) also inhibits the expression of both CBS and CSE mRNA (and 
consequent ability to synthesise H2S) at least in the liver of LPS-injected rats.  
Noteworthy, proteasome was previously implicated in LPS-induced 
degradation of IκB (Qureshi et al., 2003), since the proteasome regulates the NF-κB 
signaling pathway via the dissociation and degradation of IκB. We observed that pre-
treatment of LPS-injected animals with NOF (but not FLU) caused a dose related 
inhibition of liver proteasome activity (Figure 6-7). The present data may additionally 
be taken to suggest that NO (released from NOF) inhibits the proteasome activity 
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possibly through S-nitrosylation of the cysteine residues of the proteasome. Inhibition 
of proteasome activity would thus result in the inhibition of NF-κB activation (due to 
decrease in IκB dissociation and degradation (Qureshi et al., 2003; Shen et al., 2006)) 
and subsequent down-regulation of gene expression of TNF-α, IL-1β, iNOS, CBS 
and CSE, which are involved in inflammation. It is also likely that S-nitrosylation of 
other proteins found upstream or downstream to the proteasome could very well 
regulate the NF-κB activation pathway. The present data suggests that iNOS and both 
CBS and CSE mRNA expression may be regulated by exogenous NO and is therefore 
of potential significance in a range of different disease states. 
Notwithstanding the interaction between NO and H2S identified in this present 
experiments also offer an opportunity to probe further the complex anti-inflammatory 
effect of NOF (for review, see Scatena, 2004). On a mol for mol basis, NOF has been 
reported to exhibit greater anti-inflammatory activity in animal models of 
Alzheimer’s disease (injection of preaggregated Aβ 1-42 into the nucleus basalis in 
the rat) (Prosperi et al, 2004) and experimental autoimmune encephalomyelitis 
(Furlan et al., 2004). NOF also reduced brain inflammation resulting form chronic 
infusion of LPS into the fourth ventricle in the rat (Wenk et al., 2002). Since the brain 
contains high levels of H2S (approx. 100-150 μM) and is an excellent source of CBS 
(which, like CSE, acts on cysteine to form H2S) it is tempting to suggest that the 
augmented anti-inflammatory effect of NOF (c.f. FLU) noted in the brain may also be 
due, at least in part, to inhibition of H2S biosynthesis.   
In conclusion, we show here that NO (provided by NOF) abrogates the up-
regulation of both NO and H2S biosynthesis following LPS injection in the rat. The 
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mechanism involved may be by inhibition of transduction via the proteasome – NF-
κB pathway. The data suggests, (i) that NO and H2S interact together to promote 
inflammatory changes in endotoxic shock and (ii) lend further support to our proposal 
that inhibition of H2S formation or action may represent a novel approach to the 
treatment of this and perhaps other inflammatory disorders. 
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Chapter 7: 1400W, a selective iNOS inhibitor, reduces pro-
inflammatory H2S formation in LPS rats 
7.1 Introduction 
As previously mentioned, hydrogen sulphide (H2S) has been shown to be 
involved in a range of physiological and pathophysiological processes (Chapters 3 
and 6). Similarly, nitric oxide (NO), which is a free radical synthesized from oxygen 
and L-arginine by NO synthase (NOS) namely, endothelial NOS (eNOS), neuronal 
NOS (nNOS) and inducible NOS (iNOS), has often been said to act as a “double-
edged sword” playing both a deleterious and potentially beneficial role in many 
biological processes (Chapter 2, Section 2.2.4). In the context of the present work, 
numerous contradictory reports exist in the literature suggesting that both inhibitors 
of nitric oxide synthase (NOS) and NO donors (e.g. nitroflurbiprofen (NOF) see 
Chapter 6, Section 6.1) are beneficial in animal models of such disparate clinical 
conditions as septic and endotoxic shock.  
Thus, in an attempt, (i) to examine in more detail the apparent conundrum of 
the role of NO in sepsis and at the same time, (ii) provide data for comparison with 
the effect of NOF, experiments were undertaken to examine the effect of nitric oxide 
synthase (NOS) inhibitors, namely L-NAME (non-selective NOS inhibitor) and 
1400W (selective iNOS inhibitor), in the LPS-induced endotoxic shock model. Data 
presented in this chapter therefore represent the third and final part of the project 
making up this thesis. 
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7.2 Results 
7.2.1 Effect of L-NAME and 1400W on plasma NOx, TNF-α and IL-1β  in 
LPS rats 
As noted previously (Chapter 6, Section 6.2.1), low concentrations of 
nitrite/nitrate (NOx) (<50 µM) and both TNF-α, and IL-1β  (<10 pg ml-1) were 
detected in plasma of rats 6 h after injection with saline (Figure 7-1). The lower 
limit of NOx and cytokines (TNF-α, IL-1β) detection are 50nM and <5 pg ml-1 
respectively. Conversely, evidence of inflammation in LPS-injected rats (6 h) was 
indicated by a significant increase (n=5, P<0.05) in plasma concentrations of 
NOx, TNF-α and IL-1β  (c.f. sham rats) (Figure 7-1). Pre-treatment of LPS-
injected rats with L-NAME resulted in a significantly greater (n=5, P<0.05) dose-
dependent inhibition of plasma NOx concentration as compared to pre-treatment 
of LPS-injected rats with 1400W (Figure 7-1a). However, pre-treatment of LPS-
injected rats with L-NAME was without effect on plasma TNF-α and IL-
1β concentrations except at the highest dose which significantly increased (n=5, 
P<0.05) plasma TNF-α and IL-1β concentrations (c.f. LPS rats) (Figure 7-1b, c). 
On the other hand, pre-treatment of LPS-injected rats with 1400W caused a 
significant (n=5, P<0.05) dose-dependent reduction in plasma TNF-α and IL-1β 


















Figure 7-1a: Plasma concentration of NOx of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results 
show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, 























Figure 7-1b: Plasma concentration of TNF-α of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results 
show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, 

























Figure 7-1c: Plasma concentration of IL-1β of rats killed 6 h after injection of either saline 
(sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results 
show plasma concentration and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, 
#P<0.05 c.f. L-NAME (25 mg kg-1), ^P<0.05 c.f. 1400W (1 mg kg-1). 
 
Chapter 7: 1400W reduces pro-inflammatory H2S formation in LPS rats 143
7.2.2 Effect of L-NAME and 1400W on liver and kidney injury in LPS rats 
Evidence of liver and kidney injury in rats injected with LPS and killed 6 
h thereafter was indicated by a significant increase (n=5, P<0.05) in liver and 
kidney myeloperoxidase (MPO) activity (c.f. sham rats) as a measure of 
neutrophil infiltration (Figure 7-2). Pre-treatment of LPS-injected rats with L-
NAME resulted in a significant (n=5, P<0.05), dose-dependent increase in MPO 
activity in liver but not kidney (c.f. LPS rats) (Figure 7-2). Pre-treatment of LPS-
injected rats with 1400W resulted in a significant (n=5, P<0.05), dose-dependent 
inhibition of MPO activity in both liver and kidney (c.f. LPS rats) (Figure 7-2). 
 
7.2.3 Effect of L-NAME and 1400W on liver eNOS and iNOS expression in 
LPS rats 
Rats injected with LPS and killed 6 h thereafter showed significant 
increase in iNOS expression in the liver, whereas eNOS expression in the liver 
was significantly down-regulated (n=5, P<0.05, c.f. sham rats) (Figure 7-3). Pre-
treatment of LPS-injected rats with 1400W resulted in a significantly greater 
(n=5, P<0.05) down-regulation of liver iNOS expression as compared to pre-
treatment of LPS-injected rats with L-NAME (Figure 7-3). Conversely, pre-
treatment of LPS-injected rats with either L-NAME or 1400W resulted in a 
significant (n=5, P<0.05) dose-dependent down-regulation or up-regulation of 
eNOS expression in the liver respectively (c.f. LPS rats) (Figure 7-3). Thus, 
1400W, an iNOS selective inhibitor, was more selective for iNOS than eNOS as 
compared to L-NAME, a non-selective NOS inhibitor.  














Figure 7-2: Effect of L-NAME or 1400W on MPO activity. Homogenates were prepared from 
liver or kidney removed from rats killed 6 h after injection of either saline (Sham), E.Coli LPS 
(LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), L-
NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results indicate the fold increase in 
MPO activity over control in arbitrary units, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, 



























Figure 7-3: (a) Representative blots from one liver showing the presence of eNOS and iNOS 
(~140kDa and ~130kDa respectively). (b) Quantitation of liver (shown in (a)) eNOS and 
iNOS. Homogenates were prepared from liver removed from rats killed 6 h after injection of 
either saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of 
vehicle (2 ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). 
Results indicate fold increase over control (eNOS) or LPS (iNOS) in arbitrary units, and are mean 
± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. L-NAME (25 mg kg-1), ^P<0.05 
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7.2.4 Effect of L-NAME and 1400W on liver and kidney H2S biosynthesis in 
LPS rats 
Incubation of liver or kidney homogenates (30 min, 37°C) with L-cysteine 
(10mM) and pyridoxal 5’-phosphate (2mM) resulted in the formation of 
significant amounts of H2S as determined spectrophotometrically. The formation 
of H2S by liver and kidney homogenates from rats injected with LPS was 
significantly greater (n=5, P<0.05) than in homogenates prepared from rats 
injected with saline (Figure 7-4). Pre-treatment of LPS-injected rats with L-
NAME resulted in a significant (n=5, P<0.05) dose-dependent increase in H2S 
formation in both liver and kidney (c.f. LPS rats) (Figure 7-4). On the contrary, 
1400W administration resulted in a significant (n=5, P<0.05) dose-dependent 
inhibition of H2S formation in both liver and kidney homogenates (c.f. LPS rats) 
(Figure 7-4). 
 
7.2.5 Effect of L-NAME and 1400W on liver CBS and CSE mRNA in LPS 
rats 
Rat liver homogenates from sham rats contained detectable amounts of 
mRNA for CBS and CSE (Figure 7-5). Rats injected with LPS and killed 6 h 
thereafter showed significant increases (n=5, P<0.05) in CBS and CSE mRNA 
expression (c.f. sham rats) (Figure 7-5). Pre-treatment of LPS-injected rats with 
L-NAME resulted in a significant (n=5, P<0.05) dose-dependent increase in both 
CBS and CSE mRNA expression (c.f. LPS rats) (Figure 7-5). Conversely, 1400W 
administration resulted in a significant (n=5, P<0.05) dose-dependent inhibition of  













Figure 7-4: Formation of H2S from cysteine (10 mM) in the presence of pyridoxal 5’-
phosphate (1 mM) following incubation (37°C, 30 min). Homogenates were prepared from liver 
removed from rats killed 6 h after injection of either saline (Sham), E.Coli LPS (LPS) or LPS pre-
treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), L-NAME (25-100 mg 
kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results show H2S formation as nmole formed mg protein-
1, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. L-NAME (25 mg 



























Figure 7-5: (a) Representative blots from one liver showing the presence of CBS and CSE 
(579 bp and 445 bp respectively, 36 cycles). (b) Quantitation of liver (shown in (a)) CBS and 
CSE. Homogenates were prepared from liver removed from rats killed 6 h after injection of either 
saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent volume of vehicle (2 
ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results 
indicate fold increase over control in arbitrary units, and are mean ± SEM, n=5, *P<0.05 c.f. 
Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. L-NAME (25 mg kg-1), ^P<0.05 c.f. 1400W (1 mg kg-1). 
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LPS-mediated increase in both CBS and CSE mRNA expression (c.f. LPS rats) 
(Figure 7-5). 
 
7.2.6 Effect of L-NAME and 1400W on liver NF-κB activation in LPS rats 
Rats injected with LPS and killed 6 h thereafter showed significant 
increase (n=5, P<0.05) in NF-κB activation in the liver as compared to rats 
injected with saline (Figure 7-6). Pre-treatment of LPS-injected rats with L-
NAME resulted in a significant (n=5, P<0.05) dose-dependent increase in NF-κB 
activation in the liver (c.f. LPS rats) (Figure 7-6). On the contrary, a significant 
(n=5, P<0.05) dose-dependent inhibition of NF-κB activation in the liver was 
observed for pre-treatment of LPS-injected rats with 1400W (c.f. LPS rats) 
(Figure 7-6). 
 
7.2.7 Effect of L-NAME and 1400W on proteolytic activity of liver 
proteasome in LPS rats 
Low proteolytic activity of liver proteasome was detected for 3 different 
substrates namely, substrates II, III and VI (<20 RFU/min) in sham animals 
(Figure 7-7). Conversely, a significant increase (n=5, P<0.05) in proteolytic 
activity in liver proteasome for substrates II, III and VI, in LPS-injected rats was 
observed (c.f. sham rats) (Figure 7-7). Pre-treatment of LPS-injected rats with L-
NAME resulted in a significant (n=5, P<0.05) dose-dependent increase in 
proteolytic activity in liver proteasome for substrate VI in the liver (c.f. LPS rats)  
 














Figure 7-6: Effect of L-NAME or 1400W on NF-κB activation in the liver of rats at 6 h after 
LPS injection. Nuclear extracts from liver homogenates were prepared from rats killed 6 h after 
injection of either saline (Sham), E.Coli LPS (LPS) or LPS pre-treatment with either equivalent 
volume of vehicle (2 ml kg-1, i.p., VEH), L-NAME (25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, 
i.p.). Results indicate the relative percentage of NF-κB activation over the positive control (TNF-
α-stimulated HeLa whole cell extract) provided by the manufacturer, and are mean ± SEM, n=5, 























Figure 7-7: Effect of L-NAME or 1400W on the proteolytic activity of liver proteasome. 
Substrate II (Z-Leu-Leu-Glu-AMC), substrate III (Suc-Leu-Leu-Val-Tyr-AMC) and substrate VI 
(Z-Ala-Arg-Arg-AMC) were used to assay for the postglutamate, chymotrypsin-like and trypsin-
like peptidase activities of the liver cells proteasome, respectively. Homogenates were prepared 
from liver removed from rats killed 6 h after injection of either saline (Sham), E.Coli LPS (LPS) 
or LPS pre-treatment with either equivalent volume of vehicle (2 ml kg-1, i.p., VEH), L-NAME 
(25-100 mg kg-1, i.p.) or 1400W (1-10 mg kg-1, i.p.). Results indicate the proteolytic activity in 
RFU/min, and are mean ± SEM, n=5, *P<0.05 c.f. Sham, +P<0.05 c.f. LPS, #P<0.05 c.f. L-NAME 
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(Figure 7-7). Pre-treatment of LPS-injected rats with 1400W instead resulted in a 
significant (n=5, P<0.05) dose-dependent inhibition in proteolytic activity in liver 
proteasome for both substrates III and VI in the liver (c.f. LPS rats) (Figure 7-7). 
 
7.3 Discussion 
We demonstrate here that 1400W produced a dose related inhibition of LPS-
mediated endotoxic shock in the rat as evidenced by reduced plasma TNF-α and IL-
1β concentration (Figure 7-1b, c) and liver and kidney MPO activity (indicative of 
neutrophil infiltration in these organs) (Figure 7-2). This was coupled with both a 
significant fall in plasma NOx concentration (Figure 7-1a) and liver iNOS protein 
expression and a concomitant significant restoration in liver eNOS protein expression 
back to normal sham levels (Figure 7-3). Previous studies have shown that ‘high-
output’ iNOS-derived NO exerts an inhibitory effect on eNOS (Fischer et al., 1999; 
Ichihara et al., 2000; Schwartz et al., 1997). Thus it is possible that the selective 
inhibition of iNOS by 1400W in LPS rats resulted in the restoration of eNOS activity 
to normal sham levels.  
On the other hand, pre-treatment of LPS-injected rats with L-NAME resulted 
in a significantly greater fall in plasma NOx concentration (Figure 7-1a) as compared 
to pre-treatment of LPS-injected rats with 1400W. This result could be explained by 
the indiscriminate inhibition of liver NOS isoforms (Figure 7-3) in LPS-injected rats 
pre-treated with L-NAME (Chapter 2, Section 2.3.3). For the other parameters 
studied, pre-treatment of LPS-injected rats with L-NAME was without effect though 
indiscriminate inhibition of NOS isoforms by L-NAME (especially at the highest 
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dose, 100mg kg-1) resulted in the exacerbation of inflammation and organ damage 
(increase TNF-α and IL-1β concentration, and liver MPO activity) (Figure 7-1, 7-2). 
However, L-NAME at the lowest dose (25 mg kg-1) significantly inhibited liver and 
kidney MPO activity (Figure 7-2). These data suggest that at least part of the 
mechanism of action of 1400W is due to its ability to selectively inhibit iNOS and in 
turn downregulate the expression of inflammatory mediators, consequently reducing 
organ damage. Studies carried out by other investigators also showed such a 
protection conferred upon endotoxic shock and other inflammatory disease models by 
1400W (Kawanishi et al., 2004; Parmentier et al., 1999; Pullamsetti et al., 2006; 
Robinson et al., 2005). It is also possible that the consequent restoration of eNOS 
activity back to normal sham levels in LPS rats pre-treated with 1400W, might very 
well be attributed to a yet unknown ability of eNOS-derived NO directly 
downregulating the expression of inflammatory mediators, and in turn reducing organ 
damage. In fact, the importance of eNOS-derived NO in endotoxic shock is 
emphasized by the observation that transgenic mice overexpressing eNOS were partly 
protected against LPS (Yamashita et al., 2000). In any case, the abovementioned 
observations demonstrate the need for NO to maintain adequate organ function, 
supporting the idea that eNOS-derived NO could possibly be the molecule 
responsible for the changes observed (Chapter 2, Section 2.3.3).  
Of potentially greater importance, we also provide evidence that 1400W 
administration affects the metabolism of endogenous H2S. Animals administered 
1400W exhibited significantly reduced liver and kidney H2S synthesising activity 
(measured ex vivo) (Figure 7-4) associated with decreased liver CBS and CSE mRNA 
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expression (Figure 7-5). Again, L-NAME was devoid of such activity except at the 
lowest dose used which did reduce liver H2S synthesising activity. Again this data 
suggests that not only was inhibition of iNOS-derived NO responsible for the down-
regulation of the biosynthesis of H2S, but also that restoration of eNOS-derived NO to 
normal sham levels might play a part in this process. Moreover, the potential 
importance of eNOS-derived NO in endotoxic shock was suggested in previous 
studies, which showed that some detrimental effects of non-selective inhibitors could 
be abrogated by the co-administration of an NO donor, such as S-nitroso-N-acetyl-
penicillamine (Boughton-Smith et al., 1990) (Chapter 2, Section 2.3.3).  
The molecular mechanism by which 1400W is able to downregulate both CBS 
and CSE mRNA expression was also investigated. We observed that pre-treatment of 
LPS-injected animals with 1400W caused a dose related inhibition of liver NF-κB 
activation (to a much greater extent as compared with L-NAME) (Figure 7-6). As 
mentioned previously (Chapter 6, Section 6.3), several reports in the literature suggest 
that NO modulates NF-κB activity either by interfering with the phosphorylation of 
IκB and/or by inhibition of NF-κB-DNA binding affinity by nitrosation of the p50 
subunit. The present data may additionally be taken to suggest that eNOS-derived NO 
inhibits the expression of both CBS and CSE mRNA (and consequent ability to 
synthesise H2S) at least in the liver of LPS-injected rats. Noteworthy, proteasome was 
previously implicated in LPS-induced degradation of IκB (Qureshi et al., 2003) since 
these enzymes lie upstream to, and in turn regulate, the NF-κB signaling pathway via 
the dissociation and degradation of IκB. We observed in the present study that pre-
treatment of LPS-injected animals with 1400W caused a dose related inhibition of 
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liver proteasome activity to a much greater extent as compared to L-NAME (Figure 
7-7). The present data may additionally be taken to suggest that NO, synthesized from 
eNOS, inhibits the proteasome activity possibly through S-nitrosylation of the 
cysteine residues of the proteasome. In support of this possibility, previous studies 
have established the ability of NO to S-nitrosylate (NO covalently modify cysteine 
residues in proteins (Stamler et al., 1992) and in turn inhibit NF-κB activation 
(Marshall & Stamler, 2001).  
Consequently, we hypothesize that eNOS-derived NO is able to inhibit 
proteasome activity possibly through S-nitrosylation of the cysteine residues of the 
proteasome. Inhibition of proteasome activity would thus result in the inhibition of 
NF-κB activation (due to decrease in IκB dissociation and degradation (Qureshi et 
al., 2003)) and subsequent downregulation of gene expression of TNF-α, IL-1β, 
iNOS, CBS and CSE, which are involved in inflammation. It is also likely that S-
nitrosylation of other proteins found upstream or downstream to the proteasome could 
very well regulate the NF-κB activation pathway. Furthermore, other investigators 
have shown that the possible degradation of caveolin-1 by proteasome activates 
eNOS (Govers et al., 2003; Merkel et al., 2005). Hence this might possibly act as a 
negative feedback mechanism for eNOS activation and subsequent NO biosynthesis. 
The present data suggests that both CBS and CSE mRNA expression may be 
regulated by NO, from eNOS, and is therefore of potential significance in a range of 
different disease states. 
As mentioned above, 1400W inhibits the formation of pro-inflammatory H2S 
in the LPS-treated rats. At first sight, this observation seems to contradict our earlier 
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findings (see Chapter 6, Section 6.2) involving the NO donor, nitroflurbiprofen 
(NOF), which showed a similar inhibition of the formation of pro-inflammatory H2S. 
Thus, it might perhaps be expected that a selective iNOS inhibitor, such as 1400W, 
would increase pro-inflammatory H2S. This conundrum may possibly be explained by 
the fact that eNOS-derived NO might behave in a similar manner to the slow release 
of NO from the NO donor (NOF) (Chapter 6, Section 6.2), which is to reduce 
inflammation and in turn organ damage possibly via the inhibition of proteasome 
activity and subsequent inhibition of NF-κB activation, TNF-α, IL-1β and CBS/CSE 
mRNA expression (Chapter 7, Section 7.2). Although a previous study by Cuzzocrea 
et al., (2006) showed that the selective iNOS inhibitor, 1400W did not improve 
overall survival when compared to FeTTPs (a peroxynitrite decomposition catalyst) 
in LPS-injected rats. This however does not belie the ability of 1400W to inhibit pro-
inflammatory mediators of endotoxic shock (TNF-α, IL-1β, H2S) and, in turn, reduce 
organ damage as shown by our findings above (Chapter 7, Section 7.2). 
Another point of contention arises from a study carried out by Connelly et al., 
(2005) which showed that in LPS-treated eNOS knock-out (KO) mice, eNOS is 
needed to obtain maximal iNOS expression and, in turn, eNOS might play a pro-
inflammatory role in septic shock. The requirement for eNOS to obtain maximal 
iNOS expression could very well be the case in the present study. However, due to 
the selective inhibition of iNOS by 1400W and inhibition of NOS isoforms by L-
NAME, we are unable to demonstrate the possible physiological activation (if any) of 
iNOS by eNOS in this set of experiments. Moreover, the discrepancy observed 
between our results and Connelly et al., (2005) might be explained by the different 
Chapter 7: 1400W reduces pro-inflammatory H2S formation in LPS rats 157
experimental protocols adopted. Thus, Connelly et al., (2005), undertook experiments 
in vitro using human umbilical vein endothelial cells (HUVECs) and bone marrow-
derived macrophages (BMDMφs) whilst the present data comes from LPS-treated 
rats. Also, compensation for a missing enzyme is common in biology. This may occur 
via a normally present redundant pathway with functions similar to the missing 
enzyme (Mashimo & Goyal, 1999). It has been shown that various NOS isoforms 
also have splice variants that may provide redundant parallel pathways to the 
functions of the main enzyme (Huber et al., 1998; Snyder et al., 1998) 
It must also be noted that besides eNOS-derived NO possibly being the 
molecule responsible for the modulation of pro-inflammatory mediators of endotoxic 
shock, nNOS-derived NO could also play a part. Thus, future work involving the 
administration of 1400W in LPS-treated rats, might examine the expression of tissue 
nNOS so as to ascertain whether or not this is so. Furthermore, the development of 
NOS knockout mice for the different isoforms (eNOS, nNOS and iNOS) with regards 
to sepsis and endotoxemia would be very useful in determining which isoform is the 
source of anti-inflammatory NO. In addition, measuring S-nitrosylation of NF-κB 
and/or proteasome should be carried out, so as to determine whether or not eNOS-
derived NO directly modulates NF-κB and/or proteasome activity. 
In conclusion, results presented in this chapter, reveal for the first time, that 
1400W, a selective iNOS inhibitor, downregulates pro-inflammatory H2S 
biosynthesized from CBS/CSE possibly via inhibition of transduction of the 
proteasome – NF-κB pathway. Hence the proteasome may be intricately linked in the 
‘cross talk’ between NO and H2S and perhaps prove to be a novel approach to the 
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treatment of septic/endotoxic shock and perhaps other inflammatory disorders. 
Furthermore the conundrum which exists between NO donors and NOS inhibitors 
(Chapter 2, Section 2.3.3 and 2.3.4) could very well be due to the dysregulation in the 
balance between NO synthesized from either eNOS or iNOS, leading to the 
subsequent increase in mediators of inflammation and eventual organ damage. More 
importantly, our present results together with our previous findings (Chapter 6, 
Section 6.2) and studies done by others (Oh et al., 2006; Li et al., 2007) suggest that 
NO and H2S may very well act not only to inhibit their own biosynthesis, but might 
also inhibit each other’s biosynthesis, breakdown, or biological effects (Chapter 6, 
Section 6.1), hence the existence of ‘cross talk’. 
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Chapter 8: Discussion 
8.1 Flurbiprofen and Nitroflurbiprofen protect against septic shock in rats 
Several years ago, Wichterman and coworkers (1980) developed a 
reproducible caecal ligation and puncture (CLP) model in the rat which produced the 
clinical signs of sepsis. The rationale for using the CLP model in the present study 
over other models of sepsis was to better simulate the conditions of sepsis bearing 
clinical relevance to the human septic condition. Most rodent species are relatively 
insensitive to endotoxin and require large amounts (milligrams) of endotoxin to 
induce a sepsis state (Wichterman et al., 1980). The physiological relevance of 
injecting a large bolus of endotoxin to induce sepsis is perhaps questionable, since 
such an injection is most unlikely to occur in clinical circumstances. In addition, 
circulating levels of endotoxin in septic patients are often low and mere micrograms 
of endotoxin can account for a lethal dose (Wichterman et al., 1980). Endotoxin 
models do not necessarily reproduce the circulatory and metabolic alterations that 
occur in sepsis. Therefore such models are not optimal for examining the 
haemodynamics of sepsis (Chapter 1, Section 1.2). 
The advantage of using the CLP model is that it results in contamination of 
intestinal flora into the peritoneal cavity, which is commonly seen in laporatomies 
and perforated appendicitis (Fink & Heard, 1990). Furthermore, the CLP procedure 
requires an incubation interval for evolution of the septic response which is relevant 
to the clinical septic condition. Thus, this model might be associated with a "milder" 
form of sepsis compared to endotoxin models (Tyml et al., 1998). 
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In the first set of experiments described in this thesis, CLP-induced septic 
shock led to a fall in mean arterial blood pressure (MABP) which was accompanied 
by increases in plasma nitrite/nitrate (NOx), IL-1β and TNF-α concentration, signs of 
inflammatory damage in liver, lung and caecum, and increased mortality. 
Flurbiprofen (FLU) or nitroflurbiprofen (NOF) pre-treatment in CLP animals resulted 
in increased blood pressure, reduced organ damage and prolonged survival time. 
Furthermore, NOF (but not FLU) significantly reduced plasma TNF-α concentration 
at all time points. Neither drug affected plasma IL-1β and NOx concentration. In 
contrast, animals administered NOF did show a significant increase in plasma NOx at 
an earlier time point (1 h after CLP). 
Pre-treatment with NOF (but not FLU) resulted in a significantly reduced 
plasma TNF-α concentration but not plasma IL-1β concentration possibly due to the 
release of NO from the ‘parent’ NSAID which affected the different gene regulation 
pathways of TNF-α and IL-1β. Moreover, previous experiments in sepsis involving 
NSAIDs resulted in a reduction in TNF-α and IL-1β concentrations (Daphtary et al., 
2001; Qiu et al., 1996). However, this was not reproduced in the present experiment, 
possibly because of a paradoxical effect of NSAIDs, which is to increase, rather than 
inhibit, TNF-α production (Mascagni et al., 2000). Mascagni et al., (2000) reported 
that S-isomers of FLU are responsible for the TNF-α amplification induced by FLU. 
This unwanted effect of S-isomer (i.e. S-flurbiprofen) is paralleled by its inhibitory 
activity on PGE2 production. This "NSAID paradox" is well documented and has 
been observed in various experimental models of sepsis both in vitro and in vivo 
(Jorres et al., 1997; Kunkel et al., 1988; Renz et al., 1988). Furthermore, the 
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enhancement of TNF-α production by NSAIDs was associated with an increase in 
animal mortality in animal models of endotoxic shock (Pettipher & Wimberly, 1994). 
In addition, it has been reported that NSAIDs can directly induce TNF-α release, this 
effect being apparently critical in the pathogenesis of NSAID-induced gastric injury 
(Santucci et al., 1994; Appleyard et al., 1996).  
In addition, one might expect to observe a decrease in MABP following the 
administration of NOF to CLP-induced septic shock rats, since the release of NO 
from the ‘parent’ NSAID should, at least in theory cause vasodilation. However, our 
findings showed otherwise in that administration of NOF led to significantly higher 
MABP comparable to experiments in either CLP or VEH groups. Likewise, 
administration of FLU also increased MABP. Thus, it is likely that the ‘parent’ 
NSAID moiety is responsible for the maintenance of MABP observed along with the 
reduction in inflammation in both NOF and FLU treatment groups, possibly through 
the inhibition of the COX-1 and COX-2 pathway (Figure 8-1). This in turn would 
inhibit the vasodilator effect attributable to the release of prostaglandins PGD2, PGE2, 
and PGI2, and hence resulting in increased MABP (Keeble & Moore, 2002; Takewa 
et al., 2001). Furthermore, the slow-release of the NO moiety from the ‘parent’ 
NSAID probably results in a ‘slow trickle’ of NO into the bloodstream, which is 
consequently rapidly sequestered by binding to haemoglobin (or other 
macromolecules), or by reacting with other free radicals such as superoxide anion 
(Keeble & Moore, 2002). Hence, this may explain the lack of a vasodepressor effect 
of NOF.  
 















Figure 8-1: Summary diagram of the inflammatory mediators derived from phospholipids with 
an outline of their actions, and the site of action of NSAIDs (taken from BioCarta – Charting 
Pathways of Life. Pathways – Eicosanoid Metabolism. 
http://www.biocarta.com/pathfiles/h_eicosanoidPathway.asp). 
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Thus, in the first set of experiments (Chapter 5), we show that both FLU and 
NOF offer protection against CLP-induced septic shock and prolong survival in such 
animals. As mentioned previously, the mechanism of action of these compounds does 
not appear to involve inhibition of the formation of pro-inflammatory NO, TNF-α or 
IL-1β (Chapter 5, Section 5.3) but possibly the inhibition of the COX-1 and COX-2 
pathway. The therapeutic use of FLU is associated with significant gastrotoxocity 
which is not apparent after NOF use (Chapter 5, Section 5.1). Furthermore, 
maintenance of the gastrointestinal mucosa by NOF may be critical in sepsis, since it 
would prevent the translocation of bacteria from the intestine into the systemic 
circulation (Hotchkiss et al., 2003). Thus the present data suggest that NOF may 
instead be of value in the treatment of septic shock in man (Chapter 2, Section 2.3.4).  
 
8.2 Nitroflurbiprofen reduces pro-inflammatory H2S formation in LPS rats 
As mentioned previously (Chapter 8, Section 8.1), the experimental model of 
CLP in rodents is a more realistic sepsis model with clear parallels to the clinical 
situation. However, there are major differences when the roles of cytokines in these 
experimental models are considered (Villa et al., 1995). For instance, TNF-α, one of 
the key mediators of endotoxic shock (Beutler et al., 1985), is barely detected after 
CLP (Alexander et al., 1991; Eskandari et al., 1992; Evans et al., 1989), and anti-
TNF antibodies are not able to protect animals against sepsis (Echtenacher et al., 
1990; Eskandari et al., 1992). Furthermore, as discussed earlier in Chapter 1, Section 
1.2, endotoxemia induction results in a more direct and reproducible alteration in host 
responses to the immune challenge (Sam II et al., 1997). 
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Thus, in the second set of experiments (Chapter 6), we employed the LPS-
induced septic shock model in the rat in order to elucidate further the effect of NOF 
not only on NO metabolism but also on the biosynthesis of H2S. To date, the results 
obtained showed a much significant increase in plasma NOx, TNF-α and IL-1β 
concentration, MPO activity (marker for neutrophil infiltration), H2S synthesizing 
activity, liver iNOS protein and CBS/CSE mRNA expression in LPS-treated animals 
(c.f. sham). FLU pre-treatment did not affect plasma NOx, TNF-α, and IL-1β 
concentration, MPO activity, liver and kidney H2S biosynthesis from cysteine, liver 
iNOS protein and CBS/CSE mRNA expression, liver NF-κB or proteasome activity 
in LPS-injected animals. NOF administration however did result in a significant dose-
dependent inhibition of the LPS-mediated rise in plasma NOx, TNF-α and IL-1β, 
formation of H2S from cysteine (liver and kidney) coupled with reduction in liver 
MPO activity, liver iNOS protein and CBS/CSE mRNA expression, and liver NF-κB 
and proteasome activity.  
However, it must be noted that our previous results in the CLP model showed 
a slight protective effect conferred by FLU administration as indicated by the increase 
in mean survival time (Chapter 5, Section 5.2). This was not the case for FLU 
administration in the LPS model (although a survival study was not carried out in this 
LPS model, MPO activity and plasma cytokines are linked to the survival outcome). 
Such a discrepancy may be attributed to the fact that the LPS model is a more acute 
and severe model as compared to the CLP model. In fact, in the LPS model, plasma 
levels of cytokines attain much higher values (~80% more) in endotoxemic rats than 
in sepsis (CLP model) (Chapter 1, Section 1.2.2).  
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In the LPS model, NOF administration was able to confer a much more 
significant protection against organ damage (as indicated by MPO activity), as 
compared to FLU administration, unlike that seen in the CLP model (Chapter 5, 
Section 5.2). This could be due to the fact that rats, which are more resistant to LPS, 
would thus be more responsive to the treatment at hand as compared to CLP rats 
(Chapter 1, Section 1.2). Moreover, subject-to-subject variability may exist due to the 
nature of the CLP surgical procedure, in turn resulting in a less significant difference 
observed between NOF and FLU treatment groups (Chapter 1, Section 1.2.1). 
Hence, these results show for the first time that, NO (provided by NOF) 
abrogates the up-regulation of both NO and H2S biosynthesis following LPS injection 
in the rat. This suggests that NOF may contribute to the augmented anti-inflammatory 
activity of this compound as compared to its ‘parent’ NSAID FLU via the inhibition 
of transduction of the proteasome – NF-κB pathway (Chapter 6, Section 6.3). The 
possibility of endogenous NO (NOS-derived NO) exerting a similar effect on H2S 
metabolism in either physiological or pathophysiological states will be examined and 
discussed later (Chapter 8, Section 8.3).  
These data also suggest the possibility of ‘cross talk’ between NO and H2S in 
this model of septic shock and thus further supports previous findings. For example, 
other investigators have found that NO increases both H2S synthesis and CSE mRNA 
expression in cultured smooth muscle cells (Zhao et al., 2001). While in the presence 
of H2S, the vasodilator effect of NO is variously increased or inhibited (Zhao et al., 
2003). Also, H2S scavenges peroxynitrite (Whiteman et al., 2004) whilst more recent 
evidence points to the formation of a nitrosothiol from NO and H2S (Roediger & 
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Babidge, 2000; Sorensen et al., 1980). Finally, H2S donors have been shown to 
downregulate expression of genes encoding enzymes which synthesize NO and 
cytokines via the inhibition of NF-κB activation (Li et al., 2007). Thus the inhibition 
of H2S formation or action may represent a novel approach to the treatment of this 
and perhaps other inflammatory disorders. 
 
8.3 1400W reduces pro-inflammatory H2S formation in LPS rats 
The biosynthesis of both NO and H2S is increased in lipopolysaccharide 
(LPS)-injected rats but the possible interaction between these gases in this model is 
not clear.  In the last set of experiments (Chapter 7), we examined the effect of the 
NOS inhibitors, L-NAME and 1400W on NO and H2S metabolism in tissues from 
LPS-treated rats. Administration of LPS resulted in an increase in plasma NOx, TNF-
α and IL-1β concentrations, MPO activity, liver and kidney H2S synthesis (from 
added cysteine), liver iNOS protein and CBS/CSE mRNA expression, liver NF-κB 
and proteasome activity, whilst a decrease in liver eNOS protein expression was 
observed. L-NAME administration in LPS-treated rats resulted in a dose-dependent 
increase in plasma TNF-α, IL-1β concentrations,  MPO activity, liver and kidney H2S 
synthesis, CBS/CSE mRNA, liver NF-κB and proteasome activity, whereas a dose-
dependent inhibition of plasma NOx concentration, liver eNOS and iNOS protein 
expression. 1400W administration to LPS-treated rats resulted in a dose-dependent 
increase of liver eNOS protein back to normal sham levels, whereas a dose-dependent 
inhibition of plasma NOx, TNF-α and IL-1β concentrations, MPO activity, liver 
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iNOS protein expression, H2S synthesis, CBS/CSE mRNA, NF-κB and proteasome 
activity.  
Our earlier findings showed that NOF’s (NO donor) mechanism of action for 
conferring protection against sepsis did not appear to involve the inhibition of the 
formation of pro-inflammatory NO (derived from iNOS) (Chapter 5, Section 5.3). In 
fact, in the second part of our experiments, NO (released from NOF) inhibited both 
iNOS protein and CBS/CSE mRNA expression, possibly via the inhibition of 
transduction of the proteasome – NF-κB pathway (Chapter 6, Section 6.3). This may 
additionally be taken to suggest that exogenous NO inhibits proteasome activity 
possibly by S-nitrosylating cysteine residues of the proteasome. Inhibition of 
proteasome activity would thus be expected to result in inhibition of NF-κB 
activation (due to decrease in IκB dissociation and degradation) and subsequent 
down-regulation of gene expression of TNF-α, IL-1β, iNOS, CBS and CSE, which 
are involved in inflammation (Chapter 6, Section 6.3).  
It is also likely that S-nitrosylation of other proteins found upstream or 
downstream to the proteasome could very well regulate the NF-κB activation 
pathway (Marshall et al., 2004, Shen et al., 2006). Drawing parallels from this, it is 
also possible that endogenous NO (derived from constitutive NOS isoforms such as 
nNOS and/or eNOS) might possibly act in the same manner as exogenous NO (from 
NOF) conferring protection against LPS-induced endotoxic shock by 1400W 
(selective iNOS inhibitor). This however remains to be investigated and is discussed 
in more detail below (Chapter 8, Section 8.4). 
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Nonetheless, these results show for the first time that 1400W, similar to NOF, 
downregulates the biosynthesis of pro-inflammatory H2S possibly via the inhibition 
of transduction of the proteasome – NF-κB pathway. Hence the proteasome may be 
intricately linked in the ‘cross talk’ between NO and H2S and may prove to be a novel 
approach to the treatment of septic/endotoxic shock and perhaps other inflammatory 
disorders (see Figure 8-2). Our present results (Chapter 7, Section 7.2), together with 
our previous studies (Chapter 5, Section 5.2, and Chapter 6, Section 6.2), suggest that 
NO and H2S could very well act not only to inhibit their own biosynthesis but also to 
inhibit each other’s biosynthesis, breakdown, or even biological effects, hence the 
existence of ‘cross talk’. 
 
8.4 Conclusions 
Future experiments should concentrate on measuring blood pressure at 
different time intervals (1 h, 3 h, and 6 h after LPS or saline injection i.p.), 
performing survival studies and histology, treating plasma indices of liver (AST, 
ALT), kidney (urea, creatinine), and pancreas (amylase) in the LPS-induced 
endotoxic shock model. Other future related experiments should concentrate on the 
molecular mechanisms involved in the effect of pre- or post-treatment of NO donors 
(e.g.NOF), H2S donors (e.g. H2S-ketonolac, H2S-diclofenac) and CSE inhibitors (e.g. 
PAG, BCA). This not only involves the measurement of plasma NOx, cytokines (e.g. 
IL-1β and TNF-α), iNOS, H2S biosynthesis, mRNA CSE, and MPO activity, but also 
measurement of COX-2.   
As mentioned, genomic manipulation of H2S biosynthesis is an 
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underdeveloped area with great potential. Thus the development of CBS and/or CSE 
knockout mice with regards to sepsis and endotoxemia would be very useful in 
elucidating the role of H2S (Chapter 3, Section 3.3.2). 
 A proteomics approach should also be undertaken to examine tissues from 
sham and LPS-treated animals to identify proteins which are affected by the 
administration of the above mentioned drugs. In the first instance, emphasis will be 
placed on the interactions of such drugs on intracellular transduction mechanisms 
(e.g. NF-κB, proteasome). Measuring levels of S-nitrosylation of NF-κB and/or 
proteasome should be carried out, so as to determine whether or not eNOS-derived 
NO directly modulates NF-κB and/or proteasome activity. This approach seems 
relevant since it has recently become evident that a number of phosphorylation 
cascades including MAP kinase pathways and NF-κB activation pathway are initiated 
by exposure of cells to LPS. These cascades act at both the transcriptional and 
translational levels to regulate cytokine production (Mariotto et al., 1995a; Horn, 
1998). Moreover, the use of an ELISA-based assay system (Chapter 4, Section 4.7.8) 
to measure NF-κB-DNA binding in our study might not truly reflect NF-κB 
activation. Thus potential studies involving EMSA gelshifts, immunoblots to detect 
the protein expression of p50, p65, c-Rel and RelB in nuclear extracts, and luciferase 
reporter gene assays in LPS-treated RAW 264.7 cells, should be considered. 
It must also be noted that eNOS-derived NO and/or nNOS-derived NO could 
play a part in the modulation of pro-inflammatory mediators of endotoxic shock as 
mentioned above (Chapter 8, Section 8.3). Thus future studies involving the 
administration of 1400W in LPS-treated rats, should examine the expression of not 
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only eNOS but also nNOS, so as to ascertain which NOS form is responsible for the 
observed effects. Furthermore, the development of NOS knockout mice for the 
different isoforms (eNOS, nNOS and iNOS) with regards to sepsis and endotoxemia 
would be very useful in determining which isoform is the source of anti-inflammatory 
NO. Hopefully this will shed more light on the intracellular roles of NO and H2S in 
cardiovascular diseases such as septic shock. 
With all these in mind, it would be foolhardy to oversimplify the roles of NO 
and H2S in the physiological and pathophysiological processes of sepsis (Figure 8-2), 
since it not only involve the balance between constitutive-inducible NOS isoforms at 
a cellular level, but also the complex interaction along with the supply and demand of 
NO and H2S at the systemic level (Wolkow, 1998). Notwithstanding, Occam’s razor 




























Figure 8-2: Hypothesized scheme of the interaction of NO and H2S with the proteasome along 
the NF-κB activation pathway. The diagram indicates the steps where there are evidence for 
modulation by S-nitrosylation (SNO) or yet unknown modulation by H2S. Solid lines indicate 
stimulatory inputs and the dashed lines, inhibitory inputs. TLR4, Toll-like receptor 4; IKK, IκB 
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